

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025874
Article Type:	Research
Date Submitted by the Author:	10-Aug-2018
Complete List of Authors:	<p>Eyawo, Oghenowede; British Columbia Centre for Excellence in HIV/AIDS, Epidemiology and Population Health; Simon Fraser University, Faculty of Health Sciences</p> <p>Brockman, Gwenyth; University of Manitoba, George & Fay Yee Centre for Healthcare Innovation</p> <p>Goldsmith, Charles; University of British Columbia, 4. Department of Occupational Science and Occupational Therapy, Faculty of Medicine</p> <p>Hull, Mark; British Columbia Centre for Excellence in HIV/AIDS, Lear, Scott; Simon Fraser University, Faculty of Health Sciences; St. Paul's Hospital, Providence Health Care, Healthy Heart Program</p> <p>Bennett, Matthew; University of British Columbia, Division of Cardiology, Department of Medicine</p> <p>Guillemi, Silvia; BC Centre for Excellence in HIV/AIDS,</p> <p>Franco-Villalobos, Conrado; University of Alberta, School of Public Health</p> <p>Adam, Ahmed; Simon Fraser University, Faculty of Health Sciences</p> <p>Mills, Edward; McMaster University, Department of Clinical Epidemiology & Biostatistics</p> <p>Montaner, Julio; BC Centre for Excellence in HIV/AIDS,</p> <p>Hogg, Robert; Simon Fraser University, Faculty of Health Sciences; British Columbia Centre for Excellence in HIV/AIDS,</p>
Keywords:	Myocardial infarction < CARDIOLOGY, Cardiovascular disease, HIV & AIDS < INFECTIOUS DISEASES, Combination antiretroviral therapy, Relative risk, systematic review and meta-analysis

SCHOLARONE™
Manuscripts

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

Oghenowede Eyawo,^{1,2} Gwennyth Brockman,³ Charlie H. Goldsmith,^{2,4} Mark W. Hull,¹ Scott A Lear,^{2,5} Matthew Bennett,⁶ Silvia Guillemi,¹ Conrado Franco-Villalobos,⁷ Ahmed Adam,² Edward Mills,⁸ Julio SG Montaner,^{1,9} Robert S Hogg^{1,2}

1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, CANADA
2. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, CANADA
3. George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, MB, CANADA
4. Department of Occupational Science and Occupational Therapy, Faculty of Medicine, University of British Columbia, Vancouver, BC, CANADA
5. Healthy Heart Program, St. Paul's Hospital, Providence Health Care, Vancouver, BC, CANADA
6. Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, BC, CANADA
7. School of Public Health, University of Alberta, Edmonton, AB, CANADA
8. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CANADA
9. Department of Medicine, University of British Columbia, Vancouver, BC, CANADA

Send correspondence to: Oghenowede Eyawo, PhD, MPH, MSc
Faculty of Health Sciences, Simon Fraser University
Post-doctoral Fellow, B.C. Centre for Excellence in HIV/AIDS
St. Paul's Hospital, 608-1081 Burrard Street,
Vancouver, B.C., V6Z 1Y6, Canada
Tel: (604) 806-8477
Email: oeal@sfu.ca

Abstract

Objective: Cardiovascular disease is one of the leading non-AIDS-defining causes of death among HIV-positive (HIV+) individuals. However, the evidence surrounding specific components of cardiovascular disease risk remains inconclusive. We conducted a systematic review and meta-analysis to synthesize the available evidence and estimate the relative risk (RR) of myocardial infarction (MI) among HIV+ compared with uninfected individuals.

Methods: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Database of Systematic Reviews until July 18, 2018. Furthermore, we scanned recent HIV conference abstracts (CROI, IAS/AIDS) and bibliographies of relevant articles. Original studies published after December 1999 and reporting comparative data relating to the rate of MI among HIV+ individuals were included. We examined MI risk within subgroups of HIV+ individuals according to exposure to combination antiretroviral therapy (ART), ART class/regimen, CD4 cell count and plasma viral load levels. Data were pooled using random-effects meta-analysis.

Results: Thirty-two of the 8,130 identified records were included in the review. The pooled RR suggests that HIV+ individuals have a greater risk of MI compared to uninfected individuals (RR=1.60; 95%CI: 1.38-1.85). Depending on risk stratification, there was moderate variation according to ART uptake (RR, ART-treated=1.80; 95%CI: 1.17-2.77; ART-untreated HIV+ individuals: 1.25; 95%CI: 0.93-1.67, both relative to uninfected individuals). We found certain ART characteristics including cumulative ART exposure, any/cumulative use of protease inhibitors as a class, and specific ART drugs (e.g. abacavir) to be importantly associated with a greater MI risk.

1
2
3 **Conclusions:** Our results indicate that HIV infection, low CD4, high plasma viral load,
4
5 cumulative ART use in general including certain exposure to specific ART class/regimen are
6
7 associated with increased risk of MI. The association with cumulative ART may be an index of
8
9 the duration of HIV infection with its attendant inflammation, and not entirely the effect of
10
11 the duration of HIV infection with its attendant inflammation, and not entirely the effect of
12
13 cumulative exposure to ART per se.
14
15

16
17 **PROSPERO registration number:** CRD42014012977
18
19

20
21
22
23
24 **Keywords:** Myocardial infarction, Cardiovascular disease, HIV, Combination antiretroviral
25
26 therapy (ART), Relative risk, systematic review, meta-analysis
27
28
29
30
31
32

33 Word count: 3903
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Strengths and limitations of this study

- Strengths of this study includes the comprehensive search strategy as well as the independent and duplicate reviews employed for study selection and data extraction
- This systematic review and meta-analysis analyzed several additional drug exposure comparisons and clinical measures (e.g. CD4 cell count, plasma viral load) that had not been previously examined in relation to MI risk among HIV-positive individuals
- We observed heterogeneity across results of studies included in some of the meta-analyses, although this is a common limitation in meta-analysis especially those involving observational studies. Our *a priori* choice of employing the random-effects modeling strategy was driven in part by this expected variability among studies.

INTRODUCTION

Cardiovascular disease (CVD) is one of the leading non-AIDS causes of death and disability among people living with HIV in the combination antiretroviral therapy (ART) era.^{1 2} Although HIV-positive (HIV+) individuals are believed to be at higher risk of CVD compared to uninfected individuals,^{3 4} the results and conclusions from the studies that have examined the nature of the risk of CVD, in particular myocardial infarction (MI) among HIV+ individuals have been conflicting. While some cohort studies have suggested a positive association between ART including specific drug (e.g. abacavir) or drug class (e.g. protease inhibitors [PI]) use and MI, or CVD risk,⁵⁻⁹ others have not.¹⁰⁻¹² Furthermore, there has been a lack of agreement between observational studies,^{8 11 13} and randomized controlled trials (RCT).^{14 15} Clearly, the evidence regarding the nature of, and extent of the risk of MI and other CVD events among HIV+ individuals is far from uniform.

Five meta-analyses have been conducted in an attempt to synthesize the data on CVD risk among HIV+ individuals.¹⁶⁻²⁰ These have either been limited in scope by assessing only the association between ART use and risk of CVD;¹⁶ included trials that lacked MI event adjudication;¹⁷ included trials where CVD events were not among the pre-specified outcomes of interest;¹⁸ provided incomplete results on MI risk;¹⁹ or amalgamated all CVD events (e.g. MI, stroke) as a single outcome.²⁰ In addition, this latter meta-analysis was fraught with a number of methodological ambiguities.²¹

Given these limitations, coupled with the publication of several new and updated study reports on the topic, we sought to undertake an updated systematic review and meta-analysis of studies

1
2
3 assessing the risk of CVD among persons living with HIV. Considering the scope, diversity and
4 differences in the etiology of CVD events, coupled with the complexity surrounding the
5 available evidence, we have elected to focus primarily on MI as the outcome of interest for this
6 meta-analysis, as it is the most widely researched CVD outcome among HIV+ individuals. The
7 objective of our study was to estimate the risk of MI among HIV+ individuals relative to
8 uninfected individuals. Additionally, we examined MI risk within subgroups of HIV+
9 individuals according to exposure to ART, ART class, specific ART regimen, CD4 cell count
10 and plasma viral load levels.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **METHODS**

25 **Search strategy and selection criteria**

26
27
28
29 The systematic review and meta-analysis was performed in accordance with the PRISMA
30 Statement.²² A protocol describing the inclusion criteria and analysis methods for this systematic
31 review was specified in advance, registered and published at the international prospective
32 register of systematic reviews (PROSPERO, registration number CRD42014012977).²³
33
34
35
36
37
38
39
40

41 The search strategy (see Appendix Table 1) was developed in consultation with a medical
42 librarian at Simon Fraser University, BC, Canada. The search terms were based on a
43 combination of indexed and free-text terms reflecting clinical outcomes of interest to the review,
44 and included the following keywords: ‘HIV, human immunodeficiency virus, acquired
45 immunodeficiency syndrome, HIV/AIDS, stroke, myocardial infarction, cardiac death,
46 cerebrovascular disease, ischemic heart disease, cardiovascular disease and CVD’. These terms
47 were used in combination to execute the searches, which were up to July 18, 2018. Using the
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Ovid platform, we searched the following electronic databases: MEDLINE, EMBASE, Cochrane
4
5 Central Register of Controlled Trials (CENTRAL) and the Cochrane Database of Systematic
6
7 Reviews. In addition, we screened the abstracts of the International AIDS Society conferences
8
9 (AIDS 2012, 2014, 2016; IAS 2013) and the Conference on Retroviruses and Opportunistic
10
11 Infections (CROI 2014, 2015, and 2016). We also searched the reference lists of relevant articles
12
13 and previous systematic reviews for additional eligible publications. Finally, we set up automatic
14
15 PubMed literature alerts to identify any new relevant article published while the manuscript was
16
17 under development.
18
19
20
21
22
23

24 We included original research published in English where at least one of the participant groups
25
26 were individuals living with HIV, and presenting comparative data on the incidence of MI. We
27
28 included studies in which results were stratified according to HIV status; CD4 cell count; plasma
29
30 viral load (pVL) levels; ART use; or exposure to particular ART class or regimen. Studies
31
32 involving non-human populations, children, as well as those reporting only intermediate,
33
34 surrogate or CVD biomarker outcomes were excluded (for additional information, see 'study
35
36 selection' in the Appendix, p1). To reflect the current context of HIV treatment and disease
37
38 management, we selected studies published from the year 2000 onwards. Although both
39
40 observational studies and RCTs were eligible for inclusion, we did not include RCTs that were
41
42 not designed to assess CVD events as a pre-specified outcome to avoid bias.
43
44
45
46

47 Working independently and in duplicate, two reviewers (OE and GB) scanned the titles and
48
49 abstracts of the retrieved records for eligibility. The full-text articles of potentially eligible
50
51 studies were obtained and reviewed in greater details. Disagreements in study selection were
52
53
54
55
56
57
58
59
60

1
2
3 resolved through discussion, and where necessary, a third investigator (RSH) was invited to
4 facilitate consensus.
5
6
7
8
9

10 **Data extraction and quality assessment**

11
12
13 The same two reviewers (OE and GB) conducted data extraction independently using a pre-
14 designed data abstraction sheet. We extracted data on study descriptors, sample characteristics,
15 outcome assessment, risk estimate for relevant comparisons, and study quality features. Where
16 necessary, we sought clarification directly from study authors through email contact. In cases
17 where data from the same study described the same event risk in multiple publications, we
18 extracted data from the most comprehensive report while supplementing missing study-level
19 information from the others.
20
21
22
23
24
25
26
27
28
29
30

31
32 The quality of the included studies was assessed according to risk of bias criteria based on the
33 type of study design. Briefly, we made this assessment by evaluating study design features
34 including participant selection, comparability of groups, exposure and outcome assessments,²⁴ as
35 only observational studies were eventually included in the meta-analysis since eligible RCTs
36 were not identified.
37
38
39
40
41
42
43
44
45

46 **Patient and public involvement**

47
48 No patients were involved in this study. We used data from published materials only
49
50
51

52 **Data analysis**

1
2
3 We calculated the kappa statistic as a measure of the inter-reviewer agreement for the selection
4 of articles meeting the inclusion/exclusion criteria. For interpretation, we defined *a priori* the
5 interval for the kappa result using Landis and Koch criteria.²⁵ For effect measure, we assumed
6 the incidence rate ratio (IRR), odds ratio (OR) and hazard ratio (HR) with corresponding
7 sampling variance to be numerical approximate measures of the relative risk (RR) for a given
8 association of interest with the underlying assumption of a generally low event risk (< 20%),²⁶⁻³¹
9 and thus combined them as previously described.^{19 32-35} We tested this assumption in sensitivity
10 analyses by performing separate meta-analyses where studies presenting results reported using a
11 similar effect measure type were pooled. Given the expected variability among eligible studies,
12 we pooled studies using the DerSimonian-Laird random-effects model.³⁶ To minimize bias in our
13 pooled estimates, adjusted risk estimates were not combined with unadjusted estimates. The final
14 set of studies that adjusted for confounders did not consistently adjust for the same set of
15 confounders but were deemed to have sufficient internal validity to permit pooling. Given the
16 limitations of the I^2 statistics with observational studies and Cochran Q test when the number of
17 studies is small,^{37 38} we assessed heterogeneity by visual inspection of the forest plots for overlap
18 in the confidence intervals of the individual studies, although the I^2 and Cochran Q are reported
19 in the forest plots for completeness sake. We were unable to perform meta-regression analyses to
20 assess the potential effect of study-level covariates on the pooled estimate due to insufficient
21 studies (< 10),³⁹ in each of the meta-analyses. A p-value < 0.05 was considered statistically
22 significant. The meta-analysis was conducted using the *metafor* package of the R statistical
23 program (version 3.3.1)⁴⁰.

RESULTS

Of 8,130 records identified through the database search, the final screening process yielded 64 potentially eligible publications on CVD outcomes, 32 of which had relevant data on MI and were included in this meta-analysis (Figure 1). Overall, there was near perfect agreement between reviewers on the inclusion of studies (kappa statistic = 0.94; 95% confidence interval (95%CI): 0.89, 0.99). The included studies, most of which were conducted in the United States and Europe, were published between 2000 and 2017 and involved approximately 383,471 HIV+ and > 798, 424 HIV- individuals (Appendix Table 2: characteristics of the included studies; *note: the number of individuals in cohorts with multiple publications was accessed only from one of the publications*). The mean duration of follow-up varied across studies from approximately one to twenty years. All 32 publications were non-randomized studies and included two nested case-control studies,^{11 41} one cohort/nested case-control study,⁴² and 29 cohort studies; 15 of which were prospective studies, by design.^{3 7 8 13 43-53} Twenty-nine studies were published as full-text journal articles, while three were available as conference abstracts.

In general, the reporting and quality of the methodological aspects of the included studies were variable. Three studies did not provide sufficient information necessary to assess the study quality, as they were reported and available as conference abstract/poster.^{46 48 54} The eligibility criteria were clearly defined in the majority of studies (94%), description of study participants/groups was sufficient (100%); however, the exposure or outcome was not adequately ascertained in 15 studies (47%);^{8 12 42 45 47 51 54-62} one (7%) of which was published as an abstract⁵⁴ (see Appendix Table 3: risk of bias in the included studies).

Meta-analysis of the risk of MI

Below, we summarize the results of the meta-analyses of MI risk according to the various risk stratifications assessed. To avoid duplication of reporting, only statistically important RR are stated in text; although both statistically significant and insignificant results are presented in the figures (forest plots).

The pooled RR from the seven studies that met eligibility for this assessment of MI risk according to HIV serostatus suggests that HIV+ individuals are more likely to have an MI event compared to uninfected individuals (RR: 1.60; 95%CI: 1.38, 1.85).^{3 42 43 47 61 63 64} Figure 2 shows the forest plots for the association between HIV serostatus and MI risk. Two studies assessed the risk of MI by HIV serostatus according to whether ART treatment was received.^{51 65} Relative to uninfected individuals, the pooled RR of MI was significantly higher only among ART-treated individuals (RR: 1.80; 95%CI: 1.17, 2.77), and not the ART-untreated HIV+ individuals (RR: 1.25; 95%CI: 0.93, 1.67).

The pooled RR based on combining data from three studies suggests that low CD4 cell count (< 200 cells/mm³) is associated with higher MI risk compared to CD4 ≥ 200 (RR: 1.60; 95%CI: 1.25, 2.04).^{3 48 60} Conversely, a high pVL ($\geq 100,000$ copies/mL) was found to be associated with increased MI risk compared to pVL $< 100,000$ (RR: 1.45; 95%CI: 1.11, 1.90), based on the pooled results from two studies (Figure 3).^{45 60}

With regards to *recent treatment exposure* (i.e. within the preceding six months), four eligible studies with data on nucleoside reverse transcriptase inhibitors (NRTI) exposure assessed the risk

1
2
3 of MI associated with recent compared to not recent abacavir exposure.^{42 44 46 58} The pooled result
4
5 from these four studies suggests that recent abacavir exposure is associated with increased risk of
6
7 MI compared to not recent exposure (RR: 1.71; 95%CI: 1.39, 2.10). Similarly, recent didanosine
8
9 (RR: 1.29; 95%CI: 1.04, 1.60),^{42 49 58} and lamivudine (RR: 1.50; 95%CI: 1.18, 1.90),^{13 42 58}
10
11 exposure is associated with increased risk of MI compared to not recent exposures. In contrast,
12
13 there was no association between recent tenofovir,^{42 49 58} zidovudine,^{13 42 58} stavudine,^{13 42 58}
14
15 emtricitabine,^{42 58} and MI risk compared to not recent exposure (Figure 4). Based on pooling data
16
17 from two studies with data on non-nucleoside reverse transcriptase inhibitors (NNRTI)
18
19 exposure,^{42 58} no association was found between recent efavirenz or nevirapine exposure and MI
20
21 risk compared to not recent exposure (Figure 5). Based on pooled results from the studies
22
23 assessing the MI risk of individual PIs, recent indinavir was associated with increased MI risk
24
25 compared to not recent exposure (RR: 1.46; 95%CI: 1.08, 1.95).^{42 58} Recent exposure to other PI
26
27 regimens including atazanavir,^{42 58} lopinavir,^{42 58} ritonavir,^{42 58} nelfinavir,^{42 58} and saquinavir,^{42 58}
28
29 was not found to be significantly associated with MI risk compared to not recent exposure
30
31 (Figure 6).
32
33
34
35
36
37
38
39

40 In terms of *any treatment exposure*, our meta-analysis did not find an association between
41
42 exposure to ART and risk of MI compared to no exposure (Appendix Figure A1).^{53 65} Based on
43
44 the pooled results from six studies with data on NRTI exposure,^{8 11 13 42 54 60} individuals receiving
45
46 abacavir were more likely to have an MI compared to those who did not (RR: 1.58; 95%CI: 1.25,
47
48 2.00). We found a similar association between didanosine exposure and MI risk (RR: 1.48; 1.16,
49
50 1.90).^{13 42 60} No important association was found between exposure to tenofovir,^{42 60}
51
52 zidovudine,^{13 42} stavudine,^{13 42 60} emtricitabine,^{42 60} and MI risk, based on our pooled results
53
54
55
56
57
58
59

1
2
3 (Appendix Figure A2). The meta-analysis of studies with data on NNRTI exposure did not find
4 any evidence of an association between either efavirenz,^{42 56} or nevirapine exposure,^{42 60} and MI
5 risk compared to no exposure (Appendix Figure A3). The pooled RR from four studies
6 demonstrates that PI exposure is associated with an increase in the risk of MI events compared to
7 no exposure to PI (RR: 1.49; 95%CI: 1.16, 1.91).^{3 6 52 54} When the analysis was limited to two
8 studies comparing recent PI exposure to no exposure,^{3 54} similar results were found (RR: 1.40;
9 95%CI: 1.16, 1.69 [data not shown]). For the individual PIs, there was no association between
10 either atazanavir,^{42 55 57 60} saquinavir,^{42 60} or nelfinavir exposure,^{42 60} and MI risk, compared to no
11 exposure (Appendix Figure A4).
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 With regards to *cumulative treatment exposure*, three eligible studies provided relevant data
27 regarding the risk of MI and cumulative ART exposure.^{12 60 62} We found that cumulative
28 exposure to ART was associated with an increase in the risk of MI per year of exposure (RR:
29 1.12; 95%CI: 1.06, 1.18) (Appendix Figure A5). For exposure to NRTI regimens, we estimated
30 an increase in MI risk per year of exposure to abacavir (RR: 1.08; 95%CI: 1.01, 1.15) based on
31 pooling data from two eligible studies.^{12 49} Similar to abacavir, cumulative zidovudine exposure
32 was associated with an increase in MI risk per year of exposure (RR: 1.05; 95%CI: 1.01, 1.10).¹¹
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

¹³ We found no association between cumulative exposure to either didanosine,^{11 13} tenofovir,^{11 49} lamivudine,^{11 13} or stavudine,^{11 13} and MI risk per year of exposure (Appendix Figure A6). The overall RR suggests that cumulative NNRTI exposure as a class (RR: 1.02; 95%CI: 0.97, 1.08),⁵⁰ or as individual drugs (nevirapine, and efavirenz),^{11 49} is not significantly associated with increased risk of MI events per year of exposure (Appendix Figure A7). Three eligible studies reported data assessing the risk of MI associated with cumulative exposure to PIs as a class.^{50 62}

1
2
3 ⁶⁵ There was an increase in risk of MI per year of exposure to PIs (RR: 1.14; 95%CI: 1.03, 1.26).
4
5 For individual drugs, cumulative exposure to lopinavir with ritonavir (RR: 1.19; 95%CI: 1.03,
6
7 1.39),^{11 49} but not nelfinavir,^{11 49} was found to be associated with increase in the risk of MI events
8
9 per year of exposure (Appendix Figure A8).
10
11
12
13

14
15 The strength and direction of the overall RR from the various meta-analyses remained robust in
16
17 sensitivity analyses where estimates reported using similar effect measures were pooled. For
18
19 example, HIV+ individuals continued to have higher risk of MI events compared to uninfected
20
21 individuals when pooled using either IRRs (overall effect: 1.51; 95%CI: 1.13, 2.01) or HRs
22
23 (overall effect: 1.75; 95%CI: 1.24, 2.48) effect measures, compared to a RR of 1.60; 95%CI:
24
25 1.38, 1.85, obtained from pooling results reported using multiple relative effect measures
26
27 (Appendix Figure A9).
28
29
30
31
32

33 **DISCUSSION**

34
35 This updated systematic review and meta-analysis assessing the risk of MI among people living
36
37 with HIV reflects contemporary ART era and found the following: (1) HIV+ individuals have a
38
39 greater risk of MI compared to uninfected individuals; and among HIV+ individuals, (2) low
40
41 CD4 cell count (< 200 cells/mm³) and high pVL (> 100,000 copies/mL) are associated with
42
43 increases in MI risk compared to higher CD4 or lower pVL respectively; (3) cumulative ART
44
45 exposure is associated with a greater risk of MI per year of exposure; (4) among NRTIs, any type
46
47 of exposure to abacavir; cumulative exposure to zidovudine; and recent exposure to either
48
49 didanosine or lamivudine are significantly associated with higher risk of MI; (5) compared to no
50
51 exposure, any or cumulative exposure to PIs as a class; cumulative exposure to lopinavir with
52
53
54
55
56
57
58
59
60

1
2
3 ritonavir; and recent indinavir exposure was associated with higher risk of MI; (6) NNRTIs
4 assessed either as a class or individually were not associated with increased MI risk.
5
6
7
8
9

10 Previous meta-analyses comparing CVD risk among HIV+ and uninfected individuals reported
11 estimates for the association between HIV-seropositivity and MI (RR: 1.75)¹⁹ or CVD (RR:
12 1.61)²⁰ risk that are similar to our findings (RR: 1.60). Relative to uninfected individuals and
13 similar to what we found (RR: 1.80), one of these studies also reported a higher risk of CVD
14 among ART-treated individuals (RR: 2.00).²⁰ As has been previously hypothesized,^{3 66-69} the
15 probable mechanistic pathway through which HIV infection can induce MI may include a
16 cascade of events involving chronic inflammation, immunodeficiency/CD4 cell depletion,
17 endothelial dysfunction, increased thrombosis and accelerated atherosclerosis that typically
18 accompany both controlled and uncontrolled HIV disease. We suspect that the higher MI risk
19 among ART-treated HIV+ individuals may not necessarily be attributable to ART alone but
20 rather to the combined effect from a host of factors including HIV itself, ART, and other
21 comorbid risk factors which have been individually shown to contribute to MI risk.^{3 5 70 71}
22 Furthermore, the risk associated with cumulative ART exposure may be an index of the duration
23 of HIV infection with its attendant inflammation, and not entirely the effect of cumulative
24 exposure to ART per se.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Specific to abacavir and MI risk, our findings were similar to reports from a previous meta-
48 analysis of observational studies of MI,¹⁶ but different from those of the meta-analysis of
49 RCTs,^{17 18} or reports from aggregate clinical trial studies,^{14 15} that suggested no risk associated
50 with abacavir exposure. Although observational studies and RCT results regarding MI and CVD
51
52
53
54
55
56
57
58
59
60

1
2
3 risk due to abacavir exposure among people living with HIV are largely at odds, the
4
5 Simplification with Tenofovir-Emtricitabine or Abacavir-Lamivudine (STEAL) trial is the first
6
7 RCT to support observational studies finding of increased risk of CVD with exposure to
8
9 abacavir.⁷² Based on the available evidence to date, the controversy regarding the potential
10
11 association between abacavir use and risk of MI will likely continue to plague the field of HIV
12
13 therapeutics until such a time when definitive evidence describing the underlying mechanism can
14
15 be produced.^{73 74} A sufficiently powered RCT with long follow-up and including real-world
16
17 populations reflective of those typically seen clinically may be needed to fully resolve this
18
19 clinical controversy.
20
21
22
23
24
25

26 Unlike our results where a class-level effect was evident for PIs, pooled aggregate clinical trial
27
28 data after one year of treatment with four different PI-based regimens did not find evidence of an
29
30 increased risk associated with PI compared to NRTI regimen (RR: 1.69; 95%CI: 0.54, 7.48).⁷⁵
31
32 When we pooled data of individual PIs separately, we did not observe the same ‘class-level’
33
34 results. In our analysis, different PI regimens carried different risks. For example, while recent
35
36 indinavir and cumulative lopinavir-ritonavir exposure were associated with increased MI risk,
37
38 nelfinavir or atazanavir did not appear to contribute to MI risk irrespective of the type of
39
40 exposure data that were pooled.
41
42
43
44
45
46

47 In terms of the scope and design, our study differs from previous meta-analyses on this topic in
48
49 several ways. First, we used an expanded search strategy that included more data sources and
50
51 search of conference archives compared to prior meta-analyses.¹⁶⁻²⁰ Second, as the association of
52
53 HIV and ART may affect the risk of MI and other CVD events differently, we did not assess the
54
55
56
57
58
59

1
2
3 risk of CVD in general, as was done in previous meta-analysis.²⁰ Third, we have used more
4 recent risk estimates from studies with longer follow-up such as the Data Collection on Adverse
5 Events of Anti-HIV Drugs (D:A:D) study. Fourth, we have included studies published between
6
7 2000 and 2017 with reported data from the post-ART era. The historical nature of some of the
8 studies included in previous meta-analysis may have limited their relevance in contemporary
9
10 times. Finally, this systematic review analyzed several additional drug exposure comparisons and
11 clinical measures (e.g. CD4 cell count, plasma viral load) in relation to MI risk that had not been
12
13 previously examined.
14
15
16
17
18
19
20
21
22
23

24 There are several important considerations that should be taken into account in the interpretation
25 of the results of this study. Accurate characterization of the risk of MI and CVD outcomes in
26 general may be confounded by a number of factors that may have affected our conclusions. The
27 first concern has to do with the differences in the risk factors, drug exposure, HIV-related
28 variables, or population considered in the included studies. No two studies of HIV+ individuals
29 can have participants with the same demographic, clinical and drug exposure profile – all of
30 which play a role in overall health outcomes. Therefore, heterogeneity arising from differences
31 in study design features may have influenced the results and thus the overall conclusions drawn.
32
33 Although we observed heterogeneity across results of studies included in some of the meta-
34 analyses, this is a common limitation in meta-analysis especially those involving observational
35 studies.³⁷ Our *a priori* choice of employing the random-effects modeling strategy was driven in
36 part by this expected variability among studies.⁷⁶ It is unclear how differences in MI definition
37 may have affected our results. While some studies retrospectively assessed MI and relied on
38 International Classification of Diseases (ICD) codes alone, others followed participants over time
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and prospectively assessed and validated the MI events.^{5 44} Furthermore, our study combined
4 results presented using several different relative effect measures with the assumption that these
5 represent approximately the same numerical value.²⁶⁻³¹ In sensitivity analyses, we did not find
6 any evidence of bias in our pooled estimates, as these did not differ importantly from the pooled
7 estimates we obtained when we combined studies reporting results using the same effect
8 measure. Moreover, we reached comparable conclusions with previous meta-analyses that
9 combined,¹⁹ or did not combine HR estimates with OR, and RR.¹⁶
10
11
12
13
14
15
16
17
18
19
20

21 CONCLUSIONS

22
23 In summary, this updated systematic review and meta-analysis suggests that HIV infection, ART
24 use in general including exposure to specific ART class (e.g. PIs) and regimen (e.g. abacavir) are
25 associated with increased risk of MI. We found the totality of the evidence for an association
26 between HIV infection and MI to be compelling. With respect to ART and MI risk, HIV
27 treatment strategies should certainly consider cardiovascular risk factors including exposure to
28 particular ART drugs as part of patient-tailored care. However, given what we currently know
29 about ART's effectiveness, the benefits of ART for the treatment of HIV infection in terms of
30 viral suppression and immune reconstitution should be balanced against its potential unfavorable
31 impact on MI. Specific to abacavir and MI risk where there is conflicting evidence between
32 observational studies and RCTS, additional rigorously conducted studies in real-world
33 populations are needed to definitively validate our findings and strengthen the existing evidence
34 on this topic. Given the multiple potential contributory and mechanistic pathways to developing
35 MI among HIV+ individuals and the complexity/feasibility of designing a large enough study to
36 completely tease apart the potential contributions of each of the factors believed to increase the
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 risk of MI, managing known modifiable risk factors for CVD outcomes (e.g. smoking) through
4 behavioural/lifestyle interventions, would be an excellent first step in reducing the incidence and
5 risk of MI among people living with HIV.
6
7
8
9

10
11
12 **Study registration number:** PROSPERO ID# CRD2014012977
13
14

15 16 17 **Acknowledgements**

18
19 We thank Simon Fraser University library staffs for the assistance provided during the search
20 strategy development
21
22
23
24
25

26 27 **Author contributions**

28 OE, MWH, SAL, JSGM and RSH conceived and designed the study. OE, GB, and RSH acquired
29 the data. OE performed the statistical analysis with input from CHG, CF, and EM. All authors
30 contributed to the interpretation of the data. OE drafted the manuscript. All authors reviewed the
31 manuscript critically for important intellectual content and approved the final version submitted
32 for publication.
33
34
35
36
37
38
39
40
41

42 43 **Funding**

44 There was no funding for this study. The corresponding author had full access to all the data in
45 the study and had final responsibility for the decision to submit for publication.
46
47
48
49
50

51 52 **Competing interests**

53 We declare no competing interests
54
55
56
57
58
59
60

1
2
3
4
5 **Patient consent**
6

7
8 None required
9
10
11
12
13

14 **Data sharing statement**
15

16
17 All data and materials used in this research are available in Medline/PubMed. References have
18
19 been provided.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 2010;50(10):1387-96. doi: 10.1086/652283
2. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet* 2014;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA internal medicine* 2013;173(8):614-22. doi: 10.1001/jamainternmed.2013.3728
4. Marcus JL, Leyden WA, Chao CR, et al. HIV infection and incidence of ischemic stroke. *AIDS* 2014;28(13):1911-9. doi: 10.1097/QAD.0000000000000352
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 2003;349(21):1993-2003. doi: 10.1056/NEJMoa030218
6. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *AIDS* 2003;17(17):2479-86. doi: 10.1097/01.aids.0000096857.36052.23
7. D:A:D Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;356(17):1723-35. doi: 10.1056/NEJMoa062744

- 1
2
3 8. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-
4
5 infected patients on highly active antiretroviral therapy: a population-based nationwide
6
7 cohort study. *HIV Med* 2010;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x
8
9
- 10 9. Strategies for Management of Anti-Retroviral Therapy/Insight, D:A:D. Study Groups. Use of
11
12 nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-
13
14 infected patients. *AIDS* 2008;22(14):F17-24. doi: 10.1097/QAD.0b013e32830fe35e
15
16
- 17 10. Bozzette SA, Ake CF, Tam HK, et al. Long-term survival and serious cardiovascular events
18
19 in HIV-infected patients treated with highly active antiretroviral therapy. *J Acquir*
20
21 *Immune Defic Syndr* 2008;47(3):338-41. doi: 10.1097/QAI.0b013e31815e7251
22
23
- 24 11. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk
25
26 of myocardial infarction in human immunodeficiency virus-infected patients: a case-
27
28 control study nested within the French Hospital Database on HIV ANRS cohort CO4.
29
30 *Archives of internal medicine* 2010a;170(14):1228-38. doi:
31
32 10.1001/archinternmed.2010.197
33
34
- 35 12. Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial
36
37 infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin*
38
39 *Infect Dis* 2011;53(1):84-91. doi: 10.1093/cid/cir269
40
41
- 42 13. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase
43
44 inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the
45
46 D:A:D study: a multi-cohort collaboration. *Lancet* 2008a;371(9622):1417-26. doi:
47
48 10.1016/S0140-6736(08)60423-7
49
50
- 51 14. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir
52
53 therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult
54
55
56
57
58
59
60

- 1
2
3 subjects. *J Acquir Immune Defic Syndr* 2009;51(1):20-8. doi:
4
5 10.1097/QAI.0b013e31819ff0e6
6
7
8 15. Ribaldo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with
9
10 initial antiretroviral treatment containing abacavir: short and long-term results from
11
12 ACTG A5001/ALLRT. *Clin Infect Dis* 2011;52(7):929-40. doi: 10.1093/cid/ciq244
13
14
15 16. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral
16
17 therapy for HIV: a systematic review. *PLoS One* 2013;8(3):e59551. doi:
18
19 10.1371/journal.pone.0059551
20
21
22 17. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial
23
24 infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*
25
26 2012;61(4):441-7. doi: 10.1097/QAI.0b013e31826f993c
27
28
29 18. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease
30
31 events: a meta-analysis of published and unpublished data. *AIDS* 2011;25(16):1993-2004.
32
33 doi: 10.1097/QAD.0b013e328349c6ee
34
35
36 19. Shah ASV, Stelzle D, Lee KK, et al. Global Burden of Atherosclerotic Cardiovascular
37
38 Disease in People Living with the Human Immunodeficiency Virus: A Systematic
39
40 Review and Meta-Analysis. *Circulation* 2018 doi:
41
42 10.1161/CIRCULATIONAHA.117.033369 [published Online First: 2018/07/04]
43
44
45 20. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living
46
47 with HIV: a systematic review and meta-analysis. *HIV Med* 2012;13(8):453-68. doi:
48
49 10.1111/j.1468-1293.2012.00996.x
50
51
52 21. Neaton JD. HIV and cardiovascular disease: comment on Islam et al. *HIV Med*
53
54 2013;14(8):517-8. doi: 10.1111/hiv.12043
55
56
57
58
59

- 1
2
3 22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
4
5 meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264-9, W64.
6
7
8 23. Eyawo O, Brockman G, Lear S, et al. Risk of cardiovascular disease events among HIV-
9
10 positive individuals compared to HIV-negative individuals: a systematic review and
11
12 meta-analysis (number: CRD2014012977). *International prospective register of*
13
14 *systematic reviews (PROSPERO)*, 2014.
15
16 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014012977.
17
18
19 24. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the
20
21 quality of nonrandomised studies in meta-analyses, 2014:
22
23 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed July 28, 2017.
24
25
26 25. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
27
28 *Biometrics* 1977;33(1):159-74.
29
30
31 26. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. *J Clin*
32
33 *Epidemiol* 2002;55(9):893-9.
34
35
36 27. Sedgwick P. Hazards and hazard ratios. *Bmj* 2012;345:e5980.
37
38 28. Hernan MA. The hazards of hazard ratios. *Epidemiology* 2010;21(1):13-5. doi:
39
40 10.1097/EDE.0b013e3181c1ea43
41
42 29. McCullagh P, Nelder JA. Chapter 13: Models for Survival Data. In: McCullagh P, Nelder
43
44 JA, eds. *Generalized Linear Models*. 2nd ed. London, New York: Chapman & Hall/CRC
45
46 1989;pp 419-31.
47
48
49 30. Laird N, Olivier D. Covariance Analysis of Censored Survival Data Using Log-Linear
50
51 Analysis Techniques. *J Am Stat Assoc* 1981;76(374):231-40.
52
53
54
55
56
57
58
59
60

- 1
2
3 31. Symons MJ, Taulbee JD. Practical considerations for approximating relative risk by the
4
5 standardized mortality ratio. *J Occup Med* 1981;23(6):413-6.
6
7
8 32. Fernandez MDM, Saulyte J, Inskip HM, et al. Premenstrual syndrome and alcohol
9
10 consumption: a systematic review and meta-analysis. *BMJ Open* 2018;8(3):e019490. doi:
11
12 10.1136/bmjopen-2017-019490 [published Online First: 2018/04/18]
13
14
15 33. Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a
16
17 systematic review. *Int J Infect Dis* 2015;32:138-46. doi: 10.1016/j.ijid.2014.12.016
18
19
20 34. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of
21
22 physical activity and the prevention of Alzheimer's disease in older adults. *BMC Geriatr*
23
24 2015;15:9. doi: 10.1186/s12877-015-0007-2
25
26
27 35. Bateson D, Butcher BE, Donovan C, et al. Risk of venous thromboembolism in women
28
29 taking the combined oral contraceptive: A systematic review and meta-analysis. *Aust*
30
31 *Fam Physician* 2016;45(1):59-64.
32
33
34 36. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177-
35
36 88.
37
38 37. Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to
39
40 diagnose lung cancer. *JAMA* 2015;313(4):419. doi: 10.1001/jama.2014.16482
41
42
43 38. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *Bmj*
44
45 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557
46
47
48 39. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version
49
50 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011:
51
52 <http://www.cochrane.org/handbook>. Accessed July 27, 2017.
53
54
55
56
57
58
59
60

- 1
2
3 40. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw*
4
5 2010;36(3):1-48.
6
7
8 41. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent
9
10 predictors of the risk of myocardial infarction in HIV-infected individuals. *Clin Infect Dis*
11
12 2012;55(4):600-7. doi: 10.1093/cid/cis489
13
14
15 42. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral
16
17 therapy, and risk of acute myocardial infarction: a cohort and nested case-control study
18
19 using Quebec's public health insurance database. *J Acquir Immune Defic Syndr*
20
21 2011;57(3):245-53. doi: 10.1097/QAI.0b013e31821d33a5
22
23
24 43. Drozd DR, Kitahata MM, Althoff KN, et al. Increased Risk of Myocardial Infarction in HIV-
25
26 Infected Individuals in North America Compared With the General Population. *J Acquir*
27
28 *Immune Defic Syndr* 2017;75(5):568-76. doi: 10.1097/QAI.0000000000001450
29
30
31 44. Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between
32
33 abacavir usage and myocardial infarction risk in individuals with HIV? A cohort
34
35 collaboration. *BMC Med* 2016;14:61. doi: 10.1186/s12916-016-0588-4
36
37
38 45. Salinas JL, Rentsch C, Marconi VC, et al. Baseline, Time-Updated, and Cumulative HIV
39
40 Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. *Clin*
41
42 *Infect Dis* 2016;63(11):1423-30. doi: 10.1093/cid/ciw564
43
44
45 46. Palella FJ, Althoff KN, Moore R, et al. Abacavir use and risk for myocardial infarction in the
46
47 NA-ACCORD [CROI Abstract 749LB]. In Special Issue: Abstracts From the 2015
48
49 Conference on Retroviruses and Opportunistic Infections. *Top Antivir Med* 2015;23(e-
50
51 1):335-36.
52
53
54
55
56
57
58
59
60

- 1
2
3 47. Rasmussen LD, May MT, Kronborg G, et al. Time trends for risk of severe age-related
4
5 diseases in individuals with and without HIV infection in Denmark: a nationwide
6
7 population-based cohort study. *Lancet HIV* 2015;2(7):e288-98. doi: 10.1016/S2352-
8
9 3018(15)00077-6 [published Online First: 2015/10/02]
10
11
- 12 48. Drozd DR, Nance RM, Delaney JAC, et al. Lower CD4 count and higher viral load are
13
14 associated with increased risk of myocardial infarction [CROI abstract 739]. In Special
15
16 Issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections.
17
18 *Top Antivir Med* 2014;22(e-1):377.
19
20
- 21 49. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV
22
23 infection exposed to specific individual antiretroviral drugs from the 3 major drug
24
25 classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect*
26
27 *Dis* 2010;201(3):318-30. doi: 10.1086/649897
28
29
- 30 50. D:A:D Study Group, Sabin CA, d'Arminio Monforte A, et al. Changes over time in risk
31
32 factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected
33
34 individuals and impact on myocardial infarction. *Clin Infect Dis* 2008b;46(7):1101-10.
35
36 doi: 10.1086/528862
37
38
- 39 51. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-
40
41 uninfected individuals: a population-based cohort study. *Clin Infect Dis*
42
43 2007;44(12):1625-31. doi: 10.1086/518285
44
45
- 46 52. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular
47
48 outcomes in patients with HIV-1. *Lancet* 2002;360(9347):1747-8. doi: 10.1016/S0140-
49
50 6736(02)11672-2
51
52
53
54
55
56
57
58
59
60

- 1
2
3 53. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected
4 patients between 1983 and 1998: the Frankfurt HIV-cohort study. *Eur J Med Res*
5 2000;5(8):329-33.
6
7
8
9
10 54. Carman WJ, Bowlin S, McAfee AT. Human immunodeficiency (HIV) therapy and
11 cardiovascular (CV) events [ICPE Abstract 323]. In: Abstracts from the 27th
12 International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
13 *Pharmacoepidemiol Drug Saf* 2011;20(S140)
14
15
16
17
18
19 55. LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected
20 veterans receiving atazanavir. *AIDS* 2017;31(15):2095-106. doi:
21 10.1097/QAD.0000000000001594
22
23
24
25
26 56. Rosenblatt L, Farr AM, Johnston SS, et al. Risk of Cardiovascular Events Among Patients
27 Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens. *Open*
28 *Forum Infect Dis* 2016a;3(2):ofw061. doi: 10.1093/ofid/ofw061
29
30
31
32
33 57. Rosenblatt L, Farr AM, Nkhoma ET, et al. Risk of cardiovascular events among patients with
34 HIV treated with atazanavir-containing regimens: a retrospective cohort study. *BMC*
35 *Infect Dis* 2016b;16:492. doi: 10.1186/s12879-016-1827-1
36
37
38
39
40 58. Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events associated with current
41 exposure to HIV antiretroviral therapies in a US veteran population. *Clin Infect Dis*
42 2015;61(3):445-52. doi: 10.1093/cid/civ316
43
44
45
46
47 59. Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and
48 tenofovir exposure in HIV-infected persons. *AIDS* 2011;25(10):1289-98. doi:
49 10.1097/QAD.0b013e328347fa16
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 60. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with
4 myocardial infarction rates in a US healthcare system. *J Acquir Immune Defic Syndr*
5 2010;55(5):615-9. doi: 10.1097/QAI.0b013e3181f4b752
6
7
8
9
10 61. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection
11 with acute myocardial infarction. *J Acquir Immune Defic Syndr* 2009;51(3):268-73. doi:
12 10.1097/QAI.0b013e3181a9992c [published Online First: 2009/04/24]
13
14
15
16
17 62. Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events
18 versus death from other causes associated with antiretroviral use. *AIDS*
19 2006;20(15):1941-50. doi: 10.1097/01.aids.0000247115.81832.a1
20
21
22
23
24 63. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among
25 HIV-positive compared with HIV-negative individuals with access to care. *Clin Infect*
26 *Dis* 2015;60(8):1278-80. doi: 10.1093/cid/civ014
27
28
29
30
31 64. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-
32 infected patients in France, relative to the general population. *AIDS* 2010b;24(8):1228-
33 30. doi: 10.1097/QAD.0b013e328339192f
34
35
36
37
38 65. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction
39 among HIV-positive individuals with access to care. *J Acquir Immune Defic Syndr*
40 2014;65(2):160-6. doi: 10.1097/QAI.0000000000000009
41
42
43
44
45 66. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for
46 cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis*
47 2010;51(4):435-47. doi: 10.1086/655144
48
49
50
51 67. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*
52 2005;352(16):1685-95. doi: 10.1056/NEJMra043430
53
54
55
56
57
58
59

- 1
2
3 68. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic
4 mechanisms among HIV-infected patients. *J Infect Dis* 2012;205 Suppl 3:S368-74. doi:
5
6 10.1093/infdis/jis201
7
8
9
10 69. Cerrato E, Calcagno A, D'Ascenzo F, et al. Cardiovascular disease in HIV patients: from
11 bench to bedside and backwards. *Open Heart* 2015;2(1):e000174. doi: 10.1136/openhrt-
12 2014-000174
13
14
15
16
17 70. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and
18 cardiovascular risk factors among patients with human immunodeficiency virus disease. *J*
19 *Clin Endocrinol Metab* 2007;92(7):2506-12. doi: 10.1210/jc.2006-2190 [published
20 Online First: 2007/04/26]
21
22
23
24
25
26 71. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients:
27 epidemiology, pathogenesis, and clinical management. *AIDS* 2010;24(6):789-802. doi:
28 10.1097/QAD.0b013e328337afdf
29
30
31
32
33 72. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-
34 emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. *Clin Infect Dis*
35 2009;49(10):1591-601. doi: 10.1086/644769
36
37
38
39
40 73. Alvarez A, Orden S, Andujar I, et al. Cardiovascular toxicity of abacavir: a clinical
41 controversy in need of a pharmacological explanation. *AIDS* 2017;31(13):1781-95. doi:
42 10.1097/QAD.0000000000001547
43
44
45
46
47 74. Llibre JM, Hill A. Abacavir and cardiovascular disease: A critical look at the data. *Antiviral*
48 *Res* 2016;132:116-21. doi: 10.1016/j.antiviral.2016.05.015
49
50
51 75. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized
52 clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four
53
54
55
56
57
58
59
60

1
2
3 different protease inhibitors. *AIDS research and human retroviruses* 2003;19(6):449-55.

4
5 doi: 10.1089/088922203766774487

6
7
8 76. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis *Psychological*
9
10 *Methods* 1998;3(4):486-504.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Titles and Legends

Figure 1. Flow diagram of study selection

Legend: *, Includes several conference abstract records captured through the database search

ART, Combination antiretroviral therapy; CVD, Cardiovascular disease

Figure 2. Forest plot of the meta-analysis of the risk of MI according to HIV status

Legend: *, this was a general population comparison group and may not have consisted of HIV- individuals only.

Although including this study could potentially be considered a weakness in this meta-analysis, the overall pooled estimate did not change significantly when it was excluded from the meta-analysis in a sensitivity analysis, likely due to the low prevalence of HIV in the general population of the USA (RR: 1.60 [95%CI: 1.38, 1.85] including the study compared to 1.67 [95%CI: 1.45, 1.94] excluding the study); ART, Antiretroviral therapy; CI, Confidence interval

Figure 3. Forest plot of the meta-analysis of CD4 cell count, plasma viral load levels and risk of MI

Legend: CI, Confidence interval

Figure 4. Forest plot of the meta-analysis of recent exposure to drugs of the NRTI class and risk of MI

Legend: CI, Confidence interval

Figure 5. Forest plot of the meta-analysis of recent exposure to drugs of the NNRTI class and risk of MI


Legend: CI, Confidence interval

1
2
3 **Figure 6. Forest plot of the meta-analysis of recent exposure to drugs of the protease**
4
5 **inhibitor class and risk of MI**
6

7
8 Legend: CI, Confidence interval
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



42 **Figure 1. Flow diagram of study selection**

43 **Legend:** *, Includes several conference abstract records captured through the database search
44 ART, Combination antiretroviral therapy; CVD, Cardiovascular disease

45 Figure 1. Flow diagram of study selection

46 152x205mm (300 x 300 DPI)




Figure 2. Forest plot of the meta-analysis of the risk of MI according to HIV status

152x136mm (300 x 300 DPI)




Figure 3. Forest plot of the meta-analysis of CD4 cell count, plasma viral load levels and risk of MI

152x135mm (300 x 300 DPI)




Figure 4. Forest plot of the meta-analysis of recent exposure to drugs of the NRTI class and risk of MI

152x140mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 5. Forest plot of the meta-analysis of recent exposure to drugs of the NNRTI class and risk of MI

152x128mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



152x138mm (300 x 300 DPI)

Appendix

Appendix Table 1. Search strategy

1	hiv.af.
2	human immunodeficiency virus.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
3	acquired immunodeficiency syndrome.af.
4	hiv aids.af.
5	1 or 2 or 3 or 4
6	stroke.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
7	(myocardial infarction or heart attack).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
8	cardiac death.af.
9	cerebrovascular disease.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
10	(ischemic heart disease or Ischaemic heart disease).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
11	(cardiovascular disease or cvd).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
12	6 or 7 or 8 or 9 or 10 or 11
13	5 and 12
14	limit 13 to human
15	limit 14 to english language
16	Limit 15 to yr= "2000 – Current"
17	remove duplicates from 16

Note: The searches were executed in the following four databases: (1) EBM Reviews - Cochrane Central Register of Controlled Trials <June 2018>, (2) EBM Reviews - Cochrane Database of Systematic Reviews <2005 to July 11, 2018>, (3) Embase <1974 to 2018 July 17>, (4) Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily <1946 to July 17, 2018>

Study selection

The excluded studies included several key CVD review articles,¹⁻⁸ and aggregate clinical trial studies,⁹⁻¹² whose bibliographies were screened for identification of additional relevant studies. We also excluded a number of potentially eligible records when more comprehensive or updated results for the same participants and risk comparison were published in another report;¹³⁻¹⁶ risk associations were reported in a way that would not allow for pairwise grouping with other studies reporting similar associations to facilitate pooling of results;¹⁷⁻²¹ or results were reported as number of events or unadjusted risk estimates only.²²⁻²⁵

Note: the references cited in the paragraph above are listed at the end of the appendix

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Appendix Table 2. Characteristics of included studies

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
LaFleur <i>et al</i> 2017 ⁵⁵	Cohort	USA	ATV-cohort: 12 months Non-ATV: 13 months	HIV+	ATV-cohort: 1,529 (96) Non-ATV: 7,971 (92)	50 years	MI	ATV exposure vs. not exposed	HR ^β
Drozd <i>et al</i> 2017 ⁴³	Cohort	North America	HIV+: 4.5 years HIV-: 19.7 years	HIV+/HIV- (NA-ACCORD / ARIC)	HIV+: 28,912 (81) HIV-: 14,308 (44)	HIV+: 80% were < 50 years HIV-: 27% were < 50 years	Type 1 MI	HIV+ vs. HIV- ^{**}	IRR ^β
Rosenblatt <i>et al</i> 2016a ⁵⁶	Cohort	USA	EFV-cohort: 23.2 months EFV-free: 19.3 months	HIV+	EFV-cohort: 11,978 (86) EFV-free: 10,234 (79)	EFV-cohort: 40.2 years EFV-free: 40.7 years	MI	EFV exposure vs. not exposed	HR ^β
Rosenblatt <i>et al</i> 2016b ⁵⁷	Cohort	USA	ATV-cohort: 24 months ATV-free: 21 months	HIV+	ATV-cohort: 2,437 (76) ATV-free: 19,774 (84)	ATV-cohort: 41.0 years ATV-free: 40.4 years	MI	ATV exposure vs. not exposed	HR ^β
Sabin <i>et al</i> 2016 ⁴⁴	Cohort	Multi-national	7.0 (4.4-11.1) years ^a	HIV+	49,717 (74)	38 (32-44) years ^a	MI	Current ABC exposure vs. not current (1999-2013)	IRR ^β
Salinas <i>et al</i> 2016 ⁴⁵	Cohort	USA	1996-2012 (follow-up)	HIV+	8,168 (97)	46 (40-53) years ^a	AMI	VL at ART initiation ≥ 100,000 copies/mL vs. < 100,000	HR ^β
Desai <i>et al</i> 2015 ⁵⁸	Cohort	USA	~6.7 years	HIV+	24,510 (98)	46.5	MI	Current exposure to ABC vs. not currently exposed Current exposure to DDI vs. not currently exposed Current exposure to ATV vs. not currently exposed Current exposure to TDF vs. not currently exposed Current exposure to LPV vs. not currently exposed Current exposure to FTC vs. not currently exposed Current exposure to 3TC vs. not currently exposed Current exposure to d4T vs. not currently exposed Current exposure to ZDV vs. not currently exposed Current exposure to IDV vs. not currently exposed	OR ^β /HR ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Current exposure to NFV vs. not currently exposed Current exposure to SQV vs. not currently exposed Current exposure to RTV vs. not currently exposed Current exposure to EFV vs. not currently exposed Current exposure to NVP vs. not currently exposed	
Klein <i>et al</i> 2015 ⁶³	Cohort	USA	HIV+: 4.8 years HIV-: 5.8 years	HIV+/HIV-	282,368 (91)	HIV+: 41 years HIV-: 40 years	MI	HIV+ vs HIV-	IRR ^β
Palella <i>et al</i> 2015 ⁴⁶	Cohort	USA	~3.9 years	HIV+	16,733 (81)	Reported proportion of individuals by age categories	MI	Recent ABC use vs. non-recent use	HR ^β
Rasmussen <i>et al</i> 2015 ⁴⁷	Cohort	Denmark	HIV+: 55,050–57,631 PYs HIV-: 638,204–659,237 PYss	HIV+/HIV-	HIV+: 5,897 (76) HIV-: 53,073 (76)	HIV+: 36.8 years ^a HIV-: 36.8 years ^a	MI	HIV+ vs. HIV-	IRR ^β
Drozdz <i>et al</i> 2014 ⁴⁸	Cohort	USA	1996-2012 (follow-up) NR	HIV+ HIV+	18,155 (NR) 17,626 (79)	NR Reported proportion of individuals by age categories	MI Primary MI	Current HIV RNA (log (copies/mL)+1) CD4 < 200 vs ≥ 200	OR ^β HR ^β
Silverberg <i>et al</i> 2014 ⁶⁵	Cohort	USA	HIV+: 4.5 years HIV-: 5.4 years	HIV+/HIV-	HIV+: 22,081 (90.6) HIV-: 230,069 (90.5)	Reported proportion of individuals by age categories	MI	ART-treated HIV+ vs. HIV- ART-untreated HIV+ vs. HIV- Recent HIV RNA (per 1 log increase) Prior ART (yes vs no) Duration of PI use per year increase Duration of NNRTI use per year increase	IRR ^β
Freiberg <i>et al</i> 2013 ³	Cohort	USA	5.9 years ^a	HIV+/HIV-	HIV+: 27,350 (97.3) HIV-: 55,109 (97.2)	HIV+: 48.2 years HIV-: 48.8 years	AMI	HIV+ vs. HIV- Recent CD4 < 200 (yes/no) Recent PI use (yes/no)	HR ^β
Lang <i>et al</i> 2012 ⁴¹	Nested case control	France	4.0 years	HIV+	Cases: 289 (88.9) Controls: 884 (89.1)	Cases: 47 (41-54) years ^a	MI	Current ABC vs not current HIV RNA per log10 increase	OR ^β

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
						Controls: 46 (40-54) years ^a			
Bedimo <i>et al</i> 2011 ¹²	Cohort	USA	3.9 years ^a	HIV+	19,424 (98)	46 years ^a	AMI	Cumulative ABC HAART per year of exposure Current ABC HAART vs. neither ABC/TDF Cumulative ARV per year of exposure	HR ^β
Choi <i>et al</i> 2011 ⁵⁹	Cohort	USA	4.5 years ^a	HIV+	10,931 (98)	46 to 49 years (within subgroups by ART use)	MI	Recent ABC vs. not recent ABC or TDF	HR ^β
Durand <i>et al</i> 2011 ⁴²	Cohort	Canada	4.0 years	HIV+/HIV-	HIV+: 7,053 (78); HIV-: 27,681 (78) Cases: 125 (91.2); Controls: 1,084 (92.2)	HIV+: 39.5 years	AMI	HIV+ vs. HIV-	HR ^β
	Nested case control			HIV+		HIV-: 39.7 years Cases: 49.0 years Controls: 47.5 years	AMI	ABC exposure vs. no exposure Recent ABC vs. not recent DDI exposure vs. no exposure Recent DDI vs. not recent TDF exposure vs. no exposure Recent TDF vs. not recent ATV exposure vs. no exposure Recent ATV vs. not recent Recent LPV vs. not recent Recent RTV vs. not recent Recent EFV vs. not recent NVP exposure vs. no exposure Recent NVP vs. not recent FTC exposure vs. no exposure Recent FTC vs. not recent Recent 3TC vs. not recent d4T exposure vs. no exposure Recent d4T vs. not recent ZDV exposure vs. no exposure Recent ZDV vs. not recent Recent IDV vs. not recent	OR ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								NFV exposure vs. no exposure Recent NFV vs. not recent SQV exposure vs. no exposure Recent SQV vs. not recent	
Carman <i>et al</i> 2011 ⁵⁴	Cohort	USA	1998-2007 (follow-up)	HIV+	66,286 (NR)	NR	AMI	Recent ABC use vs. no use Recent PI use vs. no use	IRR ^β
Lang <i>et al</i> 2010b ⁶⁴	Cohort	France	2000-2006 (follow-up)	HIV+/ general population	HIV+: ~ 74,958 General population: unclear	35 to 64 years	MI	HIV+ vs general population	SMR
Lang <i>et al</i> 2010a ¹¹	Nested case control	France	2000-2006 (follow-up)	HIV+	Cases: 289 (89) Controls: 884 (89)	Cases: 47 (41-54) years ^a Controls: 46 (40-54) years ^a	MI	Recent ABC exposure vs. no exposure Cumulative ABC exposure vs. no exposure Cumulative DDI per year of exposure Cumulative TDF per year of exposure Cumulative ZVD per year of exposure Cumulative EFV per year of exposure Cumulative NVP per year of exposure Cumulative LPV + RTV per year of exposure Cumulative NFV per year of exposure Cumulative 3TC exposure per year Cumulative d4T exposure per year	OR ^β
Obel <i>et al</i> 2010 ⁸	Cohort	Denmark	~ 6.5 years	HIV+	2,952 (76.4)	39.1 (33.0-46.6) years ^a	MI	ABC exposure vs. no exposure	IRR ^β
Worm <i>et al</i> 2010 ⁴⁹	Cohort	Multi-national	5.8 (3.9-7.5) years ^a	HIV+	33,308 (74)	With MI: 49 (43-65) years ^a Without MI: 44 (38-50) years ^a	MI	Cumulative ABC exposure per year	Relative rate ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Recent TDF exposure vs. not recent Cumulative TDF exposure per year Recent DDI exposure vs. not recent Cumulative LPV-RTV exposure per year Cumulative NFV exposure per year Cumulative NVP exposure per year Cumulative EFV exposure per year	
Triant <i>et al</i> 2010 ⁶⁰	Cohort	USA	5.1 years ^a	HIV+	6,517 (69)	46 years	AMI	CD4 count < 200/mm ³ vs ≥ 200 Nadir CD4 per 50/mm ³ increase VL > 100,000 copies/mL vs. ≤ 100,000 HIV RNA per log 10 increase ART per year since first ART use TDF use vs. none ABC use vs. none DDI use vs. none FTC use vs. none d4T use vs. none NVP use vs. none ATV use vs. none NFV use vs. none SQV use vs. none	OR ^β
Triant <i>et al</i> 2009 ⁶¹	Cohort	USA	HIV+: 6.0 years HIV-: 5.8 years	HIV+/HIV-	HIV+: 487 (62.8) HIV-: 69,870 (45.6)	HIV+/HIV-: Reported proportion by age categories	AMI	HIV+ vs. HIV-	OR ^β
D:A:D Study Group <i>et al</i> 2008a ¹⁵	Cohort	Multi-national	5.1 years ^a	HIV+	33,347 (74)	With MI: 49 (range: 24-92) years ^a Without MI: 44 (range: 12-95) years ^a	MI	Recent ABC exposure vs. never exposed to ABC Recent DDI exposure vs. never exposed Cumulative DDI exposure per year	Relative rate ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Recent ZDV exposure vs. never exposed Recent ZDV exposure vs. not recent Cumulative ZDV exposure per year Recent 3TC exposure vs. not recent Cumulative 3TC exposure per year Recent d4T exposure vs. not recent Recent d4T exposure vs. never exposed Cumulative d4T exposure per year	
D:A:D Study Group <i>et al</i> 2008b ⁵⁰	Cohort	Multi-national	4.5 years ^a	HIV+	28,985 (NR)	Reported by calendar period	MI	Cumulative exposure to PIs per year Cumulative exposure to NNRTIs per year	Relative rate ^b
D:A:D Study Group <i>et al</i> 2007 ⁷	Cohort	Multi-national	4.5 years ^a	HIV+	23,437 (76)	39 (34-45) years ^a	MI	Nadir CD4 per 50 cells/mm ³ increase	Relative rate ^b
Obel <i>et al</i> 2007 ⁵¹	Cohort	Denmark	HIV+: 6.9 years ^a HIV-: 8.1 years ^a	HIV+/ HIV-	HIV+: 3,953 (76.8) HIV-: 373,856 (76.3)	HIV+: 36.8 (30.8-44.6) years ^a HIV-: 36.4 (30.6-44.0) years ^a	MI	HIV+, on HAART+ vs. HIV- HIV+ not on HAART- vs. HIV-	IRR ^b
Kwong <i>et al</i> 2006 ⁶²	Cohort	USA and Netherlands	3.49 (range: 0.02-18.46) years ^a	HIV+	18,603 (82.63)	36 (range: 18-92) years ^a	MI	PI per year of exposure NNRTI per year of exposure HAART per year of exposure	RR ^b
Mary-Krause <i>et al</i> 2003 ⁶	Cohort	France	With MI: 28 (18-39) months ^a Without MI: 33 (15-48) months ^a	HIV+ men	34,976 (100)	With MI: 41.9 years Without MI: 37.7 years	MI	Exposure to PI	Relative hazard ^b
Holmberg <i>et al</i> 2002 ⁵²	Cohort	USA	~ 3.1 years	HIV+	5,672 (82)	42.6 years	MI	PI use (yes vs no)	HR ^b

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
Rickerts <i>et al</i> 2000* ⁵³	Cohort	Germany	24.6 ± 18.1 months	HIV+	2,861 (78)	36.6 ± 9.5 years	MI	Prior HAART (yes vs. no)	OR ^β

Legend: ^α, median (including lower and upper quartiles, where reported); ^β, adjusted estimate; *, extracted data from the ART era only; **, this was a general population comparison group and may not have consisted of HIV- individuals only; Note: a superscript alongside the author name/year is used to denote the reference number of the study; **ABC**, abacavir; **AMI**, acute myocardial infarction; **ARIC**, Atherosclerosis Risk in Communities; **ART**, antiretroviral therapy; **ATV**, atazanavir; **DDI**, didanosine; **d4T**, stavudine; **EFV**, efavirenz; **FTC**, emtricitabine; **HAART**, highly active antiretroviral therapy; **HR**, Hazard ratio; **IDV**, indinavir; **IRR**, incidence rate ratio; **LPV**, lopinavir; **LPV-RTV**, lopinavir-ritonavir; **MI**, myocardial infarction; **NA-ACCORD/ARIC**, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)/Atherosclerosis Risk in Communities (ARIC) cohorts; **NFV**, nelfinavir; **NNRTI**, non-nucleoside reverse transcriptase inhibitor; **NR**, not reported; **NRTI**, nucleoside reverse transcriptase inhibitor; **NVP**, nevirapine; **OR**, Odds ratio; **PI**, protease inhibitor; **RR**, relative risk; **RTV**, ritonavir; **SMR**, standardized morbidity ratio; **SQV**, saquinavir; **TDF**, tenofovir; **VL**, viral load; **ZDV**, zidovudine; **3TC**, lamivudine

Peer review only


Appendix Table 3. Risk of bias in the included studies

Author, year	Publication type	Study design	Clearly defined eligibility criteria	Description of participants/ group(s) selection	Potential for bias in case/group representation	Comparability among group(s) based on design or analysis	Adequate exposure/outcome ascertainment	Sufficient follow-up for outcome occurrence?	Funding source
LaFleur <i>et al</i> 2017 ⁵⁵	Journal	Cohort (R)	+	+	No	+	-	-	Public, industry
Drozd <i>et al</i> 2017 ⁴³	Journal	Cohort (P & R)	+	+	Yes*	-	+	+	Public
Rosenblatt <i>et al</i> 2016a ⁵⁶	Journal	Cohort (R)	+	+	No	+	-	+	Industry
Rosenblatt <i>et al</i> 2016b ⁵⁷	Journal	Cohort (R)	+	+	No	+	-	+	Industry
Sabin <i>et al</i> 2016 ⁴⁴	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Salinas <i>et al</i> 2016 ⁴⁵	Journal	Cohort (P)	+	+	No	+	-	+	Public
Desai <i>et al</i> 2015 ⁵⁸	Journal	Cohort (R)	+	+	No	+	-	+	Public
Klein <i>et al</i> 2015 ⁵³	Journal	Cohort (R)	+	+	No	+	+	+	Private, industry
Palella <i>et al</i> 2015 ⁴⁶	Abstract	Cohort (P & R)	+	+	No	-	+	+	-
Rasmussen <i>et al</i> 2015 ⁴⁷	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Drozd <i>et al</i> 2014 ⁴⁸	Abstract	Cohort (P)	-	+	No	-	+	-	Public
Silverberg <i>et al</i> 2014 ⁶⁵	Journal	Cohort (R)	+	+	No	+	+	+	Private, industry
Freiberg <i>et al</i> 2013 ³	Journal	Cohort (P)	+	+	No	+	+	+	Public
Lang <i>et al</i> 2012 ⁴¹	Journal	Nested case-control	+	+	No	+	+	+	Public
Bedimo <i>et al</i> 2011 ¹²	Journal	Cohort (R)	+	+	No	+	-	+	-
Choi <i>et al</i> 2011 ⁵⁹	Journal	Cohort (R)	+	+	No	+	-	+	Public
Durand <i>et al</i> 2011 ⁴²	Journal	Cohort (R), & nested case-control	+	+	No	+	-	+	Industry
Carman <i>et al</i> 2011 ⁵⁴	Abstract	Cohort (R)	-	+	-	-	-	+	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Publication type	Study design	Clearly defined eligibility criteria	Description of participants/group(s) selection	Potential for bias in case/group representation	Comparability among group(s) based on design or analysis	Adequate exposure/outcome ascertainment	Sufficient follow-up for outcome occurrence?	Funding source
Lang <i>et al</i> 2010a ⁶⁴	Journal	Nested case-control	+	+	No	+	+	+	Public
Lang <i>et al</i> 2010b ¹¹	Journal	Cohort (R)	+	+	No	-	+	+	Public
Obel <i>et al</i> 2010 ⁸	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Worm <i>et al</i> 2010 ⁴⁹	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Triant <i>et al</i> 2010 ⁶⁰	Journal	Cohort (R)	+	+	No	+	-	+	Public
Triant <i>et al</i> 2009 ⁶¹	Journal	Cohort (R)	+	+	No	+	-	+	Public
D:A:D Study Group <i>et al</i> 2008a ¹³	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
D:A:D Study Group <i>et al</i> 2008b ⁵⁰	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
D:A:D Study Group <i>et al</i> 2007 ⁷	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Obel <i>et al</i> 2007 ⁵¹	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Kwong <i>et al</i> 2006 ⁶²	Journal	Cohort (R)	+	+	No	+	-	+	Public, industry
Mary-Krause <i>et al</i> 2003 ⁶	Journal	Cohort (R)	+	+	No	+	+	+	Public
Holmberg <i>et al</i> 2002 ⁵²	Journal	Cohort (P)	+	+	No	-	+	+	Public
Rickerts <i>et al</i> 2000 ⁵³	Journal	Cohort (P)	+	+	No	+	+	+	-


Legend: + means this is clearly described and adequate; - means this is unclear, inadequate or not reported; *, The HIV+ cohort (NA-ACCORD study) was compared to a general population cohort from a different study (Atherosclerosis Risk in Communities [ARIC] study); Note: a superscript alongside the author name/year is used to denote the reference number of the study; **NA**, Not applicable; **P**, Prospective; **R**, Retrospective



Appendix Figure A1. Forest plot of the meta-analysis of any exposure to antiretroviral therapy and risk of MI


Legend: CI, Confidence interval

View only




Appendix Figure A2. Forest plot of the meta-analysis of any exposure to drugs of the NRTI class and risk of MI

Legend: CI, Confidence interval




Appendix Figure A3. Forest plot of the meta-analysis of any exposure to drugs of the NNRTI class and risk of MI


Legend: CI, Confidence interval



36 **Appendix Figure A4. Forest plot of the meta-analysis of any exposure to protease inhibitors (both as**
 37 **a class and individually) and risk of MI**
 38 Legend: CI, Confidence interval




Appendix Figure A5. Forest plot of the meta-analysis of cumulative exposure to antiretroviral therapy (ART) including class of ART and risk of MI per year of exposure
 Legend: ART, Antiretroviral therapy; CI, Confidence interval; NNRTI, Non-nucleoside reverse transcriptase inhibitors; PI, Protease inhibitors




Appendix Figure A6. Forest plot of the meta-analysis of cumulative exposure to drugs of the NRTI class and risk of MI per year of exposure


Legend: CI, Confidence interval



Appendix Figure A7. Forest plot of the meta-analysis of cumulative exposure to NNRTI (both as a class and individually) and risk of MI per year of exposure
 Legend: CI, Confidence interval; NNRTI, Non-nucleoside reverse transcriptase inhibitors



36 **Appendix Figure A8. Forest plot of the meta-analysis of cumulative exposure to protease inhibitors**
 37 **(both as a class and individually) and risk of MI per year of exposure**
 38 Legend: CI, Confidence interval; PI, Protease inhibitors



Appendix Figure A9. Forest plot of the sensitivity analyses for the meta-analysis of the risk of MI according to HIV status, where estimates reported using similar relative effect measures were pooled
 Legend: CI, Confidence interval; HR, Hazard ratio; IRR, Incidence rate ratio

Only

Appendix References (for study selection section only)

1. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. *PLoS One*. 2013;8(3):e59551.
2. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*. 2012;61(4):441-7.
3. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. *AIDS*. 2011;25(16):1993-2004.
4. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *HIV Med*. 2012;13(8):453-68.
5. Friis-Moller N, Smieja M, Klein D. Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. *Curr Opin HIV AIDS*. 2008;3(3):220-5.
6. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. *AIDS*. 2010;24(6):789-802.
7. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. *Eur Heart J*. 2014;35(21):1373-81.
8. Escarcega RO, Franco JJ, Mani BC, Vyas A, Tedaldi EM, Bove AA. Cardiovascular disease in patients with chronic human immunodeficiency virus infection. *Int J Cardiol*. 2014;175(1):1-7.
9. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. *J Acquir Immune Defic Syndr*. 2009;51(1):20-8.
10. Ribaldo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. *Clin Infect Dis*. 2011;52(7):929-40.
11. Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. *AIDS research and human retroviruses*. 2003;19(6):449-55.
12. Da Silva B, Tschampa J, Beron J, Fredrick L, Patwardhan M, Zachry W, et al. Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases. *Int J Clin Pharmacol Ther*. 2012;50(6):391-402.
13. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med*. 2003;349(21):1993-2003.
14. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? *J Acquir Immune Defic Syndr*. 2002;30(5):471-7.
15. Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. *Clin Infect Dis*. 2015;60(4):627-38.
16. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med*. 2010;11(7):462-8.
17. Strategies for Management of Anti-Retroviral Therapy/Insight, D:A:D. Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *AIDS*. 2008;22(14):F17-24.
18. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, et al. Associations between immune depression and cardiovascular events in HIV infection. *AIDS*. 2013;27(17):2735-48.
19. Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. *AIDS*. 2013;27(3):407-15.
20. Brouwer ES, Napravnik S, Eron JJ, Jr., Stalzer B, Floris-Moore M, Simpson RJ, Jr., et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. *Epidemiology*. 2014a;25(3):406-17.
21. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Heckbert SR, Budoff MJ, et al. Incidence and risk of myocardial infarction (MI) by Type in the NA-ACCORD [CROI Abstract 748]. In Special Issue:

1
2
3 Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. *Top Antivir Med.*
4 2015;23(e-1):335.

5 22. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label,
6 prospective, observational study of the incidence of coronary artery disease in patients with HIV infection
7 receiving highly active antiretroviral therapy. *Clin Ther.* 2003;25(9):2405-18.

8 23. Engstrom K, Garcia M. Initial antiretroviral therapy with protease inhibitors is associated with
9 increased risk of heart failure in HIV-infected patients [ACC.14 Abstract 1261-192]. In: Abstracts from the
10 American College of Cardiology 63rd Annual Scientific Session & Expo. *JACC.* 2014;63(12):A955.

11 24. Triant VA, Regan S, Grinspoon SK. MACE incidence among HIV and non-HIV-infected patients
12 in a clinical care cohort [CROI abstract 738]. In Special Issue: Abstracts from the 2014 Conference on
13 Retroviruses and Opportunistic Infections. *Top Antivir Med.* 2014;22(e-1):376-77.

14 25. Brouwer E, Moga D: Differences in myocardial infarction risk among persons living and those not
15 living with HIV: an evaluation of a commercially insured population seeking care in the United States
16 [AIDS Abstract THPE038]. In:20th International AIDS Conference. Melbourne, Australia 2014b.

PROSPERO

International prospective register of systematic reviews

Risk of cardiovascular disease events among HIV-positive individuals compared to HIV-negative individuals: a systematic review and meta-analysis

Oghenowede Eyawo, Gwenyth Brockman, Scott Lear, Charles Goldsmith, Robert Hogg

Citation

Oghenowede Eyawo, Gwenyth Brockman, Scott Lear, Charles Goldsmith, Robert Hogg. Risk of cardiovascular disease events among HIV-positive individuals compared to HIV-negative individuals: a systematic review and meta-analysis. PROSPERO 2014 CRD42014012977 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42014012977

Review question

How does the risk of cardiovascular disease (CVD) events compare between HIV-positive and HIV-negative adults and what are the potential reasons underlying these differences (if any)?

Does the risk of CVD events differ between subgroups of HIV-positive individuals, for example, among those receiving antiretroviral therapy (ART) compared to those not on ART?

How does the risk of CVD events compare between particular subgroup of HIV-positive individuals (e.g., those on ART) versus HIV-negative individuals?

Searches

We will search the following bibliographic databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Databases of Systematic Reviews up to July 2014. Records published from 2000 onwards will be included. This update was necessary to enable us include several key papers that were published between 2000 and 2004.

Abstracts from two major HIV/AIDS conferences (Conference on Retroviruses and Opportunistic Infections [CROI] and the International AIDS Society [IAS] conferences) for the last two years (CROI 2013 & 2014; AIDS 2012 & IAS 2013) will also be reviewed for inclusion.

Search terms will include a combination of free and indexed terms containing keywords relating to disease and topic of interest. The keywords will include: "HIV", "HIV/AIDS", "stroke", "myocardial infarction", "cardiac death", "cardiovascular disease", "cerebrovascular disease", and "ischemic heart disease".

Types of study to be included

Inclusion criteria: Randomized controlled trials (RCT) and observational studies

Condition or domain being studied

Cardiovascular disease and HIV/AIDS

Participants/population

Inclusion: Adults only. Study inclusion requires that at least one of the studied groups/study arm includes HIV-positive individuals.

Exclusion: Non-adult population. Studies without an HIV-positive comparison group

Intervention(s), exposure(s)

HIV-seropositivity in at least one of the studied groups/arms

Comparator(s)/control

At least one of the study groups/arms should include HIV-positive individuals

Context

We would like to summarize evidence examining the risk of incident CVD events among HIV-positive adults compared to HIV-negative adults

PROSPERO International prospective register of systematic reviews

Primary outcome(s)

Incident (new) cardiovascular disease events

Timing and effect measures

For this review, we define cardiovascular disease event to include stroke, myocardial infarction and cardiac death

Secondary outcome(s)

None

Data extraction (selection and coding)

Two independent reviewers will be involved in the screening and extraction of data for this review. Discrepancies will be resolved through discussion and, where necessary, a third reviewer will be invited to assist in achieving consensus

Risk of bias (quality) assessment

The quality of the included studies will be assessed according to the type of study design (RCT or observational study).

For RCTs, we will use a modified Cochrane Risk of Bias tool and will evaluate several key domains including adequacy of randomization/sequence generation, allocation concealment, blinding, use of intention to treat analysis and other sources of bias.

For observational studies, we will make this assessment using the Newcastle-Ottawa Scale which will evaluate study design features including participant selection, comparability of groups, exposure and outcomes.

Strategy for data synthesis

Our approach to the conduct and reporting of the data synthesis will follow the guidelines in the PRISMA Statement. A flow diagram will be used to describe the study selection process. Meta-analysis of the extracted data will be performed only if there is sufficient homogeneity between studies to allow for such quantitative synthesis

Analysis of subgroups or subsets

Depending on the results, we intend to perform subgroup analyses to investigate the effect of study-level variables. The specific subgroup analyses will be informed by the nature of the evidence in the included studies.

Contact details for further information

Oghenowede Eyawo
oea1@sfu.ca

Organisational affiliation of the review

None

Review team members and their organisational affiliations

Mr Oghenowede Eyawo. Faculty of Health Sciences, Simon Fraser University
Ms Gwenyth Brockman. Faculty of Health Sciences, Simon Fraser University
Dr Scott Lear. Faculty of Health Sciences, Simon Fraser University
Dr Charles Goldsmith. Faculty of Health Sciences, Simon Fraser University
Dr Robert Hogg. Faculty of Health Sciences, Simon Fraser University

Anticipated or actual start date

01 July 2014

Anticipated completion date

PROSPERO

International prospective register of systematic reviews

31 January 2015

Funding sources/sponsors

None

Conflicts of interest

None known

Language

English

Country

Canada

Stage of review

Review_Ongoing

Subject index terms status

Subject indexing assigned by CRD

Subject index terms

Cardiovascular Diseases; HIV Infections; HIV Seropositivity; Humans

Date of registration in PROSPERO

14 August 2014

Date of publication of this version

13 November 2014

Revision note for this version

The anticipated completion date was revised based on when we now expect to complete the review. The search time frame (only records from the last 10 years) was changed. It now states that: records published from 2000 onwards will be included. This update was necessary to enable us include several key papers that were published between 2000 and 2004.

Details of any existing review of the same topic by the same authors

Stage of review at time of this submission

Stage	Started	Completed
Preliminary searches	Yes	No
Piloting of the study selection process	Yes	No
Formal screening of search results against eligibility criteria	No	No
Data extraction	No	No
Risk of bias (quality) assessment	No	No
Data analysis	No	No

Revision note

The anticipated completion date was revised based on when we now expect to complete the review. The search time frame (only records from the last 10 years) was changed. It now states that: records published from 2000 onwards will be included. This update was necessary to enable us include several key papers that

PROSPERO

International prospective register of systematic reviews

were published between 2000 and 2004.

Versions

14 August 2014

13 November 2014

PROSPERO

This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites.

For peer review only

Reporting checklist for meta-analysis of observational studies.

Based on the MOOSE guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the MOOSE reporting guidelines, and cite them as:

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-2012.

	Reporting Item	Page Number
#1	Identify the study as a meta-analysis of observational research	1
#2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number (From PRISMA checklist)	2
#3a	Problem definition	5
#3b	Hypothesis statement	6
#3c	Description of study outcomes	5
#3d	Type of exposure or intervention used	5, 6

1	#3e	Type of study designs used	6	
2				
3	#3f	Study population	7	
4				
5				
6	Search	#4a	Qualifications of searchers (eg, librarians and investigators)	6
7	strategy			
8				
9				
10		#4b	Search strategy, including time period included in the synthesis and	6
11			keywords	
12				
13		#4c	Effort to include all available studies, including contact with authors	7
14				
15				
16		#4d	Databases and registries searched	7
17				
18		#4e	Search software used, name and version, including special features	7
19			used (eg, explosion)	
20				
21				
22		#4f	Use of hand searching (eg, reference lists of obtained articles)	7
23				
24				
25		#4g	List of citations located and those excluded, including justification	See note
26				1
27				
28				
29		#4h	Method of addressing articles published in languages other than English	6
30				
31		#4i	Method of handling abstracts and unpublished studies	7
32				
33		#4j	Description of any contact with authors	8
34				
35				
36		#5a	Description of relevance or appropriateness of studies gathered for	6-8
37			assessing the hypothesis to be tested	
38				
39				
40		#5b	Rationale for the selection and coding of data (eg, sound clinical	5-8
41			principles or convenience)	
42				
43				
44		#5c	Documentation of how data were classified and coded (eg, multiple	7,8
45			raters, blinding, and interrater reliability)	
46				
47				
48		#5d	Assessment of confounding (eg, comparability of cases and controls in	n/a
49			studies where appropriate)	
50				
51				
52		#5e	Assessment of study quality, including blinding of quality assessors;	8,9
53			stratification or regression on possible predictors of study results	
54				
55				
56		#5f	Assessment of heterogeneity	9
57				
58		#5g	Description of statistical methods (eg, complete description of fixed or	8, 9
59				
60				

random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated

#5h	Provision of appropriate tables and graphics	9, 10
#6a	Graphic summarizing individual study estimates and overall estimate	10-14
#6b	Table giving descriptive information for each study included	36
#6c	Results of sensitivity testing (eg, subgroup analysis)	32
#6d	Indication of statistical uncertainty of findings	32
#7a	Quantitative assessment of bias (eg. publication bias)	9
#7b	Justification for exclusion (eg, exclusion of non-English-language citations)	10
#7c	Assessment of quality of included studies	8, 10
#8a	Consideration of alternative explanations for observed results	18
#8b	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	18
#8c	Guidelines for future research	18
#8d	Disclosure of funding source	19

Author notes

1. 10, Appendix

Reproduced with permission from JAMA. 2000. 283(15):2008-2012. Copyright © 2000 American Medical Association. All rights reserved. This checklist was completed on 06. August 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025874.R1
Article Type:	Original research
Date Submitted by the Author:	19-Feb-2019
Complete List of Authors:	<p>Eyawo, Oghenowede; British Columbia Centre for Excellence in HIV/AIDS, Epidemiology and Population Health; Simon Fraser University, Faculty of Health Sciences</p> <p>Brockman, Gwenyth; University of Manitoba, George & Fay Yee Centre for Healthcare Innovation</p> <p>Goldsmith, Charles; University of British Columbia, Department of Occupational Science and Occupational Therapy, Faculty of Medicine; Simon Fraser University, Faculty of Health Sciences</p> <p>Hull, Mark; British Columbia Centre for Excellence in HIV/AIDS, Lear, Scott; Simon Fraser University, Faculty of Health Sciences; St. Paul's Hospital, Providence Health Care, Healthy Heart Program</p> <p>Bennett, Matthew; University of British Columbia, Division of Cardiology, Department of Medicine</p> <p>Guillemi, Silvia; BC Centre for Excellence in HIV/AIDS, Franco-Villalobos, Conrado; University of Alberta, School of Public Health</p> <p>Adam, Ahmed; Simon Fraser University, Faculty of Health Sciences</p> <p>Mills, Edward; McMaster University, Department of Clinical Epidemiology & Biostatistics</p> <p>Montaner, Julio; BC Centre for Excellence in HIV/AIDS; University of British Columbia, Department of Medicine</p> <p>Hogg, Robert; Simon Fraser University, Faculty of Health Sciences; British Columbia Centre for Excellence in HIV/AIDS,</p>
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Cardiovascular medicine, HIV/AIDS
Keywords:	Myocardial infarction < CARDIOLOGY, Cardiovascular disease, HIV & AIDS < INFECTIOUS DISEASES, Combination antiretroviral therapy, Relative risk, systematic review and meta-analysis

SCHOLARONE™
Manuscripts

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

Oghenowede Eyawo,^{1,2} Gwentyth Brockman,³ Charlie H. Goldsmith,^{2,4} Mark W. Hull,¹ Scott A Lear,^{2,5} Matthew Bennett,⁶ Silvia Guillemi,¹ Conrado Franco-Villalobos,⁷ Ahmed Adam,² Edward Mills,⁸ Julio SG Montaner,^{1,9} Robert S Hogg^{1,2}

1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, CANADA
2. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, CANADA
3. George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, MB, CANADA
4. Department of Occupational Science and Occupational Therapy, Faculty of Medicine, University of British Columbia, Vancouver, BC, CANADA
5. Healthy Heart Program, St. Paul's Hospital, Providence Health Care, Vancouver, BC, CANADA
6. Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, BC, CANADA
7. School of Public Health, University of Alberta, Edmonton, AB, CANADA
8. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CANADA
9. Department of Medicine, University of British Columbia, Vancouver, BC, CANADA

Send correspondence to: Dr. Oghenowede Eyawo
Faculty of Health Sciences, Simon Fraser University
B.C. Centre for Excellence in HIV/AIDS
St. Paul's Hospital, 608-1081 Burrard Street,
Vancouver, B.C., V6Z 1Y6, Canada
Tel: (604) 806-8477
Email: oeal@sfu.ca

Abstract

Objective: Cardiovascular disease is one of the leading non-AIDS-defining causes of death among HIV-positive (HIV+) individuals. However, the evidence surrounding specific components of cardiovascular disease risk remains inconclusive. We conducted a systematic review and meta-analysis to synthesize the available evidence and establish the risk of myocardial infarction (MI) among HIV+ compared with uninfected individuals. We also examined MI risk within subgroups of HIV+ individuals according to exposure to combination antiretroviral therapy (ART), ART class/regimen, CD4 cell count and plasma viral load levels.

Design: Systematic review and meta-analysis

Data sources: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Database of Systematic Reviews until July 18, 2018. Furthermore, we scanned recent HIV conference abstracts (CROI, IAS/AIDS) and bibliographies of relevant articles.

Eligibility criteria: Original studies published after December 1999 and reporting comparative data relating to the rate of MI among HIV+ individuals were included.

Data extraction and synthesis: Two reviewers working in duplicate, independently extracted data. Data were pooled using random-effects meta-analysis and reported as relative risk (RR) with 95% confidence intervals (CI).

Results: Thirty-two of the 8,130 identified records were included in the review. The pooled RR suggests that HIV+ individuals have a greater risk of MI compared to uninfected individuals (RR: 1.67, 95%CI: 1.45, 1.94). Depending on risk stratification, there was moderate variation according to ART uptake (RR, ART-treated=1.80; 95%CI: 1.17, 2.77; ART-untreated HIV+ individuals: 1.25; 95%CI: 0.93, 1.67, both relative to uninfected individuals). We found low CD4 count, high

1
2
3 plasma viral load, and certain ART characteristics including cumulative ART exposure,
4
5 any/cumulative use of protease inhibitors as a class, and exposure to specific ART drugs (e.g.
6
7 abacavir) to be importantly associated with a greater MI risk.
8
9

10 **Conclusions:** Our results indicate that HIV infection, low CD4, high plasma viral load, cumulative
11
12 ART use in general including certain exposure to specific ART class/regimen are associated with
13
14 increased risk of MI. The association with cumulative ART may be an index of the duration of
15
16 HIV infection with its attendant inflammation, and not entirely the effect of cumulative exposure
17
18 to ART per se.
19
20
21
22
23

24 **PROSPERO registration number:** CRD42014012977
25
26
27
28
29
30

31 **Keywords:** Myocardial infarction, Cardiovascular disease, HIV, Combination antiretroviral
32
33 therapy (ART), Relative risk, Systematic review, Meta-analysis
34
35
36
37
38
39

40 Word count: 4,480
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Strengths and limitations of this study

- We used explicit eligibility criteria and a comprehensive search strategy for this systematic review and meta-analysis
- Adjudication of studies for eligibility and the data extraction was performed by two independent reviewers working in duplicate
- This systematic review and meta-analysis analyzed several additional drug exposure comparisons and clinical measures (e.g. CD4 cell count, plasma viral load) that had not been previously examined in relation to MI risk among HIV-positive individuals
- Some of the comparisons were based on a small number of studies which is a limitation
- Variability in the quality of the included studies may have influenced the results and thus the conclusions drawn.

INTRODUCTION

Cardiovascular disease (CVD) is one of the leading non-AIDS causes of death and disability among people living with HIV in the combination antiretroviral therapy (ART) era.^{1 2} Although HIV-positive (HIV+) individuals are believed to be at higher risk of CVD compared to uninfected individuals,^{3 4} the results and conclusions from the studies that have examined the nature of the risk of CVD, in particular myocardial infarction (MI) among HIV+ individuals have been conflicting. While some cohort studies have suggested a positive association between ART including specific drug (e.g. abacavir) or drug class (e.g. protease inhibitors [PI]) use and MI, or CVD risk,⁵⁻⁹ others have not.¹⁰⁻¹² Furthermore, there has been a lack of agreement between observational studies,^{8 11 13} and randomized controlled trials (RCT).^{14 15} Clearly, the evidence regarding the nature of, and extent of the risk of MI and other CVD events among HIV+ individuals is far from uniform.

Five meta-analyses have been conducted in an attempt to synthesize the data on CVD risk among HIV+ individuals.¹⁶⁻²⁰ These have either been limited in scope by assessing only the association between ART use and risk of CVD;¹⁶ included trials that lacked MI event adjudication;¹⁷ included trials where CVD events were not among the pre-specified outcomes of interest;¹⁸ provided incomplete results on MI risk;¹⁹ or amalgamated all CVD events (e.g. MI, stroke) as a single outcome.²⁰ In addition, this latter meta-analysis was fraught with a number of methodological ambiguities.²¹

Given these limitations, coupled with the publication of several new and updated study reports on the topic, we sought to undertake an updated systematic review and meta-analysis of studies

1
2
3 assessing the risk of CVD among persons living with HIV. Considering the scope, diversity and
4 differences in the definition,²²⁻²⁵ etiology and clinical picture of different CVD events,²⁶ coupled
5 with the strong body of literature related to HIV and MI and the ongoing debate around potential
6 MI risk associated with use of specific ART medications such as abacavir, we have elected to
7 focus primarily on MI as the outcome of interest for this meta-analysis, as it is the most widely
8 researched CVD outcome among HIV+ individuals. The objective of our study was to estimate
9 the risk of MI among HIV+ individuals relative to uninfected individuals. Additionally, we
10 examined MI risk within subgroups of HIV+ individuals according to exposure to ART, ART
11 class, specific ART regimen, CD4 cell count and plasma viral load levels.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **METHODS**

27 **Search strategy and selection criteria**

28
29 The systematic review and meta-analysis was performed in accordance with the PRISMA
30 Statement.²⁷ A protocol describing the inclusion criteria and analysis methods for this systematic
31 review was specified in advance, registered and published at the international prospective register
32 of systematic reviews (PROSPERO, registration number CRD42014012977).²⁸
33
34
35
36
37
38
39
40
41
42

43 The search strategy (see Appendix Table 1) was developed in consultation with a medical librarian
44 at Simon Fraser University, BC, Canada. The search terms were based on a combination of indexed
45 and free-text terms reflecting clinical outcomes of interest to the review, and included the
46 following keywords: ‘HIV, human immunodeficiency virus, acquired immunodeficiency
47 syndrome, HIV/AIDS, stroke, myocardial infarction, cardiac death, cerebrovascular disease,
48 ischemic heart disease, cardiovascular disease and CVD’. These terms were used in combination
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 to execute the searches, which were up to July 18, 2018. Using the Ovid platform, we searched the
4 following electronic databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled
5 Trials (CENTRAL) and the Cochrane Database of Systematic Reviews. In addition, we screened
6 the abstracts of the International AIDS Society conferences (AIDS 2012, 2014, 2016; IAS 2013)
7 and the Conference on Retroviruses and Opportunistic Infections (CROI 2014, 2015, and 2016).
8 We also searched the reference lists of relevant articles and previous systematic reviews for
9 additional eligible publications. Finally, we set up automatic PubMed literature alerts to identify
10 any new relevant article published while the manuscript was under development.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 We included original research published in English where at least one of the participant groups
25 were individuals living with HIV, and presenting comparative data on the incidence of MI. We
26 included studies in which results were stratified according to HIV status; CD4 cell count; plasma
27 viral load (pVL) levels; ART use; or exposure to particular ART class or regimen. Studies
28 involving non-human populations; children; as well as those reporting only unadjusted estimates,
29 intermediate, surrogate or CVD biomarker outcomes were excluded (for additional information,
30 see 'study selection' in the Appendix, p1). To reflect the current context of HIV treatment and
31 disease management, we selected studies published from the year 2000 onwards. Although both
32 observational studies and RCTs were eligible for inclusion, we did not include RCTs that were not
33 designed to assess CVD events as a pre-specified outcome to avoid bias.
34
35
36
37
38
39
40
41
42
43
44
45

46 Working independently and in duplicate, two reviewers (OE and GB) scanned the titles and
47 abstracts of the retrieved records for eligibility. The full-text articles of potentially eligible studies
48 were obtained and reviewed in greater details. Disagreements in study selection were resolved
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 through discussion, and where necessary, a third investigator (RSH) was invited to facilitate
4
5 consensus.
6
7
8
9
10

11 12 13 **Data extraction and quality assessment** 14 15

16 The same two reviewers (OE and GB) conducted data extraction independently using a pre-
17 designed data abstraction sheet. We extracted data on study descriptors, sample characteristics,
18 outcome assessment, risk estimate for relevant comparisons, and study quality features. Where
19 necessary, we sought clarification directly from study authors through email contact. In cases
20 where data from the same study described the same event risk in multiple publications, we
21 extracted data from the most comprehensive report while supplementing missing study-level
22 information from the others. In keeping with characterizations in the included studies, exposure to
23 ART was categorized as any (or prior/some *compared to none*), recent (or within the preceding six
24 months *compared to not recent*) and cumulative ART exposure per year of exposure.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The quality of the included studies was assessed according to risk of bias criteria based on the type
40 of study design. As only observational studies were eventually included in the meta-analysis since
41 eligible RCTs were not identified, we made this assessment by evaluating study design features of
42 the eligible observational studies. Following guidelines in the Newcastle-Ottawa Scale (NOS) for
43 assessing the quality of observational studies in meta-analyses²⁹ and with slight modification of
44 the scoring system to simplify reporting, the risk of bias assessment was performed based on the
45 adequacy of three key domains of the study design features namely: the group/participant
46 selection; comparability of groups; and the exposure and outcome assessments in the individual
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 studies. For each of these key features, we assigned a “+” (plus) sign when this was clearly and
4
5 adequately described in the study, and a “-“ (minus) sign when it was not clearly described or was
6
7 missing. A detailed description of the results of the quality assessment is available in the appendix.
8
9
10
11
12
13

14 **Patient and public involvement**

15
16 No patients were involved in this study. We used data from published materials only
17
18
19
20
21

22 **Data analysis**

23
24 We calculated the kappa statistic as a measure of the inter-reviewer agreement for the selection of
25
26 articles meeting the inclusion/exclusion criteria. For interpretation, we defined *a priori* the interval
27
28 for the kappa result using Landis and Koch criteria.³⁰ For effect measure, we assumed the incidence
29
30 rate ratio (IRR), odds ratio (OR) and hazard ratio (HR) with corresponding sampling variance to
31
32 be numerical approximate measures of the relative risk (RR) for a given association of interest
33
34 with the underlying assumption of a generally low event risk (< 20%),³¹⁻³⁶ and thus combined them
35
36 as previously described.^{19 37-40} We tested this assumption in sensitivity analyses by performing
37
38 separate meta-analyses where studies presenting results reported using a similar effect measure
39
40 type were pooled. Given the expected variability among eligible studies, we pooled studies using
41
42 the DerSimonian-Laird random-effects model.⁴¹ To minimize bias in our pooled estimates,
43
44 adjusted risk estimates were not combined with unadjusted estimates. The final set of studies that
45
46 adjusted for confounders did not consistently adjust for the same set of confounders but were
47
48 deemed to have sufficient internal validity to permit pooling. For the analysis that quantified the
49
50 overall RR of MI associated with HIV infection, we performed a sensitivity analysis where we
51
52
53
54
55
56
57
58
59
60

1
2
3 examined the appropriateness of the comparison group by repeating the meta-analysis and
4 including one additional study that involved a general population comparison group,⁴² as opposed
5 to an HIV-uninfected comparison group. Given the limitations of the I^2 statistics with
6 observational studies and Cochran Q test when the number of studies is small,^{43 44} we assessed
7 heterogeneity by visual inspection of the forest plots for overlap in the confidence intervals of the
8 individual studies, although the I^2 and Cochran Q are reported in the forest plots for completeness
9 sake. We were unable to perform meta-regression analyses to assess the potential effect of study-
10 level covariates on the pooled estimate due to insufficient studies (< 10),⁴⁵ in each of the meta-
11 analyses. Although we assessed publication bias by visually inspecting and testing for funnel plot
12 asymmetry,⁴⁶ its interpretation was limited by a lack of sufficient number of studies per meta-
13 analysis.^{47 48} A p-value < 0.05 was considered statistically significant. The meta-analysis was
14 conducted using the *metafor* package of the R statistical program (version 3.3.1)⁴⁹.

33 RESULTS

34
35 Of 8,130 records identified through the database search, the final screening process yielded 64
36 potentially eligible publications on CVD outcomes, 32 of which had relevant data on MI and were
37 included in this meta-analysis (Figure 1). Overall, there was near perfect agreement between
38 reviewers on the inclusion of studies (kappa statistic = 0.94; 95% confidence interval (95%CI):
39 0.89, 0.99). The included studies, most of which were conducted in the United States and Europe,
40 were published between 2000 and 2017 and involved approximately 383,471 HIV+ and > 798 ,
41 424 HIV- individuals (Appendix Table 2: characteristics of the included studies; *note: the number*
42 *of individuals in cohorts with multiple publications was accessed only from one of the*
43 *publications). The mean duration of follow-up varied across studies from approximately one to*

1
2
3 twenty years. All 32 publications were non-randomized studies and included two nested case-
4 control studies,^{11 50} one cohort/nested case-control study,⁵¹ and 29 cohort studies; 15 of which were
5 prospective studies, by design.^{3 7 8 13 42 52-61} Twenty-nine studies were published as full-text journal
6 articles, while three were available as conference abstracts.
7
8
9

10
11 In general, the reporting and quality of the methodological aspects of the included studies were
12 variable. Three studies did not provide sufficient information necessary to assess the study quality,
13 as they were reported and available as conference abstract/poster.^{54 56 62} The eligibility criteria were
14 clearly defined in the majority of studies (94%), description of study participants/ groups was
15 sufficient (100%); however, the exposure or outcome was not adequately ascertained in 15 studies
16 (47%);^{8 12 24 51 53 55 59 62-69} one (7%) of which was published as an abstract⁶² (see Appendix Table
17 3: risk of bias in the included studies).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Meta-analysis of the risk of MI**

35
36 Below, we summarize the results of the meta-analyses of MI risk according to the various risk
37 stratifications assessed. To avoid duplication of reporting, only statistically important RR are
38 stated in text; although both statistically significant and insignificant results are presented in the
39 figures (forest plots).
40
41
42
43
44
45
46
47

48 *Risk of MI associated with HIV infection*

49
50 The pooled RR from the six studies that met eligibility for this assessment of MI risk according to
51 HIV serostatus suggests that HIV+ individuals are more likely to have an MI event compared to
52 uninfected individuals (RR: 1.67; 95%CI: 1.45, 1.94).^{3 51 55 68 70 71} In sensitivity analysis (Appendix
53
54
55
56
57
58
59
60

1
2
3 Figure S1) where we repeated the meta-analysis and included one additional study that involved a
4 general population comparison group,⁴² the overall pooled RR was 1.60; 95%CI: 1.38, 1.85. Figure
5
6
7
8 2 shows the forest plots for the association between HIV infection and MI risk. Two studies
9
10 assessed the risk of MI by HIV serostatus according to whether ART treatment was received.^{59 72}
11
12 Compared to uninfected individuals, the pooled RR of MI was significantly higher among HIV+
13
14 individuals on ART (RR: 1.80; 95%CI: 1.17, 2.77), but not the ART-untreated HIV+ individuals
15
16 (RR: 1.25; 95%CI: 0.93, 1.67).
17
18
19
20

Risk of MI associated with CD4 cell count and plasma viral load levels

21
22
23
24 The pooled RR based on combining data from three studies suggests that low CD4 cell count (<
25
26 200 cells/mm³) is associated with higher MI risk compared to CD4 ≥ 200 (RR: 1.60; 95%CI: 1.25,
27
28 2.04).^{3 56 67} Conversely, a high pVL (≥ 100,000 copies/mL) was found to be associated with
29
30 increased MI risk compared to pVL < 100,000 (RR: 1.45; 95%CI: 1.11, 1.90), based on the pooled
31
32 results from two studies (Figure 3).^{53 67}
33
34
35
36
37

Risk of MI associated with recent ART exposure

38
39
40 With regards to *recent treatment exposure* (i.e. within the preceding six months), four eligible
41
42 studies with data on nucleoside reverse transcriptase inhibitors (NRTI) exposure assessed the risk
43
44 of MI associated with recent compared to not recent abacavir exposure.^{51 52 54 66} The pooled result
45
46 from these four studies suggests that recent abacavir exposure is associated with increased risk of
47
48 MI compared to not recent exposure (RR: 1.71; 95%CI: 1.39, 2.10). Similarly, recent didanosine
49
50 (RR: 1.29; 95%CI: 1.04, 1.60),^{51 57 66} and lamivudine (RR: 1.50; 95%CI: 1.18, 1.90),^{13 51 66}
51
52 exposure is associated with increased risk of MI compared to not recent exposures. In contrast,
53
54
55
56
57
58
59
60

1
2
3 there was no association between recent tenofovir,^{51 57 66} zidovudine,^{13 51 66} stavudine,^{13 51 66}
4 emtricitabine,^{51 66} and MI risk compared to not recent exposure (Figure 4). Based on pooling data
5
6 from two studies with data on non-nucleoside reverse transcriptase inhibitors (NNRTI) exposure,⁵¹
7
8 ⁶⁶ no association was found between recent efavirenz or nevirapine exposure and MI risk compared
9
10 to not recent exposure (Figure 5). Based on pooled results from the studies assessing the MI risk
11
12 of individual PIs, recent indinavir was associated with increased MI risk compared to not recent
13
14 exposure (RR: 1.46; 95%CI: 1.08, 1.95).^{51 66} Recent exposure to other PI regimens including
15
16 atazanavir,^{51 66} lopinavir,^{51 66} ritonavir,^{51 66} nelfinavir,^{51 66} and saquinavir,^{51 66} was not found to be
17
18 significantly associated with MI risk compared to not recent exposure (Figure 6).
19
20
21
22
23
24
25

26 Risk of MI associated with any ART exposure

27
28 In terms of *any treatment exposure*, our meta-analysis did not find an association between exposure
29
30 to ART and risk of MI compared to no exposure (Appendix Figure A1).^{61 72} Based on the pooled
31
32 results from six studies with data on NRTI exposure,^{8 11 13 51 62 67} individuals receiving abacavir
33
34 were more likely to have an MI compared to those who did not (RR: 1.58; 95%CI: 1.25, 2.00). We
35
36 found a similar association between didanosine exposure and MI risk (RR: 1.48; 1.16, 1.90).^{13 51}
37
38 ⁶⁷ No important association was found between exposure to tenofovir,^{51 67} zidovudine,^{13 51}
39
40 stavudine,^{13 51 67} emtricitabine,^{51 67} and MI risk, based on our pooled results (Appendix Figure A2).
41
42
43
44 The meta-analysis of studies with data on NNRTI exposure did not find any evidence of an
45
46 association between either efavirenz,^{51 64} or nevirapine exposure,^{51 67} and MI risk compared to no
47
48 exposure (Appendix Figure A3). The pooled RR from four studies demonstrates that PI exposure
49
50 is associated with an increase in the risk of MI events compared to no exposure to PI (RR: 1.49;
51
52 95%CI: 1.16, 1.91).^{3 6 60 62} When the analysis was limited to two studies comparing recent PI
53
54
55
56
57
58
59
60

1
2
3 exposure to no exposure,^{3 62} similar results were found (RR: 1.40; 95%CI: 1.16, 1.69 [data not
4 shown]). For the individual PIs, there was no association between either atazanavir,^{51 63 65 67}
5
6 saquinavir,^{51 67} or nelfinavir exposure,^{51 67} and MI risk, compared to no exposure (Appendix Figure
7
8 A4).
9
10

11 12 13 14 15 Risk of MI associated with cumulative ART exposure

16
17 With regards to *cumulative treatment exposure*, three eligible studies provided relevant data
18
19 regarding the risk of MI and cumulative ART exposure.^{12 67 69} We found that cumulative exposure
20
21 to ART was associated with an increase in the risk of MI per year of exposure (RR: 1.12; 95%CI:
22
23 1.06, 1.18) (Appendix Figure A5). For exposure to NRTI regimens, we estimated an increase in
24
25 MI risk per year of exposure to abacavir (RR: 1.08; 95%CI: 1.01, 1.15) based on pooling data from
26
27 two eligible studies.^{12 57} Similar to abacavir, cumulative zidovudine exposure was associated with
28
29 an increase in MI risk per year of exposure (RR: 1.05; 95%CI: 1.01, 1.10).^{11 13} We found no
30
31 association between cumulative exposure to either didanosine,^{11 13} tenofovir,^{11 57} lamivudine,^{11 13}
32
33 or stavudine,^{11 13} and MI risk per year of exposure (Appendix Figure A6). The overall RR suggests
34
35 that cumulative NNRTI exposure as a class (RR: 1.02; 95%CI: 0.97, 1.08),^{58 69 72} or as individual
36
37 drugs (nevirapine, and efavirenz),^{11 57} is not significantly associated with increased risk of MI
38
39 events per year of exposure (Appendix Figure A7). Three eligible studies reported data assessing
40
41 the risk of MI associated with cumulative exposure to PIs as a class.^{58 69 72} There was an increase
42
43 in risk of MI per year of exposure to PIs (RR: 1.14; 95%CI: 1.03, 1.26). For individual drugs,
44
45 cumulative exposure to lopinavir with ritonavir (RR: 1.19; 95%CI: 1.03, 1.39),^{11 57} but not
46
47 nelfinavir,^{11 57} was found to be associated with increase in the risk of MI events per year of
48
49 exposure (Appendix Figure A8).
50
51
52
53
54
55
56
57
58
59
60

Sensitivity analyses

The strength and direction of the overall RR from the various meta-analyses remained robust in sensitivity analyses where estimates reported using similar effect measures were pooled. For example, HIV+ individuals continued to have higher risk of MI events compared to uninfected individuals when pooled using either IRRs (overall effect: 1.68; 95%CI: 1.17, 2.40) or HRs (overall effect: 1.75; 95%CI: 1.24, 2.48) effect measures, compared to a RR of 1.67; 95%CI: 1.45, 1.94, obtained from pooling results reported using multiple relative effect measures (Appendix Figure S2).

DISCUSSION

This updated systematic review and meta-analysis assessing the risk of MI among people living with HIV reflects contemporary ART era and found the following: (1) HIV+ individuals have a greater risk of MI compared to uninfected individuals; and among HIV+ individuals, (2) low CD4 cell count (< 200 cells/mm³) and high pVL ($> 100,000$ copies/mL) are associated with increases in MI risk compared to higher CD4 or lower pVL respectively; (3) cumulative ART exposure is associated with a greater risk of MI per year of exposure; (4) among NRTIs, any type of exposure to abacavir; cumulative exposure to zidovudine; and recent exposure to either didanosine or lamivudine are significantly associated with higher risk of MI; (5) compared to no exposure, any or cumulative exposure to PIs as a class; cumulative exposure to lopinavir with ritonavir; and recent indinavir exposure was associated with higher risk of MI; (6) NNRTIs assessed either as a class or individually were not associated with increased MI risk.

1
2
3
4
5
6 Previous meta-analyses comparing CVD risk among HIV+ and uninfected individuals reported
7 estimates for the association between HIV-seropositivity and MI (RR: 1.79, 95%CI: 1.54, 2.08)¹⁹
8 or CVD (RR: 1.61, 95%CI: 1.43, 1.81);²⁰ risk that are similar to our findings for MI (RR: 1.67,
9 95%CI: 1.45, 1.94). Regarding studies that quantified the risk of MI associated with HIV infection,
10 the appropriateness of the HIV-uninfected group used for comparison purposes is critical; an issue
11 that has been extensively reviewed elsewhere.⁷³ In sensitivity analysis, the overall RR of MI
12 associated with HIV infection was reduced when we included one additional study involving a
13 ‘general population’ comparison group, therefore highlighting the importance of using an
14 appropriate control group. As has been previously hypothesized,^{3 23 74-76} the probable mechanistic
15 pathway through which HIV infection can induce MI may include a cascade of events involving
16 chronic inflammation, immunodeficiency/CD4 cell depletion, endothelial dysfunction, increased
17 thrombosis and accelerated atherosclerosis that typically accompany both controlled and
18 uncontrolled HIV disease. Relative to uninfected individuals and similar to what we found (RR:
19 1.80, 95%CI: 1.17, 2.77), one of the previous meta-analysis also reported a higher risk of CVD
20 among ART-treated individuals (RR: 2.00, 95%CI: 1.70, 2.37).²⁰ We suspect that the higher MI
21 risk among ART-treated HIV+ individuals may not necessarily be attributable to ART alone but
22 rather to the combined effect from a host of factors including HIV itself, ART, and other comorbid
23 risk factors which have been individually shown to contribute to MI risk.^{3 5 77 78} Furthermore, the
24 risk associated with cumulative ART exposure may be an index of the duration of HIV infection
25 with its attendant inflammation, and not entirely the effect of cumulative exposure to ART per se.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Specific to abacavir and MI risk, our findings were similar to reports from a previous meta-analysis
4 of observational studies of MI,¹⁶ but different from those of the meta-analysis of RCTs,^{17 18} or
5 reports from aggregate clinical trial studies,^{14 15} that suggested no risk associated with abacavir
6 exposure. Although observational studies and RCT results regarding MI and CVD risk due to
7 abacavir exposure among people living with HIV are largely at odds, the Simplification with
8 Tenofovir-Emtricitabine or Abacavir-Lamivudine (STEAL) trial is the first RCT to support
9 observational studies finding of increased risk of CVD with exposure to abacavir.⁷⁹ Based on the
10 available evidence to date, the controversy regarding the potential association between abacavir
11 use and risk of MI will likely continue to plague the field of HIV therapeutics until such a time
12 when definitive evidence describing the underlying mechanism can be produced.^{80 81} A sufficiently
13 powered RCT with long follow-up and including real-world populations reflective of those
14 typically seen clinically may be needed to fully resolve this clinical controversy.

15
16
17 Unlike our results where a class-level effect was evident for PIs, pooled aggregate clinical trial
18 data after one year of treatment with four different PI-based regimens did not find evidence of an
19 increased risk associated with PI compared to NRTI regimen (RR: 1.69; 95%CI: 0.54, 7.48).⁸²
20 When we pooled data of individual PIs separately, we did not observe the same ‘class-level’
21 results. In our analysis, different PI regimens carried different risks. For example, while recent
22 indinavir and cumulative lopinavir-ritonavir exposure were associated with increased MI risk,
23 nelfinavir or atazanavir did not appear to contribute to MI risk irrespective of the type of exposure
24 data that were pooled.

1
2
3 In terms of the scope and design, our study differs from previous meta-analyses on this topic in
4 several ways. First, we used an expanded search strategy that included more data sources and
5 search of conference archives compared to prior meta-analyses.¹⁶⁻²⁰ Second, as the association of
6 HIV and ART may affect the risk of MI and other CVD events differently, we did not assess the
7 risk of CVD in general, as was done in previous meta-analysis.²⁰ Third, we have used more recent
8 risk estimates from studies with longer follow-up such as the Data Collection on Adverse Events
9 of Anti-HIV Drugs (D:A:D) study. Fourth, we have included studies published between 2000 and
10 2017 with reported data from the post-ART era. The historical nature of some of the studies
11 included in previous meta-analysis may have limited their relevance in contemporary times.
12 Finally, this systematic review analyzed several additional drug exposure comparisons and clinical
13 measures (e.g. CD4 cell count, plasma viral load) in relation to MI risk that had not been previously
14 examined.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 There are several important considerations that should be taken into account in the interpretation
34 of the results of this study. Accurate characterization of the risk of MI and CVD outcomes in
35 general may be confounded by a number of factors that may have affected our conclusions. The
36 first concern has to do with the differences in the risk factors, drug exposure, HIV-related variables,
37 or population considered in the included studies. No two studies of HIV+ individuals can have
38 participants with the same demographic, clinical and drug exposure profile – all of which play a
39 role in overall health outcomes. There is also the potential for residual, unmeasured confounding
40 given the observational nature of the included studies. For example, we noted that the included
41 studies did not consistently control for the exact same set of confounders which may have
42 undermine their internal validity. Therefore, heterogeneity arising from differences in study design
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 or other features may have influenced the results and thus the overall conclusions drawn. Although
4
5 we observed heterogeneity across results of studies included in some of the meta-analyses, this is
6
7 a common limitation in meta-analysis especially those involving observational studies.⁴³ Our *a*
8
9 *priori* choice of employing the random-effects modeling strategy was driven in part by this
10
11 expected variability among studies.⁸³ It is unclear how differences in MI definition may have
12
13 affected our results. While some studies retrospectively assessed MI and relied on International
14
15 Classification of Diseases (ICD) codes alone, others followed participants over time and
16
17 prospectively assessed and validated the MI events.^{5 52} Furthermore, our study combined results
18
19 presented using several different relative effect measures with the assumption that these represent
20
21 approximately the same numerical value.³¹⁻³⁶ In sensitivity analyses, we did not find any evidence
22
23 of bias in our pooled estimates, as these did not differ importantly from the pooled estimates we
24
25 obtained when we combined studies reporting results using the same effect measure. Moreover,
26
27 we reached comparable conclusions with previous meta-analyses that combined,¹⁹ or did not
28
29 combine HR estimates with OR, and RR.¹⁶ In terms of the critical appraisal and its impact on the
30
31 interpretation of the results, variability in the quality of the included studies may have influenced
32
33 the results of the meta-analyses and thus the conclusions drawn. Also, some of the comparisons in
34
35 our study were based on a small number of studies which is a limitation. Therefore, additional
36
37 rigorously conducted studies with extensive confounding factor stratification/adjustment are
38
39 needed to confirm our findings. Furthermore, considering that the majority of the studies on this
40
41 topic are carried out in North America and Europe, our study highlights the need for more research
42
43 to be conducted in resource limited settings where most people living with HIV reside.
44
45
46
47
48
49
50
51
52

53 CONCLUSIONS

54
55
56
57
58
59
60

1
2
3 In summary, this updated systematic review and meta-analysis suggests that HIV infection, ART
4 use in general including exposure to specific ART class (e.g. PIs) and regimen (e.g. abacavir) are
5 associated with increased risk of MI. We found the totality of the evidence for an association
6 between HIV infection and MI to be compelling. With respect to ART and MI risk, HIV treatment
7 strategies should certainly consider cardiovascular risk factors including exposure to particular
8 ART drugs as part of patient-tailored care. However, given what we currently know about ART's
9 effectiveness, the benefits of ART for the treatment of HIV infection in terms of viral suppression
10 and immune reconstitution should be balanced against its potential unfavorable impact on MI.
11 Specific to abacavir and MI risk where there is conflicting evidence between observational studies
12 and RCTS, additional rigorously conducted studies in real-world populations are needed to
13 definitively substantiate our findings and strengthen the existing evidence on this topic. Given the
14 multiple potential contributory and mechanistic pathways to developing MI among HIV+
15 individuals and the complexity/feasibility of designing a large enough study to completely tease
16 apart the potential contributions of each of the factors believed to increase the risk of MI, managing
17 known modifiable risk factors for CVD outcomes (e.g. smoking) through behavioural/lifestyle
18 interventions, would be an excellent first step in reducing the incidence and risk of MI among
19 people living with HIV.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44
45 **Study registration number:** PROSPERO ID# CRD42014012977
46
47
48

49 **Acknowledgements**

50
51 We thank Simon Fraser University library staffs for the assistance provided during the search
52 strategy development
53
54
55
56
57
58
59
60

Author contributions

OE, MWH, SAL, JSGM and RSH conceived and designed the study. OE, GB, and RSH acquired the data. OE performed the statistical analysis with input from CHG, CF-V, and EM. OE, GB, CHG, MWH, SAL, MB, SG, CF-V, AA, EM, JSGM, and RSH contributed to the interpretation of the data. OE drafted the manuscript. OE, GB, CHG, MWH, SAL, MB, SG, CF-V, AA, EM, JSGM, and RSH reviewed the manuscript critically for important intellectual content and approved the final version submitted for publication.

Funding

There was no funding for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Competing interests

We declare no competing interests

Patient consent

None required

Data sharing statement

All data and materials used in this research are available in Medline/PubMed. References have been provided.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 2010;50(10):1387-96. doi: 10.1086/652283
2. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet* 2014;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA internal medicine* 2013;173(8):614-22. doi: 10.1001/jamainternmed.2013.3728
4. Marcus JL, Leyden WA, Chao CR, et al. HIV infection and incidence of ischemic stroke. *AIDS* 2014;28(13):1911-9. doi: 10.1097/QAD.0000000000000352
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 2003;349(21):1993-2003. doi: 10.1056/NEJMoa030218
6. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *AIDS* 2003;17(17):2479-86. doi: 10.1097/01.aids.0000096857.36052.23
7. D:A:D Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;356(17):1723-35. doi: 10.1056/NEJMoa062744

- 1
2
3 8. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-
4
5 infected patients on highly active antiretroviral therapy: a population-based nationwide
6
7 cohort study. *HIV Med* 2010;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x
8
9
- 10 9. Strategies for Management of Anti-Retroviral Therapy/Insight, D:A:D. Study Groups. Use of
11
12 nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-
13
14 infected patients. *AIDS* 2008;22(14):F17-24. doi: 10.1097/QAD.0b013e32830fe35e
15
16
- 17 10. Bozzette SA, Ake CF, Tam HK, et al. Long-term survival and serious cardiovascular events
18
19 in HIV-infected patients treated with highly active antiretroviral therapy. *J Acquir*
20
21 *Immune Defic Syndr* 2008;47(3):338-41. doi: 10.1097/QAI.0b013e31815e7251
22
23
- 24 11. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk
25
26 of myocardial infarction in human immunodeficiency virus-infected patients: a case-
27
28 control study nested within the French Hospital Database on HIV ANRS cohort CO4.
29
30 *Archives of internal medicine* 2010a;170(14):1228-38. doi:
31
32 10.1001/archinternmed.2010.197
33
34
- 35 12. Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial
36
37 infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin*
38
39 *Infect Dis* 2011;53(1):84-91. doi: 10.1093/cid/cir269
40
41
- 42 13. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase
43
44 inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the
45
46 D:A:D study: a multi-cohort collaboration. *Lancet* 2008a;371(9622):1417-26. doi:
47
48 10.1016/S0140-6736(08)60423-7
49
50
- 51 14. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir
52
53 therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult
54
55
56
57
58
59
60

- 1
2
3 subjects. *J Acquir Immune Defic Syndr* 2009;51(1):20-8. doi:
4
5 10.1097/QAI.0b013e31819ff0e6
6
7
8 15. Ribaldo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with
9
10 initial antiretroviral treatment containing abacavir: short and long-term results from
11
12 ACTG A5001/ALLRT. *Clin Infect Dis* 2011;52(7):929-40. doi: 10.1093/cid/ciq244
13
14
15 16. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral
16
17 therapy for HIV: a systematic review. *PLoS One* 2013;8(3):e59551. doi:
18
19 10.1371/journal.pone.0059551
20
21
22 17. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial
23
24 infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*
25
26 2012;61(4):441-7. doi: 10.1097/QAI.0b013e31826f993c
27
28
29 18. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease
30
31 events: a meta-analysis of published and unpublished data. *AIDS* 2011;25(16):1993-2004.
32
33 doi: 10.1097/QAD.0b013e328349c6ee
34
35
36 19. Shah ASV, Stelzle D, Lee KK, et al. Global Burden of Atherosclerotic Cardiovascular
37
38 Disease in People Living with the Human Immunodeficiency Virus: A Systematic
39
40 Review and Meta-Analysis. *Circulation* 2018 doi:
41
42 10.1161/CIRCULATIONAHA.117.033369 [published Online First: 2018/07/04]
43
44
45 20. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living
46
47 with HIV: a systematic review and meta-analysis. *HIV Med* 2012;13(8):453-68. doi:
48
49 10.1111/j.1468-1293.2012.00996.x
50
51
52 21. Neaton JD. HIV and cardiovascular disease: comment on Islam et al. *HIV Med*
53
54 2013;14(8):517-8. doi: 10.1111/hiv.12043
55
56
57
58
59
60

- 1
2
3 22. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of
4 cardiovascular disease in HIV-infected patients. *HIV Med* 2005;6(1):37-44. doi:
5
6 10.1111/j.1468-1293.2005.00265.x
7
8
9
10 23. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for
11 cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis*
12
13 2010;51(4):435-47. doi: 10.1086/655144
14
15
16
17 24. Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and
18 tenofovir exposure in HIV-infected persons. *AIDS* 2011;25(10):1289-98. doi:
19
20 10.1097/QAD.0b013e328347fa16
21
22
23
24 25. Klein MB, Xiao Y, Abrahamowicz M, et al. Re-assessing the cardiovascular risk of abacavir
25 in the Swiss HIV Cohort Study (SHCS) using a flexible marginal structural model [ICPE
26 Abstract 396]. In: Abstracts of the 29th International Conference on
27
28 Pharmacoeconomics & Therapeutic Risk Management. *Pharmacoeconom Drug Saf*
29
30 2013;22(S1):193-94.
31
32
33
34
35 26. Widimsky P, Coram R, Abou-Chebl A. Reperfusion therapy of acute ischaemic stroke and
36 acute myocardial infarction: similarities and differences. *Eur Heart J* 2014;35(3):147-55.
37
38 doi: 10.1093/eurheartj/eh409 [published Online First: 2013/10/08]
39
40
41
42 27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
43 meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264-9, W64.
44
45
46
47 28. Eyawo O, Brockman G, Lear S, et al. Risk of cardiovascular disease events among HIV-
48 positive individuals compared to HIV-negative individuals: a systematic review and
49 meta-analysis (number: CRD42014012977). *International prospective register of*
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 *systematic reviews (PROSPERO)*, 2014.
4
5 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014012977.
6
7
- 8 29. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the
9
10 quality of nonrandomised studies in meta-analyses, 2018:
11
12 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed January 17,
13
14 2019.
15
16
- 17 30. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
18
19 *Biometrics* 1977;33(1):159-74.
20
21
- 22 31. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. *J Clin*
23
24 *Epidemiol* 2002;55(9):893-9.
25
26
- 27 32. Sedgwick P. Hazards and hazard ratios. *Bmj* 2012;345:e5980.
28
29
- 30 33. Hernan MA. The hazards of hazard ratios. *Epidemiology* 2010;21(1):13-5. doi:
31
32 10.1097/EDE.0b013e3181c1ea43
- 33 34. McCullagh P, Nelder JA. Chapter 13: Models for Survival Data. In: McCullagh P, Nelder
34
35 JA, eds. *Generalized Linear Models*. 2nd ed. London, New York: Chapman & Hall/CRC
36
37 1989:pp 419-31.
38
39
- 40 35. Laird N, Olivier D. Covariance Analysis of Censored Survival Data Using Log-Linear
41
42 Analysis Techniques. *J Am Stat Assoc* 1981;76(374):231-40.
43
44
- 45 36. Symons MJ, Taulbee JD. Practical considerations for approximating relative risk by the
46
47 standardized mortality ratio. *J Occup Med* 1981;23(6):413-6.
48
49
- 50 37. Fernandez MDM, Saulyte J, Inskip HM, et al. Premenstrual syndrome and alcohol
51
52 consumption: a systematic review and meta-analysis. *BMJ Open* 2018;8(3):e019490. doi:
53
54 10.1136/bmjopen-2017-019490 [published Online First: 2018/04/18]
55
56
57
58
59
60

- 1
2
3 38. Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a
4
5 systematic review. *Int J Infect Dis* 2015;32:138-46. doi: 10.1016/j.ijid.2014.12.016
6
7
8 39. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of
9
10 physical activity and the prevention of Alzheimer's disease in older adults. *BMC Geriatr*
11
12 2015;15:9. doi: 10.1186/s12877-015-0007-2
13
14
15 40. Bateson D, Butcher BE, Donovan C, et al. Risk of venous thromboembolism in women
16
17 taking the combined oral contraceptive: A systematic review and meta-analysis. *Aust*
18
19 *Fam Physician* 2016;45(1):59-64.
20
21
22 41. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177-
23
24 88.
25
26 42. Drozd DR, Kitahata MM, Althoff KN, et al. Increased Risk of Myocardial Infarction in HIV-
27
28 Infected Individuals in North America Compared With the General Population. *J Acquir*
29
30 *Immune Defic Syndr* 2017;75(5):568-76. doi:10.1097/QAI.0000000000001450
31
32
33 43. Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to
34
35 diagnose lung cancer. *JAMA* 2015;313(4):419. doi: 10.1001/jama.2014.16482
36
37
38 44. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *Bmj*
39
40 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557
41
42
43 45. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version
44
45 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011:
46
47 <http://www.cochrane.org/handbook>. Accessed July 27, 2017.
48
49 46. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
50
51 graphical test. *Bmj* 1997;315(7109):629-34.
52
53
54
55
56
57
58
59
60

- 1
2
3 47. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in
4
5 meta-analyses: a large survey. *Cmaj* 2007;176(8):1091-6. doi: 10.1503/cmaj.060410
6
7 [published Online First: 2007/04/11]
8
9
- 10 48. Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. *Bmj*
11
12 2006;333(7568):597-600. doi: 10.1136/bmj.333.7568.597 [published Online First:
13
14 2006/09/16]
15
16
- 17 49. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw*
18
19 2010;36(3):1-48.
20
21
- 22 50. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent
23
24 predictors of the risk of myocardial infarction in HIV-infected individuals. *Clin Infect Dis*
25
26 2012;55(4):600-7. doi: 10.1093/cid/cis489
27
28
- 29 51. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral
30
31 therapy, and risk of acute myocardial infarction: a cohort and nested case-control study
32
33 using Quebec's public health insurance database. *J Acquir Immune Defic Syndr*
34
35 2011;57(3):245-53. doi: 10.1097/QAI.0b013e31821d33a5
36
37
- 38 52. Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between
39
40 abacavir usage and myocardial infarction risk in individuals with HIV? A cohort
41
42 collaboration. *BMC Med* 2016;14:61. doi: 10.1186/s12916-016-0588-4
43
44
- 45 53. Salinas JL, Rentsch C, Marconi VC, et al. Baseline, Time-Updated, and Cumulative HIV
46
47 Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. *Clin*
48
49 *Infect Dis* 2016;63(11):1423-30. doi: 10.1093/cid/ciw564
50
51
- 52 54. Palella FJ, Althoff KN, Moore R, et al. Abacavir use and risk for myocardial infarction in the
53
54 NA-ACCORD [CROI Abstract 749LB]. In Special Issue: Abstracts From the 2015
55
56
57
58
59
60

- 1
2
3 Conference on Retroviruses and Opportunistic Infections. *Top Antivir Med* 2015;23(e-
4 1):335-36.
5
6
7
8 55. Rasmussen LD, May MT, Kronborg G, et al. Time trends for risk of severe age-related
9 diseases in individuals with and without HIV infection in Denmark: a nationwide
10 population-based cohort study. *Lancet HIV* 2015;2(7):e288-98. doi: 10.1016/S2352-
11 3018(15)00077-6 [published Online First: 2015/10/02]
12
13
14
15
16
17 56. Drozd DR, Nance RM, Delaney JAC, et al. Lower CD4 count and higher viral load are
18 associated with increased risk of myocardial infarction [CROI abstract 739]. In Special
19 Issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections.
20
21
22
23
24
25
26
27 57. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV
28 infection exposed to specific individual antiretroviral drugs from the 3 major drug
29 classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect*
30
31
32
33
34
35
36 58. D:A:D Study Group, Sabin CA, d'Arminio Monforte A, et al. Changes over time in risk
37 factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected
38 individuals and impact on myocardial infarction. *Clin Infect Dis* 2008b;46(7):1101-10.
39
40
41
42
43
44
45 59. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-
46 uninfected individuals: a population-based cohort study. *Clin Infect Dis*
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 60. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular
4 outcomes in patients with HIV-1. *Lancet* 2002;360(9347):1747-8. doi: 10.1016/S0140-
5 6736(02)11672-2
6
7
8
9
10 61. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected
11 patients between 1983 and 1998: the Frankfurt HIV-cohort study. *Eur J Med Res*
12 2000;5(8):329-33.
13
14
15
16 62. Carman WJ, Bowlin S, McAfee AT. Human immunodeficiency (HIV) therapy and
17 cardiovascular (CV) events [ICPE Abstract 323]. In: Abstracts from the 27th
18 International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
19 *Pharmacoepidemiol Drug Saf* 2011;20(S140)
20
21
22
23
24
25 63. LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected
26 veterans receiving atazanavir. *AIDS* 2017;31(15):2095-106. doi:
27 10.1097/QAD.0000000000001594
28
29
30
31
32 64. Rosenblatt L, Farr AM, Johnston SS, et al. Risk of Cardiovascular Events Among Patients
33 Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens. *Open*
34 *Forum Infect Dis* 2016a;3(2):ofw061. doi: 10.1093/ofid/ofw061
35
36
37
38
39 65. Rosenblatt L, Farr AM, Nkhoma ET, et al. Risk of cardiovascular events among patients with
40 HIV treated with atazanavir-containing regimens: a retrospective cohort study. *BMC*
41 *Infect Dis* 2016b;16:492. doi: 10.1186/s12879-016-1827-1
42
43
44
45
46 66. Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events associated with current
47 exposure to HIV antiretroviral therapies in a US veteran population. *Clin Infect Dis*
48 2015;61(3):445-52. doi: 10.1093/cid/civ316
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 67. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with
4 myocardial infarction rates in a US healthcare system. *J Acquir Immune Defic Syndr*
5 2010;55(5):615-9. doi: 10.1097/QAI.0b013e3181f4b752
6
7
8
9
10 68. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection
11 with acute myocardial infarction. *J Acquir Immune Defic Syndr* 2009;51(3):268-73. doi:
12 10.1097/QAI.0b013e3181a9992c [published Online First: 2009/04/24]
13
14
15
16
17 69. Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events
18 versus death from other causes associated with antiretroviral use. *AIDS*
19 2006;20(15):1941-50. doi: 10.1097/01.aids.0000247115.81832.a1
20
21
22
23
24 70. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among
25 HIV-positive compared with HIV-negative individuals with access to care. *Clin Infect*
26 *Dis* 2015;60(8):1278-80. doi: 10.1093/cid/civ014
27
28
29
30
31 71. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-
32 infected patients in France, relative to the general population. *AIDS* 2010b;24(8):1228-
33 30. doi: 10.1097/QAD.0b013e328339192f
34
35
36
37
38 72. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction
39 among HIV-positive individuals with access to care. *J Acquir Immune Defic Syndr*
40 2014;65(2):160-6. doi: 10.1097/QAI.0000000000000009
41
42
43
44
45 73. Althoff KN, Gange SJ. A critical epidemiological review of cardiovascular disease risk in
46 HIV-infected adults: the importance of the HIV-uninfected comparison group,
47 confounding, and competing risks. *HIV Med* 2013;14(3):191-2. doi: 10.1111/hiv.12007
48
49
50
51 [published Online First: 2013/02/02]
52
53
54
55
56
57
58
59
60

- 1
2
3 74. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*
4
5 2005;352(16):1685-95. doi: 10.1056/NEJMra043430
6
7
8 75. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic
9
10 mechanisms among HIV-infected patients. *J Infect Dis* 2012;205 Suppl 3:S368-74. doi:
11
12 10.1093/infdis/jis201
13
14
15 76. Cerrato E, Calcagno A, D'Ascenzo F, et al. Cardiovascular disease in HIV patients: from
16
17 bench to bedside and backwards. *Open Heart* 2015;2(1):e000174. doi: 10.1136/openhrt-
18
19 2014-000174
20
21
22 77. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and
23
24 cardiovascular risk factors among patients with human immunodeficiency virus disease. *J*
25
26 *Clin Endocrinol Metab* 2007;92(7):2506-12. doi: 10.1210/jc.2006-2190 [published
27
28 Online First: 2007/04/26]
29
30
31 78. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients:
32
33 epidemiology, pathogenesis, and clinical management. *AIDS* 2010;24(6):789-802. doi:
34
35 10.1097/QAD.0b013e328337afdf
36
37
38 79. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-
39
40 emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. *Clin Infect Dis*
41
42 2009;49(10):1591-601. doi: 10.1086/644769
43
44
45 80. Alvarez A, Orden S, Andujar I, et al. Cardiovascular toxicity of abacavir: a clinical
46
47 controversy in need of a pharmacological explanation. *AIDS* 2017;31(13):1781-95. doi:
48
49 10.1097/QAD.0000000000001547
50
51
52 81. Llibre JM, Hill A. Abacavir and cardiovascular disease: A critical look at the data. *Antiviral*
53
54 *Res* 2016;132:116-21. doi: 10.1016/j.antiviral.2016.05.015
55
56
57
58
59
60

- 1
2
3 82. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized
4
5 clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four
6
7 different protease inhibitors. *AIDS research and human retroviruses* 2003;19(6):449-55.
8
9 doi: 10.1089/088922203766774487
10
11
12 83. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis *Psychological*
13
14 *Methods* 1998;3(4):486-504.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Titles and Legends

Figure 1. Flow diagram of study selection

Legend: *, Includes several conference abstract records captured through the database search; **, Includes one study involving a 'general population' comparison group

ART, Combination antiretroviral therapy; CVD, Cardiovascular disease

Figure 2. Forest plot of the meta-analysis of the risk of MI associated with HIV infection

Legend: ART, Antiretroviral therapy; CI, Confidence interval

Figure 3. Forest plot of the meta-analysis of the risk of MI associated with CD4 cell count and plasma viral load levels

Legend: CI, Confidence interval

Figure 4. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NRTI class


Legend: CI, Confidence interval

Figure 5. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NNRTI class

Legend: CI, Confidence interval

Figure 6. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the protease inhibitor class

Legend: CI, Confidence interval



41 **Figure 1. Flow diagram of study selection**

42 **Legend:** *, Includes several conference abstract records captured through the database search; **, Includes one study
43 involving a 'general population' comparison group
44 ART, Combination antiretroviral therapy; CVD, Cardiovascular disease

45 Figure 1. Flow diagram of study selection

46 177x223mm (300 x 300 DPI)




Figure 2. Forest plot of the meta-analysis of the risk of MI associated with HIV infection

656x588mm (72 x 72 DPI)




Figure 3. Forest plot of the meta-analysis of the risk of MI associated with CD4 cell count and plasma viral load levels

152x135mm (300 x 300 DPI)




Figure 4. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NRTI class

152x140mm (300 x 300 DPI)




Figure 5. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NNRTI class

152x128mm (300 x 300 DPI)




Figure 6. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the protease inhibitor class

152x138mm (300 x 300 DPI)

Appendix

Appendix Table 1. Search strategy

1	hiv.af.
2	human immunodeficiency virus.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
3	acquired immunodeficiency syndrome.af.
4	hiv aids.af.
5	1 or 2 or 3 or 4
6	stroke.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
7	(myocardial infarction or heart attack).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
8	cardiac death.af.
9	cerebrovascular disease.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
10	(ischemic heart disease or Ischaemic heart disease).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
11	(cardiovascular disease or cvd).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
12	6 or 7 or 8 or 9 or 10 or 11
13	5 and 12
14	limit 13 to human
15	limit 14 to english language
16	Limit 15 to yr= "2000 – Current"
17	remove duplicates from 16

Note: The searches were executed in the following four databases: (1) EBM Reviews - Cochrane Central Register of Controlled Trials <June 2018>, (2) EBM Reviews - Cochrane Database of Systematic Reviews <2005 to July 11, 2018>, (3) Embase <1974 to 2018 July 17>, (4) Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily <1946 to July 17, 2018>

Study selection

The excluded studies included several key CVD review articles,¹⁻⁸ and aggregate clinical trial studies,⁹⁻¹² whose bibliographies were screened for identification of additional relevant studies. We also excluded a number of potentially eligible records when more comprehensive or updated results for the same participants and risk comparison were published in another report;¹³⁻¹⁶ risk associations were reported in a way that would not allow for pairwise grouping with other studies reporting similar associations to facilitate pooling of results;¹⁷⁻²¹ or results were reported as number of events or unadjusted risk estimates only.²²⁻²⁵

Note: the references cited in the paragraph above are listed at the end of the appendix

Appendix Table 2. Characteristics of included studies

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
LaFleur <i>et al</i> 2017 ⁵⁵	Cohort	USA	ATV-cohort: 12 months Non-ATV: 13 months	HIV+	ATV-cohort: 1,529 (96) Non-ATV: 7,971 (92)	50 years	MI	ATV exposure vs. not exposed	HR ^β
Drozd <i>et al</i> 2017 ⁴³	Cohort	North America	HIV+: 4.5 years HIV-: 19.7 years	HIV+/HIV- (NA-ACCORD / ARIC)	HIV+: 28,912 (81) HIV-: 14,308 (44)	HIV+: 80% were < 50 years HIV-: 27% were < 50 years	Type 1 MI	HIV+ vs. HIV- ^{**}	IRR ^β
Rosenblatt <i>et al</i> 2016a ⁵⁶	Cohort	USA	EFV-cohort: 23.2 months EFV-free: 19.3 months	HIV+	EFV-cohort: 11,978 (86) EFV-free: 10,234 (79)	EFV-cohort: 40.2 years EFV-free: 40.7 years	MI	EFV exposure vs. not exposed	HR ^β
Rosenblatt <i>et al</i> 2016b ⁵⁷	Cohort	USA	ATV-cohort: 24 months ATV-free: 21 months	HIV+	ATV-cohort: 2,437 (76) ATV-free: 19,774 (84)	ATV-cohort: 41.0 years ATV-free: 40.4 years	MI	ATV exposure vs. not exposed	HR ^β
Sabin <i>et al</i> 2016 ⁴⁴	Cohort	Multi-national	7.0 (4.4-11.1) years ^a	HIV+	49,717 (74)	38 (32-44) years ^a	MI	Current ABC exposure vs. not current (1999-2013)	IRR ^β
Salinas <i>et al</i> 2016 ⁴⁵	Cohort	USA	1996-2012 (follow-up)	HIV+	8,168 (97)	46 (40-53) years ^a	AMI	VL at ART initiation ≥ 100,000 copies/mL vs. < 100,000	HR ^β
Desai <i>et al</i> 2015 ⁵⁸	Cohort	USA	~6.7 years	HIV+	24,510 (98)	46.5	MI	Current exposure to ABC vs. not currently exposed Current exposure to DDI vs. not currently exposed Current exposure to ATV vs. not currently exposed Current exposure to TDF vs. not currently exposed Current exposure to LPV vs. not currently exposed Current exposure to FTC vs. not currently exposed Current exposure to 3TC vs. not currently exposed Current exposure to d4T vs. not currently exposed Current exposure to ZDV vs. not currently exposed Current exposure to IDV vs. not currently exposed	OR ^β / HR ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Current exposure to NFV vs. not currently exposed Current exposure to SQV vs. not currently exposed Current exposure to RTV vs. not currently exposed Current exposure to EFV vs. not currently exposed Current exposure to NVP vs. not currently exposed	
Klein <i>et al</i> 2015 ⁶³	Cohort	USA	HIV+: 4.8years HIV-: 5.8 years	HIV+/HIV-	282,368 (91)	HIV+: 41 years HIV-: 40 years	MI	HIV+ vs HIV-	IRR ^β
Palella <i>et al</i> 2015 ⁶⁶	Cohort	USA	~3.9 years	HIV+	16,733 (81)	Reported proportion of individuals by age categories	MI	Recent ABC use vs. non-recent use	HR ^β
Rasmussen <i>et al</i> 2015 ⁴⁷	Cohort	Denmark	HIV+: 55,050–57,631 PYs HIV-: 638,204–659,237 PYss	HIV+/HIV-	HIV+: 5,897 (76) HIV-: 53,073 (76)	HIV+: 36.8 years ^a HIV-: 36.8 years ^a	MI	HIV+ vs. HIV-	IRR ^β
Drozd <i>et al</i> 2014 ⁴⁸	Cohort	USA	1996-2012 (follow-up) NR	HIV+ HIV+	18,155 (NR) 17,626 (79)	NR Reported proportion of individuals by age categories	MI Primary MI	Current HIV RNA (log (copies/mL)+1) CD4 < 200 vs ≥ 200	OR ^β HR ^β
Silverberg <i>et al</i> 2014 ⁶⁵	Cohort	USA	HIV+: 4.5 years HIV-: 5.4 years	HIV+/HIV-	HIV+: 22,081 (90.6) HIV-: 230,069 (90.5)	Reported proportion of individuals by age categories	MI	ART-treated HIV+ vs. HIV- ART-untreated HIV+ vs. HIV- Recent HIV RNA (per 1 log increase) Prior ART (yes vs no) Duration of PI use per year increase Duration of NNRTI use per year increase	IRR ^β
Freiberg <i>et al</i> 2013 ³	Cohort	USA	5.9 years ^a	HIV+/HIV-	HIV+: 27,350 (97.3) HIV-: 55,109 (97.2)	HIV+: 48.2 years HIV-: 48.8 years	AMI	HIV+ vs. HIV- Recent CD4 < 200 (yes/no) Recent PI use (yes/no)	HR ^β
Lang <i>et al</i> 2012 ⁴¹	Nested case control	France	4.0 years	HIV+	Cases: 289 (88.9) Controls: 884 (89.1)	Cases: 47 (41-54) years ^a Controls: 46 (40-54) years ^a	MI	Current ABC vs not current HIV RNA per log10 increase	OR ^β

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
Bedimo <i>et al</i> 2011 ¹²	Cohort	USA	3.9 years ^a	HIV+	19,424 (98)	46 years ^a	AMI	Cumulative ABC HAART per year of exposure Current ABC HAART vs. neither ABC/TDF Cumulative ARV per year of exposure	HR ^β
Choi <i>et al</i> 2011 ⁵⁹	Cohort	USA	4.5 years ^a	HIV+	10,931 (98)	46 to 49 years (within subgroups by ART use)	MI	Recent ABC vs. not recent ABC or TDF	HR ^β
Durand <i>et al</i> 2011 ⁴²	Cohort	Canada	4.0 years	HIV+/HIV-	HIV+: 7,053 (78); HIV-: 27,681 (78) Cases: 125 (91.2); Controls: 1,084 (92.2)	HIV+: 39.5 years	AMI	HIV+ vs. HIV-	HR ^β
	Nested case control			HIV+		HIV-: 39.7 years	AMI	ABC exposure vs. no exposure Recent ABC vs. not recent DDI exposure vs. no exposure Recent DDI vs. not recent TDF exposure vs. no exposure Recent TDF vs. not recent ATV exposure vs. no exposure Recent ATV vs. not recent Recent LPV vs. not recent Recent RTV vs. not recent Recent EFV vs. not recent NVP exposure vs. no exposure Recent NVP vs. not recent FTC exposure vs. no exposure Recent FTC vs. not recent Recent 3TC vs. not recent d4T exposure vs. no exposure Recent d4T vs. not recent ZDV exposure vs. no exposure Recent ZDV vs. not recent Recent IDV vs. not recent NFV exposure vs. no exposure Recent NFV vs. not recent SQV exposure vs. no exposure	OR ^β

For peer review only

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Recent SQV vs. not recent	
Carman <i>et al</i> 2011 ⁵⁴	Cohort	USA	1998-2007 (follow-up)	HIV+	66,286 (NR)	NR	AMI	Recent ABC use vs. no use	IRR ^β
								Recent PI use vs. no use	
Lang <i>et al</i> 2010b ⁶⁴	Cohort	France	2000-2006 (follow-up)	HIV+/ general population	HIV+: ~ 74,958 General population: unclear	35 to 64 years	MI	HIV+ vs general population	SMR
Lang <i>et al</i> 2010a ¹¹	Nested case control	France	2000-2006 (follow-up)	HIV+	Cases: 289 (89) Controls: 884 (89)	Cases: 47 (41-54) years ^a Controls: 46 (40-54) years ^a	MI	Recent ABC exposure vs. no exposure	OR ^β
								Cumulative ABC exposure vs. no exposure Cumulative DDI per year of exposure Cumulative TDF per year of exposure Cumulative ZVD per year of exposure Cumulative EFV per year of exposure Cumulative NVP per year of exposure Cumulative LPV + RTV per year of exposure Cumulative NFV per year of exposure Cumulative 3TC exposure per year Cumulative d4T exposure per year	
Obel <i>et al</i> 2010 ⁸	Cohort	Denmark	~ 6.5 years	HIV+	2,952 (76.4)	39.1 (33.0-46.6) years ^a	MI	ABC exposure vs. no exposure	IRR ^β
Worm <i>et al</i> 2010 ⁴⁹	Cohort	Multi-national	5.8 (3.9-7.5) years ^a	HIV+	33,308 (74)	With MI: 49 (43-65) years ^a Without MI: 44 (38-50) years ^a	MI	Cumulative ABC exposure per year	Relative rate ^β
								Recent TDF exposure vs. not recent Cumulative TDF exposure per year Recent DDI exposure vs. not recent Cumulative LPV-RTV exposure per year	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Cumulative NFV exposure per year Cumulative NVP exposure per year Cumulative EFV exposure per year	
Triant <i>et al</i> 2010 ⁶⁰	Cohort	USA	5.1 years ^a	HIV+	6,517 (69)	46 years	AMI	CD4 count < 200/mm ³ vs ≥ 200 Nadir CD4 per 50/mm ³ increase VL > 100,000 copies/mL vs. ≤ 100,000 HIV RNA per log 10 increase ART per year since first ART use TDF use vs. none ABC use vs. none DDI use vs. none FTC use vs. none d4T use vs. none NVP use vs. none ATV use vs. none NFV use vs. none SQV use vs. none	OR ^β
Triant <i>et al</i> 2009 ⁶¹	Cohort	USA	HIV+: 6.0 years HIV-: 5.8 years	HIV+/HIV-	HIV+: 487 (62.8) HIV-: 69,870 (45.6)	HIV+/HIV-: Reported proportion by age categories	AMI	HIV+ vs. HIV-	OR ^β
D:A:D Study Group <i>et al</i> 2008a ¹³	Cohort	Multi-national	5.1 years ^a	HIV+	33,347 (74)	With MI: 49 (range: 24-92) years ^a Without MI: 44 (range: 12-95) years ^a	MI	Recent ABC exposure vs. never exposed to ABC Recent DDI exposure vs. never exposed Cumulative DDI exposure per year Recent ZDV exposure vs. never exposed Recent ZDV exposure vs. not recent Cumulative ZDV exposure per year Recent 3TC exposure vs. not recent Cumulative 3TC exposure per year	Relative rate ^β

For peer review only

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Recent d4T exposure vs. not recent Recent d4T exposure vs. never exposed Cumulative d4T exposure per year	
D:A:D Study Group <i>et al</i> 2008b ⁵⁰	Cohort	Multi-national	4.5 years ^a	HIV+	28,985 (NR)	Reported by calendar period	MI	Cumulative exposure to PIs per year Cumulative exposure to NNRTIs per year	Relative rate ^β
D:A:D Study Group <i>et al</i> 2007 ⁷	Cohort	Multi-national	4.5 years ^a	HIV+	23,437 (76)	39 (34-45) years ^a	MI	Nadir CD4 per 50 cells/mm ³ increase	Relative rate ^β
Obel <i>et al</i> 2007 ⁵¹	Cohort	Denmark	HIV+: 6.9 years ^a HIV-: 8.1 years ^a	HIV+/ HIV-	HIV+: 3,953 (76.8) HIV-: 373,856 (76.3)	HIV+: 36.8 (30.8-44.6) years ^a HIV-: 36.4 (30.6-44.0) years ^a	MI	HIV+, on HAART+ vs. HIV- HIV+ not on HAART- vs. HIV-	IRR ^β
Kwong <i>et al</i> 2006 ⁶²	Cohort	USA and Netherlands	3.49 (range: 0.02-18.46) years ^a	HIV+	18,603 (82.63)	36 (range: 18-92) years ^a	MI	PI per year of exposure NNRTI per year of exposure HAART per year of exposure	RR ^β
Mary-Krause <i>et al</i> 2003 ⁶	Cohort	France	With MI: 28 (18-39) months ^a Without MI: 33 (15-48) months ^a	HIV+ men	34,976 (100)	With MI: 41.9 years Without MI: 37.7 years	MI	Exposure to PI	Relative hazard ^β
Holmberg <i>et al</i> 2002 ⁵²	Cohort	USA	~ 3.1 years	HIV+	5,672 (82)	42.6 years	MI	PI use (yes vs no)	HR ^β
Rickerts <i>et al</i> 2000 ^{*53}	Cohort	Germany	24.6 ± 18.1 months	HIV+	2,861 (78)	36.6 ± 9.5 years	MI	Prior HAART (yes vs. no)	OR ^β


Legend: ^a, median (including lower and upper quartiles, where reported); ^β, adjusted estimate; *, extracted data from the ART era only; **, this was a general population comparison group and may not have consisted of HIV- individuals only; Note: a superscript alongside the author name/year is used to denote the reference number of the study; **ABC**, abacavir; **AMI**, acute myocardial infarction; **ARIC**, Atherosclerosis Risk in Communities; **ART**, antiretroviral therapy; **ATV**, atazanavir; **DDI**, didanosine; **d4T**, stavudine; **EFV**, efavirenz; **FTC**, emtricitabine; **HAART**, highly active antiretroviral therapy; **HR**, Hazard ratio; **IDV**, indinavir; **IRR**, incidence rate ratio; **LPV**, lopinavir; **LPV-RTV**, lopinavir-ritonavir; **MI**, myocardial infarction; **NA-ACCORD/ARIC**, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)/Atherosclerosis Risk in Communities (ARIC) cohorts; **NFV**, nelfinavir; **NNRTI**, non-nucleoside reverse transcriptase inhibitor; **NR**, not reported; **NRTI**, nucleoside reverse transcriptase inhibitor; **NVP**, nevirapine; **OR**, Odds ratio; **PI**, protease inhibitor; **RR**, relative risk; **RTV**, ritonavir; **SMR**, standardized morbidity ratio; **SQV**, saquinavir; **TDF**, tenofovir; **VL**, viral load; **ZDV**, zidovudine; **3TC**, lamivudine

Appendix Table 3. Risk of bias in the included studies


Author, year	Publication type	Study design	Clearly defined eligibility criteria	Description of participants/group(s) selection	Potential for bias in case/group representation	Comparability among group(s) based on design or analysis	Adequate exposure/outcome ascertainment	Sufficient follow-up for outcome occurrence?	Funding source
LaFleur <i>et al</i> 2017 ⁵⁵	Journal	Cohort (R)	+	+	No	+	-	-	Public, industry
Drozd <i>et al</i> 2017 ⁴³	Journal	Cohort (P & R)	+	+	Yes*	-	+	+	Public
Rosenblatt <i>et al</i> 2016a ⁵⁶	Journal	Cohort (R)	+	+	No	+	-	+	Industry
Rosenblatt <i>et al</i> 2016b ⁵⁷	Journal	Cohort (R)	+	+	No	+	-	+	Industry
Sabin <i>et al</i> 2016 ⁴⁴	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Salinas <i>et al</i> 2016 ⁴⁵	Journal	Cohort (P)	+	+	No	+	-	+	Public
Desai <i>et al</i> 2015 ⁵⁸	Journal	Cohort (R)	+	+	No	+	-	+	Public
Klein <i>et al</i> 2015 ⁶³	Journal	Cohort (R)	+	+	No	+	+	+	Private, industry
Palella <i>et al</i> 2015 ⁴⁶	Abstract	Cohort (P & R)	+	+	No	-	+	+	-
Rasmussen <i>et al</i> 2015 ⁴⁷	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Drozd <i>et al</i> 2014 ⁴⁸	Abstract	Cohort (P)	-	+	No	-	+	-	Public
Silverberg <i>et al</i> 2014 ⁶⁵	Journal	Cohort (R)	+	+	No	+	+	+	Private, industry
Freiberg <i>et al</i> 2013 ³	Journal	Cohort (P)	+	+	No	+	+	+	Public
Lang <i>et al</i> 2012 ⁴¹	Journal	Nested case-control	+	+	No	+	+	+	Public
Bedimo <i>et al</i> 2011 ¹²	Journal	Cohort (R)	+	+	No	+	-	+	-
Choi <i>et al</i> 2011 ⁵⁹	Journal	Cohort (R)	+	+	No	+	-	+	Public
Durand <i>et al</i> 2011 ⁴²	Journal	Cohort (R), & nested case-control	+	+	No	+	-	+	Industry
Carman <i>et al</i> 2011 ⁵⁴	Abstract	Cohort (R)	-	+	-	-	-	+	-

Author, year	Publication type	Study design	Clearly defined eligibility criteria	Description of participants/group(s) selection	Potential for bias in case/group representation	Comparability among group(s) based on design or analysis	Adequate exposure/outcome ascertainment	Sufficient follow-up for outcome occurrence?	Funding source
Lang <i>et al</i> 2010a ⁶⁴	Journal	Nested case-control	+	+	No	+	+	+	Public
Lang <i>et al</i> 2010b ¹¹	Journal	Cohort (R)	+	+	No	-	+	+	Public
Obel <i>et al</i> 2010 ⁸	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Worm <i>et al</i> 2010 ⁴⁹	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Triant <i>et al</i> 2010 ⁶⁰	Journal	Cohort (R)	+	+	No	+	-	+	Public
Triant <i>et al</i> 2009 ⁶¹	Journal	Cohort (R)	+	+	No	+	-	+	Public
D:A:D Study Group <i>et al</i> 2008a ¹³	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
D:A:D Study Group <i>et al</i> 2008b ⁵⁰	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
D:A:D Study Group <i>et al</i> 2007 ⁷	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Obel <i>et al</i> 2007 ⁵¹	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Kwong <i>et al</i> 2006 ⁶²	Journal	Cohort (R)	+	+	No	+	-	+	Public, industry
Mary-Krause <i>et al</i> 2003 ⁶	Journal	Cohort (R)	+	+	No	+	+	+	Public
Holmberg <i>et al</i> 2002 ⁵²	Journal	Cohort (P)	+	+	No	-	+	+	Public
Rickerts <i>et al</i> 2000 ⁵³	Journal	Cohort (P)	+	+	No	+	+	+	-


Legend: + means this is clearly described and adequate; - means this is unclear, inadequate or not reported; *, The HIV+ cohort (NA-ACCORD study) was compared to a general population cohort from a different study (Atherosclerosis Risk in Communities [ARIC] study); Note: a superscript alongside the author name/year is used to denote the reference number of the study; NA, Not applicable; P, Prospective; R, Retrospective



Appendix Figure A1. Forest plot of the meta-analysis of the risk of MI associated with any exposure to antiretroviral therapy
 Legend: CI, Confidence interval




Appendix Figure A2. Forest plot of the meta-analysis of the risk of MI associated with any exposure to drugs of the NRTI class
 Legend: CI, Confidence interval




34 **Appendix Figure A3. Forest plot of the meta-analysis of the risk of MI associated with any exposure**
 35 **to drugs of the NNRTI class**

36 Legend: CI, Confidence interval




Appendix Figure A4. Forest plot of the meta-analysis of the risk of MI associated with any exposure to protease inhibitors (both as a class and individually)
 Legend: CI, Confidence interval

Only




36 **Appendix Figure A5. Forest plot of the meta-analysis of the risk of MI associated with cumulative**
 37 **exposure to antiretroviral therapy (ART) including class of ART**

38 Legend: ART, Antiretroviral therapy; CI, Confidence interval; NNRTI, Non-nucleoside reverse
 39 transcriptase inhibitors; PI, Protease inhibitors




Appendix Figure A6. Forest plot of the meta-analysis of the risk of MI associated with cumulative exposure to drugs of the NRTI class
 Legend: CI, Confidence interval




36 **Appendix Figure A7. Forest plot of the meta-analysis of the risk of MI associated with cumulative**
 37 **exposure to NNRTI (both as a class and individually)**

38 Legend: CI, Confidence interval; NNRTI, Non-nucleoside reverse transcriptase inhibitors




Appendix Figure A8. Forest plot of the meta-analysis of the risk of MI associated with cumulative exposure to protease inhibitors (both as a class and individually)
 Legend: CI, Confidence interval; PI, Protease inhibitors



Appendix Figure S1. Forest plot of the sensitivity analysis for the meta-analysis of the risk of MI associated with HIV infection, where one additional study involving a general population comparison group was included

Legend: *, This study had a 'general population' comparison group and may not have consisted of HIV-negative individuals only; CI, Confidence interval



Appendix Figure S2. Forest plot of the sensitivity analyses for the meta-analysis of the risk of MI associated with HIV infection, where estimates reported using similar relative effect measures were pooled

Legend: CI, Confidence interval; HR, Hazard ratio; IRR, Incidence rate ratio

Appendix References (for study selection section only)

1. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. *PLoS One*. 2013;8(3):e59551.
2. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*. 2012;61(4):441-7.
3. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. *AIDS*. 2011;25(16):1993-2004.
4. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *HIV Med*. 2012;13(8):453-68.
5. Friis-Moller N, Smieja M, Klein D. Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. *Curr Opin HIV AIDS*. 2008;3(3):220-5.
6. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. *AIDS*. 2010;24(6):789-802.
7. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. *Eur Heart J*. 2014;35(21):1373-81.
8. Escarcega RO, Franco JJ, Mani BC, Vyas A, Tedaldi EM, Bove AA. Cardiovascular disease in patients with chronic human immunodeficiency virus infection. *Int J Cardiol*. 2014;175(1):1-7.
9. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. *J Acquir Immune Defic Syndr*. 2009;51(1):20-8.
10. Ribaldo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. *Clin Infect Dis*. 2011;52(7):929-40.
11. Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. *AIDS research and human retroviruses*. 2003;19(6):449-55.
12. Da Silva B, Tschampa J, Beron J, Fredrick L, Patwardhan M, Zachry W, et al. Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases. *Int J Clin Pharmacol Ther*. 2012;50(6):391-402.
13. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med*. 2003;349(21):1993-2003.
14. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? *J Acquir Immune Defic Syndr*. 2002;30(5):471-7.
15. Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. *Clin Infect Dis*. 2015;60(4):627-38.
16. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med*. 2010;11(7):462-8.
17. Strategies for Management of Anti-Retroviral Therapy/Insight, D:A:D. Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *AIDS*. 2008;22(14):F17-24.
18. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, et al. Associations between immune depression and cardiovascular events in HIV infection. *AIDS*. 2013;27(17):2735-48.
19. Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. *AIDS*. 2013;27(3):407-15.
20. Brouwer ES, Napravnik S, Eron JJ, Jr., Stalzer B, Floris-Moore M, Simpson RJ, Jr., et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. *Epidemiology*. 2014a;25(3):406-17.
21. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Heckbert SR, Budoff MJ, et al. Incidence and risk of myocardial infarction (MI) by Type in the NA-ACCORD [CROI Abstract 748]. In Special Issue: Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. *Top Antivir Med*. 2015;23(e-1):335.

- 1
2
3 22. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label,
4 prospective, observational study of the incidence of coronary artery disease in patients with HIV infection
5 receiving highly active antiretroviral therapy. *Clin Ther.* 2003;25(9):2405-18.
- 6 23. Engstrom K, Garcia M. Initial antiretroviral therapy with protease inhibitors is associated with
7 increased risk of heart failure in HIV-infected patients [ACC.14 Abstract 1261-192]. In: Abstracts from the
8 American College of Cardiology 63rd Annual Scientific Session & Expo. *JACC.* 2014;63(12):A955.
- 9 24. Triant VA, Regan S, Grinspoon SK. MACE incidence among HIV and non-HIV-infected patients
10 in a clinical care cohort [CROI abstract 738]. In Special Issue: Abstracts from the 2014 Conference on
11 Retroviruses and Opportunistic Infections. *Top Antivir Med.* 2014;22(e-1):376-77.
- 12 25. Brouwer E, Moga D: Differences in myocardial infarction risk among persons living and those not
13 living with HIV: an evaluation of a commercially insured population seeking care in the United States
14 [AIDS Abstract THPE038]. In:20th International AIDS Conference. Melbourne, Australia 2014b.
- 15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for meta-analysis of observational studies.

Based on the MOOSE guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the MOOSE reporting guidelines, and cite them as:

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-2012.

	Reporting Item	Page Number
#1	Identify the study as a meta-analysis of observational research	1
#2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number (From PRISMA checklist)	2
#3a	Problem definition	5
#3b	Hypothesis statement	6
#3c	Description of study outcomes	5
#3d	Type of exposure or intervention used	5, 6

1	#3e	Type of study designs used	6	
2				
3	#3f	Study population	7	
4				
5				
6	Search	#4a	Qualifications of searchers (eg, librarians and investigators)	6
7	strategy			
8				
9				
10		#4b	Search strategy, including time period included in the synthesis and	6
11			keywords	
12				
13		#4c	Effort to include all available studies, including contact with authors	7
14				
15				
16		#4d	Databases and registries searched	7
17				
18		#4e	Search software used, name and version, including special features	7
19			used (eg, explosion)	
20				
21				
22		#4f	Use of hand searching (eg, reference lists of obtained articles)	7
23				
24				
25		#4g	List of citations located and those excluded, including justification	See note
26				1
27				
28				
29		#4h	Method of addressing articles published in languages other than English	6
30				
31		#4i	Method of handling abstracts and unpublished studies	7
32				
33		#4j	Description of any contact with authors	8
34				
35				
36		#5a	Description of relevance or appropriateness of studies gathered for	6-8
37			assessing the hypothesis to be tested	
38				
39				
40		#5b	Rationale for the selection and coding of data (eg, sound clinical	5-8
41			principles or convenience)	
42				
43				
44		#5c	Documentation of how data were classified and coded (eg, multiple	7,8
45			raters, blinding, and interrater reliability)	
46				
47				
48		#5d	Assessment of confounding (eg, comparability of cases and controls in	n/a
49			studies where appropriate)	
50				
51				
52		#5e	Assessment of study quality, including blinding of quality assessors;	8,9
53			stratification or regression on possible predictors of study results	
54				
55				
56		#5f	Assessment of heterogeneity	9
57				
58		#5g	Description of statistical methods (eg, complete description of fixed or	8, 9
59				
60				

random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated

#5h	Provision of appropriate tables and graphics	9, 10
#6a	Graphic summarizing individual study estimates and overall estimate	10-14
#6b	Table giving descriptive information for each study included	36
#6c	Results of sensitivity testing (eg, subgroup analysis)	32
#6d	Indication of statistical uncertainty of findings	32
#7a	Quantitative assessment of bias (eg. publication bias)	9
#7b	Justification for exclusion (eg, exclusion of non-English-language citations)	10
#7c	Assessment of quality of included studies	8, 10
#8a	Consideration of alternative explanations for observed results	18
#8b	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	18
#8c	Guidelines for future research	18
#8d	Disclosure of funding source	19

Author notes

1. 10, Appendix

Reproduced with permission from JAMA. 2000. 283(15):2008-2012. Copyright © 2000 American Medical Association. All rights reserved. This checklist was completed on 06. August 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025874.R2
Article Type:	Original research
Date Submitted by the Author:	14-Aug-2019
Complete List of Authors:	<p>Eyawo, Oghenowede; British Columbia Centre for Excellence in HIV/AIDS, Epidemiology and Population Health; Simon Fraser University, Faculty of Health Sciences</p> <p>Brockman, Gwenyth; University of Manitoba, George & Fay Yee Centre for Healthcare Innovation</p> <p>Goldsmith, Charles; University of British Columbia, Department of Occupational Science and Occupational Therapy, Faculty of Medicine; Simon Fraser University, Faculty of Health Sciences</p> <p>Hull, Mark; British Columbia Centre for Excellence in HIV/AIDS, Lear, Scott; Simon Fraser University, Faculty of Health Sciences; St. Paul's Hospital, Providence Health Care, Healthy Heart Program</p> <p>Bennett, Matthew; University of British Columbia, Division of Cardiology, Department of Medicine</p> <p>Guillemi, Silvia; BC Centre for Excellence in HIV/AIDS, Franco-Villalobos, Conrado; University of Alberta, School of Public Health</p> <p>Adam, Ahmed; Simon Fraser University, Faculty of Health Sciences</p> <p>Mills, Edward; McMaster University, Department of Clinical Epidemiology & Biostatistics</p> <p>Montaner, Julio; BC Centre for Excellence in HIV/AIDS; University of British Columbia, Department of Medicine</p> <p>Hogg, Robert; Simon Fraser University, Faculty of Health Sciences; British Columbia Centre for Excellence in HIV/AIDS,</p>
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Cardiovascular medicine, HIV/AIDS
Keywords:	Myocardial infarction < CARDIOLOGY, Cardiovascular disease, HIV & AIDS < INFECTIOUS DISEASES, Combination antiretroviral therapy, Relative risk, systematic review and meta-analysis

SCHOLARONE™
Manuscripts

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

Oghenowede Eyawo,^{1,2,3} Gwentyth Brockman,⁴ Charles H. Goldsmith,^{3,5,6} Mark W. Hull,² Scott A Lear,^{3,7} Matthew Bennett,⁸ Silvia Guillemi,² Conrado Franco-Villalobos,⁹ Ahmed Adam,³ Edward Mills,⁶ Julio SG Montaner,^{2,10} Robert S Hogg^{2,3}

1. Faculty of Health, York University, Toronto, ON, CANADA
2. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, CANADA
3. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, CANADA
4. George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, MB, CANADA
5. Department of Occupational Science and Occupational Therapy, Faculty of Medicine, University of British Columbia, Vancouver, BC, CANADA
6. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CANADA
7. Healthy Heart Program, St. Paul's Hospital, Providence Health Care, Vancouver, BC, CANADA
8. Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, BC, CANADA
9. School of Public Health, University of Alberta, Edmonton, AB, CANADA
10. Department of Medicine, University of British Columbia, Vancouver, BC, CANADA

Send correspondence to: Dr. Oghenowede Eyawo
Faculty of Health, York University
5022 Victor Dahdaleh Building, Keele Campus
88 The Pond Road
Toronto, ON, Canada, M3J 2S6
Tel: (416) 736-2100
Email: oeyawo@yorku.ca

Abstract

Objective: Cardiovascular disease is one of the leading non-AIDS-defining causes of death among HIV-positive (HIV+) individuals. However, the evidence surrounding specific components of cardiovascular disease risk remains inconclusive. We conducted a systematic review and meta-analysis to synthesize the available evidence and establish the risk of myocardial infarction (MI) among HIV+ compared with uninfected individuals. We also examined MI risk within subgroups of HIV+ individuals according to exposure to combination antiretroviral therapy (ART), ART class/regimen, CD4 cell count and plasma viral load levels.

Design: Systematic review and meta-analysis

Data sources: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Database of Systematic Reviews until July 18, 2018. Furthermore, we scanned recent HIV conference abstracts (CROI, IAS/AIDS) and bibliographies of relevant articles.

Eligibility criteria: Original studies published after December 1999 and reporting comparative data relating to the rate of MI among HIV+ individuals were included.

Data extraction and synthesis: Two reviewers working in duplicate, independently extracted data. Data were pooled using random-effects meta-analysis and reported as relative risk (RR) with 95% confidence intervals (CI).

Results: Thirty-two of the 8,130 identified records were included in the review. The pooled RR suggests that HIV+ individuals have a greater risk of MI compared to uninfected individuals (RR: 1.73, 95%CI: 1.44, 2.08). Depending on risk stratification, there was moderate variation according to ART uptake (RR, ART-treated = 1.80; 95%CI: 1.17, 2.77; ART-untreated HIV+ individuals: 1.25; 95%CI: 0.93, 1.67, both relative to uninfected individuals). We found low CD4 count, high

1
2
3 plasma viral load, and certain ART characteristics including cumulative ART exposure,
4 any/cumulative use of protease inhibitors as a class, and exposure to specific ART drugs (e.g.
5 abacavir) to be importantly associated with a greater MI risk.
6
7
8
9

10 **Conclusions:** Our results indicate that HIV infection, low CD4, high plasma viral load, cumulative
11 ART use in general including certain exposure to specific ART class/regimen are associated with
12 increased risk of MI. The association with cumulative ART may be an index of the duration of
13 HIV infection with its attendant inflammation, and not entirely the effect of cumulative exposure
14 to ART per se.
15
16
17
18
19
20
21
22
23

24 **PROSPERO registration number:** CRD42014012977
25
26
27
28
29
30

31 **Keywords:** Myocardial infarction, Cardiovascular disease, HIV, Combination antiretroviral
32 therapy (ART), Relative risk, Systematic review, Meta-analysis
33
34
35
36
37
38
39

40 Word count: 4,997
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Strengths and limitations of this study

- We used explicit eligibility criteria and a comprehensive search strategy for this systematic review and meta-analysis
- Adjudication of studies for eligibility and the data extraction were performed by two independent reviewers working in duplicate
- This systematic review and meta-analysis analyzed several additional drug exposure comparisons and clinical measures (e.g. CD4 cell count, plasma viral load) that had not been previously examined in relation to MI risk among HIV-positive individuals
- Some of the meta-analyses were based on a small number of studies which is a limitation
- Variability in the quality of the included studies may have influenced the results and thus the conclusions drawn.

INTRODUCTION

Cardiovascular disease (CVD) is one of the leading non-AIDS causes of death and disability among people living with HIV in the combination antiretroviral therapy (ART) era.^{1 2} Although HIV-positive (HIV+) individuals are believed to be at higher risk of CVD compared to uninfected individuals,^{3 4} the results and conclusions from the studies that have examined the nature of the risk of CVD, in particular myocardial infarction (MI) among HIV+ individuals have been conflicting. While some cohort studies have suggested a positive association between ART including specific drug (e.g. abacavir) or drug class (e.g. protease inhibitors [PI]) use and MI, or CVD risk,⁵⁻⁹ others have not.¹⁰⁻¹² Furthermore, there has been a lack of agreement between observational studies,^{8 11 13} and randomized controlled trials (RCT).^{14 15} Clearly, the evidence regarding the nature of, and extent of the risk of MI and other CVD events among HIV+ individuals is far from uniform.

Five meta-analyses have been conducted in an attempt to synthesize the data on CVD risk among HIV+ individuals.¹⁶⁻²⁰ These have either been limited in scope by assessing only the association between ART use and risk of CVD;¹⁶ included trials that lacked MI event adjudication;¹⁷ included trials where CVD events were not among the pre-specified outcomes of interest;¹⁸ provided incomplete results on MI risk;¹⁹ or amalgamated all CVD events (e.g. MI, stroke) as a single outcome.²⁰ In addition, this latter meta-analysis was fraught with a number of methodological ambiguities.²¹

Given these limitations, coupled with the publication of several new and updated study reports on the topic, we sought to undertake an updated systematic review and meta-analysis of studies

1
2
3 assessing the risk of CVD among persons living with HIV. Considering the scope, diversity and
4 differences in the definition,²²⁻²⁵ etiology and clinical picture of different CVD events,²⁶ coupled
5 with the strong body of literature related to HIV and MI and the ongoing debate around potential
6 MI risk associated with use of specific ART medications such as abacavir, we have elected to
7 focus primarily on MI as the outcome of interest for this meta-analysis, as it is the most widely
8 researched CVD outcome among HIV+ individuals. The objective of our study was to estimate
9 the risk of MI among HIV+ individuals relative to uninfected individuals. Additionally, we
10 examined MI risk within subgroups of HIV+ individuals according to exposure to ART, ART
11 class, specific ART regimen, CD4 cell count and plasma viral load levels.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **METHODS**

27 **Search strategy and selection criteria**

28
29 The systematic review and meta-analysis was performed in accordance with the PRISMA
30 Statement.²⁷ A protocol describing the inclusion criteria and analysis methods for this systematic
31 review was specified in advance, registered and published at the international prospective register
32 of systematic reviews (PROSPERO, registration number CRD42014012977).²⁸
33
34
35
36
37
38
39
40
41
42

43 The search strategy (see Appendix Table 1) was developed in consultation with a medical librarian
44 at Simon Fraser University, BC, Canada. The search terms were based on a combination of indexed
45 and free-text terms reflecting clinical outcomes of interest to the review, and included the
46 following keywords: ‘HIV, human immunodeficiency virus, acquired immunodeficiency
47 syndrome, HIV/AIDS, stroke, myocardial infarction, cardiac death, cerebrovascular disease,
48 ischemic heart disease, cardiovascular disease and CVD’. These terms were used in combination
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 to execute the searches, which were up to July 18, 2018. Using the Ovid platform, we searched the
4
5 following electronic databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled
6
7 Trials (CENTRAL) and the Cochrane Database of Systematic Reviews. In addition, we screened
8
9 the abstracts of the International AIDS Society conferences (AIDS 2012, 2014, 2016; IAS 2013)
10
11 and the Conference on Retroviruses and Opportunistic Infections (CROI 2014, 2015, and 2016).
12
13 We also searched the reference lists of relevant articles and previous systematic reviews for
14
15 additional eligible publications. Finally, we set up automatic PubMed literature alerts to identify
16
17 any new relevant article published while the manuscript was under development.
18
19
20
21
22
23

24 We included original research published in English where at least one of the participant groups
25
26 were individuals living with HIV, and presenting comparative data on the incidence of MI. We
27
28 included studies in which results were stratified according to HIV status; CD4 cell count; plasma
29
30 viral load (pVL) levels; ART use; or exposure to particular ART class or regimen. Studies
31
32 involving non-human populations; children; as well as those reporting only unadjusted estimates,
33
34 intermediate, surrogate or CVD biomarker outcomes were excluded (for additional information,
35
36 see 'study selection' in the Appendix, p1). To reflect the current context of HIV treatment and
37
38 disease management, we selected studies published from the year 2000 onwards. Although both
39
40 observational studies and RCTs were eligible for inclusion, we did not include RCTs that were not
41
42 designed to assess CVD events as a pre-specified outcome to avoid bias.
43
44
45

46 Working independently and in duplicate, two reviewers (OE and GB) scanned the titles and
47
48 abstracts of the retrieved records for eligibility. The full-text articles of potentially eligible studies
49
50 were obtained and reviewed in greater details. Disagreements in study selection were resolved
51
52
53
54
55
56
57
58
59
60

1
2
3 through discussion, and where necessary, a third investigator (RSH) was invited to facilitate
4
5 consensus.
6
7
8
9

10 11 **Data extraction and quality assessment** 12

13
14 The same two reviewers (OE and GB) conducted data extraction independently using a pre-
15 designed data abstraction sheet. We extracted data on study descriptors, sample characteristics,
16 outcome assessment, risk estimate for relevant comparisons, and study quality features. Where
17 necessary, we sought clarification directly from study authors through email contact. In cases
18 where data from the same study described the same event risk in multiple publications, we
19 extracted data from the most comprehensive report while supplementing missing study-level
20 information from the others. In keeping with characterizations in the included studies, exposure to
21 ART was categorized as any (or prior/some *compared to none*), recent (or within the preceding six
22 months *compared to not recent*) and cumulative ART exposure per year of exposure.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 The quality of the included studies was assessed according to risk of bias criteria based on the type
38 of study design. As only observational studies were eventually included in the meta-analysis since
39 eligible RCTs were not identified, we made this assessment by evaluating study design features of
40 the eligible observational studies. Following guidelines in the Newcastle-Ottawa Scale (NOS) for
41 assessing the quality of observational studies in meta-analyses²⁹ and with slight modification of
42 the scoring system to simplify reporting, the risk of bias assessment was performed based on the
43 adequacy of three key domains of the study design features namely: the group/participant
44 selection; comparability of groups; and the exposure and outcome assessments in the individual
45 studies. For each of these key features, we assigned a “+” (plus) sign when this was clearly and
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 adequately described in the study, and a “–“ (minus) sign when it was not clearly described or was
4
5 missing. A detailed description of the results of the quality assessment is available in the appendix.
6
7
8
9

10 **Patient and public involvement**

11
12 No patients were involved in this study. We used data from published materials only.
13
14
15

16 **Data analysis**

17
18 We calculated the kappa statistic as a measure of the inter-reviewer agreement for the selection of
19
20 articles meeting the inclusion/exclusion criteria. For interpretation, we defined *a priori* the interval
21
22 for the kappa result using Landis and Koch criteria.³⁰ For effect measure, we assumed the incidence
23
24 rate ratio (IRR), odds ratio (OR) and hazard ratio (HR) with corresponding sampling variance to
25
26 be numerical approximate measures of the relative risk (RR) for a given association of interest
27
28 with the underlying assumption of a generally low event risk (< 20%),³¹⁻³⁶ and thus combined them
29
30 as previously described.^{19 37-40} We tested this assumption in sensitivity analyses by performing
31
32 separate meta-analyses where studies presenting results reported using a similar effect measure
33
34 type were pooled. Given the expected variability among eligible studies, we pooled studies using
35
36 the DerSimonian-Laird random-effects model.⁴¹ To minimize bias in our pooled estimates,
37
38 adjusted risk estimates were not combined with unadjusted estimates. The final set of studies that
39
40 adjusted for confounders did not consistently adjust for the same set of confounders but were
41
42 deemed to have sufficient internal validity to permit pooling. For the analysis that quantified the
43
44 overall RR of MI associated with HIV infection, we performed a sensitivity analysis where we
45
46 examined the appropriateness of the comparison group by repeating the meta-analysis and
47
48 including two additional studies that involved a general population comparison group,^{42 43} as
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 opposed to an HIV-uninfected comparison group. Given the limitations of the I^2 statistics with
4 observational studies and Cochran Q test when the number of studies is small,^{44 45} we assessed
5 heterogeneity by visual inspection of the forest plots for overlap in the confidence intervals of the
6 individual studies, although the I^2 as a measure of the degree of heterogeneity across studies is
7 reported in the forest plots for completeness. We were unable to perform meta-regression analyses
8 to assess the potential effect of study-level covariates on the pooled estimate due to insufficient
9 studies (< 10),⁴⁶ in each of the meta-analyses. Although we assessed publication bias by visually
10 inspecting and testing for funnel plot asymmetry,⁴⁷ its interpretation was limited by a lack of
11 sufficient number of studies per meta-analysis.^{48 49} A p-value < 0.05 was considered statistically
12 significant. The meta-analysis was conducted using the *metafor* package of the R statistical
13 program (version 3.3.1) ⁵⁰.

30 31 RESULTS

32
33 Of 8,130 records identified through the database search, the final screening process yielded 64
34 potentially eligible publications on CVD outcomes, 32 of which had relevant data on MI and were
35 included in this meta-analysis (Figure 1). Overall, there was near perfect agreement between
36 reviewers on the inclusion of studies (kappa statistic = 0.94; 95% confidence interval (95%CI):
37 0.89, 0.99). The included studies, most of which were conducted in the United States and Europe,
38 were published between 2000 and 2017 and involved approximately 383,471 HIV+ and > 798,
39 424 HIV- individuals (Appendix Table 2: characteristics of the included studies; *note: the number*
40 *of individuals in cohorts with multiple publications was accessed only from one of the*
41 *publications). The mean duration of follow-up varied across studies from approximately one to*
42 *twenty years. All 32 publications were non-randomized studies and included two nested case-*
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 control studies,^{11 51} one cohort/nested case-control study,⁵² and 29 cohort studies; 15 of which were
4
5 prospective studies, by design.^{3 7 8 13 42 53-62} Twenty-nine studies were published as full-text journal
6
7 articles, while three were available as conference abstracts.
8
9

10
11
12 In general, the reporting and quality of the methodological aspects of the included studies were
13
14 variable. Three studies did not provide sufficient information necessary to assess the study quality,
15
16 as they were reported and available as conference abstract/poster.^{55 57 63} The eligibility criteria were
17
18 clearly defined in the majority of studies (94%), description of study participants/ groups was
19
20 sufficient (100%); however, the exposure or outcome was not adequately ascertained in 15 studies
21
22 (47%);^{8 12 24 52 54 56 60 63-70} one (7%) of which was published as an abstract⁶³ (see Appendix Table
23
24
25 3: risk of bias in the included studies).
26
27
28
29
30

31 **Meta-analysis of the risk of MI**

32
33
34 Below, we summarize the results of the meta-analyses of MI risk according to the various risk
35
36 stratifications assessed. To avoid duplication of reporting, only statistically important RR are
37
38 stated in text; although both statistically significant and insignificant results are presented in the
39
40 figures (forest plots).
41
42
43
44

45 *Risk of MI associated with HIV infection*

46
47
48 The pooled RR from the five studies that met eligibility for this assessment of MI risk according
49
50 to HIV serostatus suggests that HIV+ individuals are more likely to have an MI event compared
51
52 to uninfected individuals (RR: 1.73; 95%CI: 1.44, 2.08).^{3 52 56 69 71} In sensitivity analysis (Appendix
53
54 Figure S1) where we repeated the meta-analysis and included two additional studies that involved
55
56
57
58
59
60

1
2
3 a general population comparison group,^{42 43} the overall pooled RR was 1.60; 95%CI: 1.38, 1.85.
4
5 Figure 2 shows the forest plots for the association between HIV infection and MI risk. Two studies
6
7 assessed the risk of MI by HIV serostatus according to whether ART treatment was received.^{60 72}
8
9 Compared to uninfected individuals, the pooled RR of MI was significantly higher among HIV+
10
11 individuals on ART (RR: 1.80; 95%CI: 1.17, 2.77), but not the ART-untreated HIV+ individuals
12
13 (RR: 1.25; 95%CI: 0.93, 1.67).
14
15
16
17
18

19 Risk of MI associated with CD4 cell count and plasma viral load levels

20
21 The pooled RR based on combining data from three studies suggests that low CD4 cell count (<
22
23 200 cells/mm³) is associated with higher MI risk compared to CD4 ≥ 200 (RR: 1.60; 95%CI: 1.25,
24
25 2.04).^{3 57 68} Conversely, a high pVL (≥ 100,000 copies/mL) was found to be associated with
26
27 increased MI risk compared to pVL < 100,000 (RR: 1.45; 95%CI: 1.11, 1.90), based on the pooled
28
29 results from two studies (Figure 3).^{54 68}
30
31
32
33
34

35 Risk of MI associated with recent ART exposure

36
37 With regards to *recent treatment exposure* (i.e. within the preceding six months), four eligible
38
39 studies with data on nucleoside reverse transcriptase inhibitors (NRTI) exposure assessed the risk
40
41 of MI associated with recent compared to not recent abacavir exposure.^{52 53 55 67} The pooled result
42
43 from these four studies suggests that recent abacavir exposure is associated with increased risk of
44
45 MI compared to not recent exposure (RR: 1.71; 95%CI: 1.39, 2.10). Similarly, recent didanosine
46
47 (RR: 1.29; 95%CI: 1.04, 1.60),^{52 58 67} and lamivudine (RR: 1.50; 95%CI: 1.18, 1.90),^{13 52 67}
48
49 exposure is associated with increased risk of MI compared to not recent exposures. In contrast,
50
51 there was no detectable association between recent tenofovir,^{52 58 67} zidovudine,^{13 52 67} stavudine,¹³
52
53
54
55
56
57
58
59
60

1
2
3 ^{52 67} emtricitabine,^{52 67} and MI risk compared to not recent exposure (Figure 4). Based on pooling
4
5 data from two studies with data on non-nucleoside reverse transcriptase inhibitors (NNRTI)
6
7 exposure,^{52 67} no association was found between recent efavirenz or nevirapine exposure and MI
8
9 risk compared to not recent exposure (Figure 5). Based on pooled results from the studies assessing
10
11 the MI risk of individual PIs, recent indinavir was associated with increased MI risk compared to
12
13 not recent exposure (RR: 1.46; 95%CI: 1.08, 1.95).^{52 67} Recent exposure to other PI regimens
14
15 including atazanavir,^{52 67} lopinavir,^{52 67} ritonavir,^{52 67} nelfinavir,^{52 67} and saquinavir,^{52 67} were not
16
17 found to be significantly associated with MI risk compared to not recent exposure (Figure 6).
18
19
20
21
22
23

Risk of MI associated with any ART exposure

24
25
26 In terms of *any treatment exposure*, our meta-analysis did not find an association between exposure
27
28 to ART and risk of MI compared to no exposure (Appendix Figure A1).^{62 72} Based on the pooled
29
30 results from six studies with data on NRTI exposure,^{8 11 13 52 63 68} individuals receiving abacavir
31
32 were more likely to have an MI compared to those who did not (RR: 1.58; 95%CI: 1.25, 2.00). We
33
34 found a similar association between didanosine exposure and MI risk (RR: 1.48; 1.16, 1.90).^{13 52}
35
36 ⁶⁸ No detectable association was found between exposure to tenofovir,^{52 68} zidovudine,^{13 52}
37
38 stavudine,^{13 52 68} emtricitabine,^{52 68} and MI risk, based on our pooled results (Appendix Figure A2).
39
40
41 The meta-analysis of studies with data on NNRTI exposure did not find any evidence of an
42
43 association between either efavirenz,^{52 65} or nevirapine exposure,^{52 68} and MI risk compared to no
44
45 exposure (Appendix Figure A3). The pooled RR from four studies demonstrates that PI exposure
46
47 is associated with an increase in the risk of MI events compared to no exposure to PI (RR: 1.49;
48
49 95%CI: 1.16, 1.91).^{3 6 61 63} When the analysis was limited to two studies comparing recent PI
50
51 exposure to no exposure,^{3 63} similar results were found (RR: 1.40; 95%CI: 1.16, 1.69 [data not
52
53
54
55
56
57
58
59
60

1
2
3 shown]). For the individual PIs, there was no association between either atazanavir,^{52 64 66 68}
4 saquinavir,^{52 68} or nelfinavir exposure,^{52 68} and MI risk, compared to no exposure (Appendix Figure
5
6
7
8 A4).
9

10 11 12 Risk of MI associated with cumulative ART exposure 13

14
15 With regards to *cumulative treatment exposure*, three eligible studies provided relevant data
16 regarding the risk of MI and cumulative ART exposure.^{12 68 70} We found that cumulative exposure
17 to ART was associated with an increase in the risk of MI per year of exposure (RR: 1.12; 95%CI:
18 1.06, 1.18) (Appendix Figure A5). For exposure to NRTI regimens, we estimated an increase in
19 MI risk per year of exposure to abacavir (RR: 1.08; 95%CI: 1.01, 1.15) based on pooling data from
20 two eligible studies.^{12 58} Similar to abacavir, cumulative zidovudine exposure was associated with
21 an increase in MI risk per year of exposure (RR: 1.05; 95%CI: 1.01, 1.10).^{11 13} We found no
22 association between cumulative exposure to either didanosine,^{11 13} tenofovir,^{11 58} lamivudine,^{11 13}
23 or stavudine,^{11 13} and MI risk per year of exposure (Appendix Figure A6). The overall RR suggests
24 that cumulative NNRTI exposure as a class (RR: 1.02; 95%CI: 0.97, 1.08),^{59 70 72} or as individual
25 drugs (nevirapine, and efavirenz),^{11 58} is not significantly associated with increased risk of MI
26 events per year of exposure (Appendix Figure A7). Three eligible studies reported data assessing
27 the risk of MI associated with cumulative exposure to PIs as a class.^{59 70 72} There was an increase
28 in risk of MI per year of exposure to PIs (RR: 1.14; 95%CI: 1.03, 1.26). For individual drugs,
29 cumulative exposure to lopinavir with ritonavir (RR: 1.19; 95%CI: 1.03, 1.39),^{11 58} but not
30 nelfinavir,^{11 58} was found to be associated with increase in the risk of MI events per year of
31 exposure (Appendix Figure A8).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sensitivity analyses

The strength and direction of the overall RR from the various meta-analyses remained robust in sensitivity analyses where estimates reported using similar effect measures were pooled. For example, HIV+ individuals continued to have higher risk of MI events compared to uninfected individuals when pooled using either IRRs (overall effect: 1.68; 95%CI: 1.17, 2.40) or HRs (overall effect: 1.75; 95%CI: 1.24, 2.48) effect measures, compared to a RR of 1.73; 95%CI: 1.44, 2.08, obtained from pooling results reported using multiple relative effect measures (Appendix Figure S2).

DISCUSSION

This updated systematic review and meta-analysis assessing the risk of MI among people living with HIV reflects contemporary ART era and found the following: (1) HIV+ individuals have a greater risk of MI compared to uninfected individuals; and among HIV+ individuals, (2) low CD4 cell count (< 200 cells/mm³) and high pVL (> 100,000 copies/mL) are associated with increases in MI risk compared to higher CD4 or lower pVL respectively; (3) cumulative ART exposure is associated with a greater risk of MI per year of exposure; (4) among NRTIs, any type of exposure to abacavir; cumulative exposure to zidovudine; and recent exposure to either didanosine or lamivudine are significantly associated with higher risk of MI; (5) compared to no exposure, any or cumulative exposure to PIs as a class; cumulative exposure to lopinavir with ritonavir; and recent indinavir exposure were associated with higher risk of MI; (6) NNRTIs assessed either as a class or individually were not associated with increased MI risk.

1
2
3 Previous meta-analyses comparing CVD risk among HIV+ and uninfected individuals reported
4 estimates for the association between HIV-seropositivity and MI (RR: 1.79, 95%CI: 1.54, 2.08)¹⁹
5
6 or CVD (RR: 1.61, 95%CI: 1.43, 1.81);²⁰ risk that are similar to our findings for MI (RR: 1.73;
7
8 95%CI: 1.44, 2.08). As has been previously hypothesized,^{3 23 73-75} the probable mechanistic
9
10 pathway through which HIV infection can induce MI may include a cascade of events involving
11
12 chronic inflammation, immunodeficiency/CD4 cell depletion, endothelial dysfunction, increased
13
14 thrombosis and accelerated atherosclerosis that typically accompany both controlled and
15
16 uncontrolled HIV disease. Relative to uninfected individuals and similar to what we found (RR:
17
18 1.80, 95%CI: 1.17, 2.77), one of the previous meta-analysis also reported a higher risk of CVD
19
20 among ART-treated individuals (RR: 2.00, 95%CI: 1.70, 2.37).²⁰ We suspect that the higher MI
21
22 risk among ART-treated HIV+ individuals may not necessarily be attributable to ART alone but
23
24 rather to the combined effect from a host of factors including HIV itself, ART, and other comorbid
25
26 risk factors which have been individually shown to contribute to MI risk.^{3 5 76 77} Furthermore, the
27
28 risk associated with cumulative ART exposure may be an index of the duration of HIV infection
29
30 with its attendant inflammation, and not entirely the effect of cumulative exposure to ART per se.
31
32
33
34
35
36
37
38
39
40 Specific to abacavir and MI risk, our findings were similar to reports from a previous meta-analysis
41
42 of observational studies of MI,¹⁶ but different from those of the meta-analysis of RCTs,^{17 18} or
43
44 reports from aggregate clinical trial studies,^{14 15} that suggested no risk associated with abacavir
45
46 exposure. Although observational studies and RCT results regarding MI and CVD risk due to
47
48 abacavir exposure among people living with HIV are largely at odds, the Simplification with
49
50 Tenofovir-Emtricitabine or Abacavir-Lamivudine (STEAL) trial is the first RCT to support
51
52 observational studies finding of increased risk of CVD with exposure to abacavir.⁷⁸ Based on the
53
54
55
56
57
58
59
60

1
2
3 available evidence to date, the controversy regarding the potential association between abacavir
4 use and risk of MI will likely continue to plague the field of HIV therapeutics until such a time
5 when definitive evidence describing the underlying mechanism can be produced.^{79 80} A sufficiently
6 powered RCT with long follow-up and including real-world populations reflective of those
7 typically seen clinically may be needed to fully resolve this clinical controversy.
8
9
10
11
12
13

14
15
16
17 Unlike our results where a class-level effect was evident for PIs, pooled aggregate clinical trial
18 data after one year of treatment with four different PI-based regimens did not find evidence of an
19 increased risk associated with PI compared to NRTI regimen (RR: 1.69; 95%CI: 0.54, 7.48).⁸¹
20
21 When we pooled data of individual PIs separately, we did not observe the same ‘class-level’
22 results. In our analysis, different PI regimens carried different risks. For example, while recent
23 indinavir and cumulative lopinavir-ritonavir exposure were associated with increased MI risk,
24 nelfinavir or atazanavir did not appear to contribute to MI risk irrespective of the type of exposure
25 data that were pooled.
26
27
28
29
30
31
32
33
34
35
36
37

38 In terms of the scope and design, our study differs from previous meta-analyses on this topic in
39 several ways. First, we used an expanded search strategy that included more data sources and
40 search of conference archives compared to prior meta-analyses.¹⁶⁻²⁰ Second, as the association of
41 HIV and ART may affect the risk of MI and other CVD events differently, we did not assess the
42 risk of CVD in general, as was done in previous meta-analysis.²⁰ Third, we have used more recent
43 risk estimates from studies with longer follow-up such as the Data Collection on Adverse Events
44 of Anti-HIV Drugs (D:A:D) study. Fourth, we have included studies published between 2000 and
45 2017 with reported data from the post-ART era. The historical nature of some of the studies
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 included in previous meta-analysis may have limited their relevance in contemporary times.
4
5 Finally, this systematic review analyzed several additional drug exposure comparisons and clinical
6
7 measures (e.g. CD4 cell count, plasma viral load) in relation to MI risk that had not been previously
8
9 examined.
10

11
12
13
14
15 There are several important considerations that should be taken into account in the interpretation
16
17 of the results of this study. Accurate characterization of the risk of MI and CVD outcomes in
18
19 general may be confounded by a number of factors that may have affected our conclusions. The
20
21 first concern has to do with the differences in the risk factors, drug exposure, HIV-related variables,
22
23 or population considered in the included studies. Indeed, no two studies of HIV+ individuals from
24
25 different underlying populations can have participants with the same exact demographic, clinical
26
27 and drug exposure profile – all of which play a role in overall health outcomes. Given that studies
28
29 typically included in a global meta-analysis such as ours do not come from the same underlying
30
31 source population, we acknowledge that there may be some differences in the population
32
33 distribution in the included studies (e.g., in the distribution by age, sex, disease stage, medication
34
35 profile/history) that we were unable to account for. A second concern relates to the variability in
36
37 the quality and design features of the included studies, which may have influenced the results of
38
39 the meta-analyses and thus the conclusions drawn. Although the majority of included studies were
40
41 cohort-based (90%), almost one half (47%) were retrospective in nature and did not adequately
42
43 report how the exposure or outcome was ascertained including whether an adjudication protocol
44
45 was applied in the ascertainment of MIs. It has been shown that the application of an adjudication
46
47 protocol in the study of MI and other CVD events is important to ensuring accurate identification
48
49 of events as relying only on administrative diagnostic codes could result in misclassification.⁸²
50
51
52
53
54
55
56
57
58
59
60

1
2
3 While some studies retrospectively assessed MI and relied on International Classification of
4 Diseases (ICD) codes alone – something that is quite common in large epidemiological studies of
5 MI,⁷⁶ others followed participants over time and prospectively assessed and validated the MI
6 events. It is unclear how differences in MI definition across studies may have affected our results
7 although in two studies from the same underlying population (Veterans Aging Cohort Study
8 (VACS)) that used similar but not the same definitions for MI,^{3 83} the RR differed slightly: 1.48
9 (95%CI: 1.27, 1.72)³ vs. 1.76 (95%CI: 1.49, 2.07).⁸³ Regarding studies that quantified the risk of
10 MI associated with HIV infection, the available evidence based on the included studies all point
11 in the same direction suggesting an increase in MI risk. However, we noted some variability in the
12 design and quality of the studies, something that may have contributed in part to the observed
13 heterogeneity. For example, three studies did not provide sufficient information on the exposure
14 or outcome ascertainment in the studies.^{52 56 69} Furthermore, the appropriateness of the HIV-
15 uninfected group used for comparison purposes is critical in the assessment of MI risk associated
16 with HIV infection; an issue that has been extensively reviewed elsewhere.⁸⁴ While some studies
17 made this comparison using an HIV-uninfected group, other studies used the general population
18 group for comparison. In sensitivity analysis, the overall RR of MI associated with HIV infection
19 was reduced when we included in the meta-analysis two additional studies involving a ‘general
20 population’ comparison group,^{42 43} therefore highlighting the importance of using an appropriate
21 control group.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47 Another potential concern relates to differences in the extent to which key confounding
48 factors were adjusted for in the individual analysis contributing to the meta-analysis. For example,
49 some studies lacked data on smoking – an important risk factor for CVD in general, and therefore
50 did not account for it in the analyses.^{52 60 65} In this regard, we noted that the included studies did
51
52
53
54
55
56
57
58
59
60

1
2
3 not consistently control for the exact same set of confounders which may have undermined their
4 internal validity and explained some of the differences in the effect measures from the individual
5 studies. There is also the potential for residual, unmeasured confounding given the observational
6 nature of the included studies. Therefore, heterogeneity arising from differences in study design
7 or other quality features may have influenced the results and thus the overall conclusions drawn.
8 Although we observed heterogeneity across results of studies included in some of the meta-
9 analyses, this is a common limitation in meta-analysis especially those involving observational
10 studies.⁴⁴ Our *a priori* choice of employing the random-effects modeling strategy was driven in
11 part by this expected variability among studies.⁸⁵ Furthermore, our study combined results
12 presented using several different relative effect measures with the assumption that these represent
13 approximately the same numerical value.³¹⁻³⁶ In sensitivity analyses, we did not find any evidence
14 of bias in our pooled estimates, as these did not differ importantly from the pooled estimates we
15 obtained when we combined studies reporting results using the same effect measure. Moreover,
16 we reached comparable conclusions with previous meta-analyses that combined,¹⁹ or did not
17 combine HR estimates with OR, and RR.¹⁶

18
19 Also, some of the meta-analyses in our study such as those examining the risk of MI in
20 relation to CD4, pVL, or use of specific ARV regimens were based on a small number of studies
21 (only 2-3 studies), which is a serious limitation. It is important to also consider this point in the
22 interpretation of these specific findings. We acknowledge that the results from such meta-analyses
23 could have been strengthened with the inclusion of additional eligible studies. Nevertheless, in the
24 absence of sufficient number of studies examining these relationships, our results could be viewed
25 as the best available evidence summarizing the risk of MI associated with CD4, pVL, or use of
26 specific ARV regimens among people living with HIV.

1
2
3
4
5
6 Given the foregoing discussion in relation to the design and quality aspects of the included studies
7
8 as well as issues of sufficiency of available studies examining several potential associations with
9
10 MI risk, additional rigorously conducted studies with extensive confounding factor
11
12 stratification/adjustment are needed to further confirm our findings. Furthermore, considering that
13
14 the majority of the studies on this topic are carried out in North America and Europe, our study
15
16 highlights the need for more research to be conducted in resource limited settings where most
17
18 people living with HIV reside.
19
20
21
22
23

24 **CONCLUSIONS**

25
26 In summary, this updated systematic review and meta-analysis suggests that HIV infection, ART
27
28 use in general including exposure to specific ART class (e.g. PIs) and regimen (e.g. abacavir) are
29
30 associated with increased risk of MI. These findings should be interpreted in light of the key
31
32 considerations that we have highlighted in this review. We found the totality of the evidence for
33
34 an association between HIV infection and MI to be compelling. With respect to ART and MI risk,
35
36 HIV treatment strategies should certainly consider cardiovascular risk factors including exposure
37
38 to particular ART drugs as part of patient-tailored care. However, given what we currently know
39
40 about ART's effectiveness, the benefits of ART for the treatment of HIV infection in terms of viral
41
42 suppression and immune reconstitution should be balanced against its potential unfavorable impact
43
44 on MI. Specific to abacavir and MI risk where there is conflicting evidence between observational
45
46 studies and RCTS, additional rigorously conducted studies in real-world populations are needed
47
48 to definitively substantiate our findings and strengthen the existing evidence on this topic. Given
49
50 the multiple potential contributory and mechanistic pathways to developing MI among HIV+
51
52
53
54
55
56
57
58
59
60

1
2
3 individuals and the complexity/feasibility of designing a large enough study to completely tease
4
5 apart the potential contributions of each of the factors believed to increase the risk of MI, managing
6
7 known modifiable risk factors for CVD outcomes (e.g. smoking) through behavioural/lifestyle
8
9 interventions, would be an excellent first step in reducing the incidence and risk of MI among
10
11 people living with HIV.
12
13

14
15
16
17 **Study registration number:** PROSPERO ID# CRD42014012977
18

19 20 21 **Acknowledgements**

22 We thank Simon Fraser University library staff for the assistance provided during the search
23
24 strategy development.
25
26
27

28 29 30 31 **Author contributions**

32
33 OE, MWH, SAL, JSGM and RSH conceived and designed the study. OE, GB, and RSH acquired
34
35 the data. OE performed the statistical analysis with input from CHG, CF-V, and EM. OE, GB,
36
37 CHG, MWH, SAL, MB, SG, CF-V, AA, EM, JSGM, and RSH contributed to the interpretation of
38
39 the data. OE drafted the manuscript. OE, GB, CHG, MWH, SAL, MB, SG, CF-V, AA, EM, JSGM,
40
41 and RSH reviewed the manuscript critically for important intellectual content and approved the
42
43 final version submitted for publication.
44
45
46
47
48

49 50 51 **Funding**

52 There was no funding for this study. The corresponding author had full access to all the data in the
53
54 study and had final responsibility for the decision to submit for publication.
55
56
57
58
59

1
2
3
4
5 **Competing interests**
6

7 We declare no competing interests
8
9
10

11
12 **Patient consent**
13

14 None required
15
16
17

18
19 **Data sharing statement**
20

21 All data and materials used in this research are available in Medline/PubMed. References have
22 been provided.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 2010;50(10):1387-96. doi: 10.1086/652283
2. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet* 2014;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA internal medicine* 2013;173(8):614-22. doi: 10.1001/jamainternmed.2013.3728
4. Marcus JL, Leyden WA, Chao CR, et al. HIV infection and incidence of ischemic stroke. *AIDS* 2014;28(13):1911-9. doi: 10.1097/QAD.0000000000000352
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 2003;349(21):1993-2003. doi: 10.1056/NEJMoa030218
6. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *AIDS* 2003;17(17):2479-86. doi: 10.1097/01.aids.0000096857.36052.23
7. D:A:D Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;356(17):1723-35. doi: 10.1056/NEJMoa062744

- 1
2
3 8. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-
4
5 infected patients on highly active antiretroviral therapy: a population-based nationwide
6
7 cohort study. *HIV Med* 2010;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x
8
9
- 10 9. Strategies for Management of Anti-Retroviral Therapy/Insight, D:A:D. Study Groups. Use of
11
12 nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-
13
14 infected patients. *AIDS* 2008;22(14):F17-24. doi: 10.1097/QAD.0b013e32830fe35e
15
16
- 17 10. Bozzette SA, Ake CF, Tam HK, et al. Long-term survival and serious cardiovascular events
18
19 in HIV-infected patients treated with highly active antiretroviral therapy. *J Acquir*
20
21 *Immune Defic Syndr* 2008;47(3):338-41. doi: 10.1097/QAI.0b013e31815e7251
22
23
- 24 11. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk
25
26 of myocardial infarction in human immunodeficiency virus-infected patients: a case-
27
28 control study nested within the French Hospital Database on HIV ANRS cohort CO4.
29
30 *Archives of internal medicine* 2010a;170(14):1228-38. doi:
31
32 10.1001/archinternmed.2010.197
33
34
- 35 12. Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial
36
37 infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin*
38
39 *Infect Dis* 2011;53(1):84-91. doi: 10.1093/cid/cir269
40
41
- 42 13. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase
43
44 inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the
45
46 D:A:D study: a multi-cohort collaboration. *Lancet* 2008a;371(9622):1417-26. doi:
47
48 10.1016/S0140-6736(08)60423-7
49
50
- 51 14. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir
52
53 therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult
54
55
56
57
58
59
60

- 1
2
3 subjects. *J Acquir Immune Defic Syndr* 2009;51(1):20-8. doi:
4
5 10.1097/QAI.0b013e31819ff0e6
6
7
8 15. Ribaldo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with
9
10 initial antiretroviral treatment containing abacavir: short and long-term results from
11
12 ACTG A5001/ALLRT. *Clin Infect Dis* 2011;52(7):929-40. doi: 10.1093/cid/ciq244
13
14
15 16. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral
16
17 therapy for HIV: a systematic review. *PLoS One* 2013;8(3):e59551. doi:
18
19 10.1371/journal.pone.0059551
20
21
22 17. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial
23
24 infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*
25
26 2012;61(4):441-7. doi: 10.1097/QAI.0b013e31826f993c
27
28
29 18. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease
30
31 events: a meta-analysis of published and unpublished data. *AIDS* 2011;25(16):1993-2004.
32
33 doi: 10.1097/QAD.0b013e328349c6ee
34
35
36 19. Shah ASV, Stelzle D, Lee KK, et al. Global Burden of Atherosclerotic Cardiovascular
37
38 Disease in People Living with the Human Immunodeficiency Virus: A Systematic
39
40 Review and Meta-Analysis. *Circulation* 2018 doi:
41
42 10.1161/CIRCULATIONAHA.117.033369 [published Online First: 2018/07/04]
43
44
45 20. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living
46
47 with HIV: a systematic review and meta-analysis. *HIV Med* 2012;13(8):453-68. doi:
48
49 10.1111/j.1468-1293.2012.00996.x
50
51
52 21. Neaton JD. HIV and cardiovascular disease: comment on Islam et al. *HIV Med*
53
54 2013;14(8):517-8. doi: 10.1111/hiv.12043
55
56
57
58
59
60

- 1
2
3 22. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of
4 cardiovascular disease in HIV-infected patients. *HIV Med* 2005;6(1):37-44. doi:
5
6 10.1111/j.1468-1293.2005.00265.x
7
8
9
10 23. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for
11 cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis*
12
13 2010;51(4):435-47. doi: 10.1086/655144
14
15
16 24. Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and
17 tenofovir exposure in HIV-infected persons. *AIDS* 2011;25(10):1289-98. doi:
18
19 10.1097/QAD.0b013e328347fa16
20
21
22
23 25. Klein MB, Xiao Y, Abrahamowicz M, et al. Re-assessing the cardiovascular risk of abacavir
24 in the Swiss HIV Cohort Study (SHCS) using a flexible marginal structural model [ICPE
25 Abstract 396]. In: Abstracts of the 29th International Conference on
26
27 Pharmacoeconomics & Therapeutic Risk Management. *Pharmacoeconom Drug Saf*
28
29 2013;22(S1):193-94.
30
31
32
33
34 26. Widimsky P, Coram R, Abou-Chebl A. Reperfusion therapy of acute ischaemic stroke and
35 acute myocardial infarction: similarities and differences. *Eur Heart J* 2014;35(3):147-55.
36
37 doi: 10.1093/eurheartj/eh409 [published Online First: 2013/10/08]
38
39
40
41 27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
42 meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264-9, W64.
43
44
45
46 28. Eyawo O, Brockman G, Lear S, et al. Risk of cardiovascular disease events among HIV-
47 positive individuals compared to HIV-negative individuals: a systematic review and
48
49 meta-analysis (number: CRD42014012977). *International prospective register of*
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 *systematic reviews (PROSPERO)*, 2014.
4
5 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014012977.
6
7
- 8 29. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the
9
10 quality of nonrandomised studies in meta-analyses, 2018:
11
12 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed January 17,
13
14 2019.
15
- 16 30. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
17
18 *Biometrics* 1977;33(1):159-74.
19
- 20 31. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. *J Clin*
21
22 *Epidemiol* 2002;55(9):893-9.
23
24
- 25 32. Sedgwick P. Hazards and hazard ratios. *Bmj* 2012;345:e5980.
26
27
- 28 33. Hernan MA. The hazards of hazard ratios. *Epidemiology* 2010;21(1):13-5. doi:
29
30 10.1097/EDE.0b013e3181c1ea43
31
32
- 33 34. McCullagh P, Nelder JA. Chapter 13: Models for Survival Data. In: McCullagh P, Nelder
34
35 JA, eds. *Generalized Linear Models*. 2nd ed. London, New York: Chapman & Hall/CRC
36
37 1989:pp 419-31.
38
39
- 40 35. Laird N, Olivier D. Covariance Analysis of Censored Survival Data Using Log-Linear
41
42 Analysis Techniques. *J Am Stat Assoc* 1981;76(374):231-40.
43
44
- 45 36. Symons MJ, Taulbee JD. Practical considerations for approximating relative risk by the
46
47 standardized mortality ratio. *J Occup Med* 1981;23(6):413-6.
48
- 49 37. Fernandez MDM, Saulyte J, Inskip HM, et al. Premenstrual syndrome and alcohol
50
51 consumption: a systematic review and meta-analysis. *BMJ Open* 2018;8(3):e019490. doi:
52
53 10.1136/bmjopen-2017-019490 [published Online First: 2018/04/18]
54
55
56
57
58
59
60

- 1
2
3 38. Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a
4
5 systematic review. *Int J Infect Dis* 2015;32:138-46. doi: 10.1016/j.ijid.2014.12.016
6
7
8 39. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of
9
10 physical activity and the prevention of Alzheimer's disease in older adults. *BMC Geriatr*
11
12 2015;15:9. doi: 10.1186/s12877-015-0007-2
13
14
15 40. Bateson D, Butcher BE, Donovan C, et al. Risk of venous thromboembolism in women
16
17 taking the combined oral contraceptive: A systematic review and meta-analysis. *Aust*
18
19 *Fam Physician* 2016;45(1):59-64.
20
21
22 41. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177-
23
24 88.
25
26 42. Drozd DR, Kitahata MM, Althoff KN, et al. Increased Risk of Myocardial Infarction in HIV-
27
28 Infected Individuals in North America Compared With the General Population. *J Acquir*
29
30 *Immune Defic Syndr* 2017;75(5):568-76. doi:10.1097/QAI.0000000000001450
31
32
33 43. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-
34
35 infected patients in France, relative to the general population. *AIDS* 2010b;24(8):1228-
36
37 30. doi: 10.1097/QAD.0b013e328339192f
38
39
40 44. Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to
41
42 diagnose lung cancer. *JAMA* 2015;313(4):419. doi: 10.1001/jama.2014.16482
43
44
45 45. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *Bmj*
46
47 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557
48
49
50 46. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version
51
52 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011:
53
54 <http://www.cochrane.org/handbook>. Accessed July 27, 2017.
55
56
57
58
59
60

- 1
2
3 47. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
4
5 graphical test. *Bmj* 1997;315(7109):629-34.
6
7
8 48. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in
9
10 meta-analyses: a large survey. *Cmaj* 2007;176(8):1091-6. doi: 10.1503/cmaj.060410
11
12 [published Online First: 2007/04/11]
13
14
15 49. Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. *Bmj*
16
17 2006;333(7568):597-600. doi: 10.1136/bmj.333.7568.597 [published Online First:
18
19 2006/09/16]
20
21
22 50. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw*
23
24 2010;36(3):1-48.
25
26 51. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent
27
28 predictors of the risk of myocardial infarction in HIV-infected individuals. *Clin Infect Dis*
29
30 2012;55(4):600-7. doi: 10.1093/cid/cis489
31
32
33 52. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral
34
35 therapy, and risk of acute myocardial infarction: a cohort and nested case-control study
36
37 using Quebec's public health insurance database. *J Acquir Immune Defic Syndr*
38
39 2011;57(3):245-53. doi: 10.1097/QAI.0b013e31821d33a5
40
41
42 53. Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between
43
44 abacavir usage and myocardial infarction risk in individuals with HIV? A cohort
45
46 collaboration. *BMC Med* 2016;14:61. doi: 10.1186/s12916-016-0588-4
47
48
49 54. Salinas JL, Rentsch C, Marconi VC, et al. Baseline, Time-Updated, and Cumulative HIV
50
51 Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. *Clin*
52
53 *Infect Dis* 2016;63(11):1423-30. doi: 10.1093/cid/ciw564
54
55
56
57
58
59
60

- 1
2
3 55. Palella FJ, Althoff KN, Moore R, et al. Abacavir use and risk for myocardial infarction in the
4
5 NA-ACCORD [CROI Abstract 749LB]. In Special Issue: Abstracts From the 2015
6
7 Conference on Retroviruses and Opportunistic Infections. *Top Antivir Med* 2015;23(e-
8
9 1):335-36.
10
11
- 12 56. Rasmussen LD, May MT, Kronborg G, et al. Time trends for risk of severe age-related
13
14 diseases in individuals with and without HIV infection in Denmark: a nationwide
15
16 population-based cohort study. *Lancet HIV* 2015;2(7):e288-98. doi: 10.1016/S2352-
17
18 3018(15)00077-6 [published Online First: 2015/10/02]
19
20
- 21 57. Drozd DR, Nance RM, Delaney JAC, et al. Lower CD4 count and higher viral load are
22
23 associated with increased risk of myocardial infarction [CROI abstract 739]. In Special
24
25 Issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections.
26
27 *Top Antivir Med* 2014;22(e-1):377.
28
29
- 30 58. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV
31
32 infection exposed to specific individual antiretroviral drugs from the 3 major drug
33
34 classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect*
35
36 *Dis* 2010;201(3):318-30. doi: 10.1086/649897
37
38
39
- 40 59. D:A:D Study Group, Sabin CA, d'Arminio Monforte A, et al. Changes over time in risk
41
42 factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected
43
44 individuals and impact on myocardial infarction. *Clin Infect Dis* 2008b;46(7):1101-10.
45
46 doi: 10.1086/528862
47
48
- 49 60. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-
50
51 uninfected individuals: a population-based cohort study. *Clin Infect Dis*
52
53 2007;44(12):1625-31. doi: 10.1086/518285
54
55
56
57
58
59
60

- 1
2
3 61. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular
4 outcomes in patients with HIV-1. *Lancet* 2002;360(9347):1747-8. doi: 10.1016/S0140-
5 6736(02)11672-2
6
7
8
9
10 62. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected
11 patients between 1983 and 1998: the Frankfurt HIV-cohort study. *Eur J Med Res*
12 2000;5(8):329-33.
13
14
15
16 63. Carman WJ, Bowlin S, McAfee AT. Human immunodeficiency (HIV) therapy and
17 cardiovascular (CV) events [ICPE Abstract 323]. In: Abstracts from the 27th
18 International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
19 *Pharmacoepidemiol Drug Saf* 2011;20(S140)
20
21
22
23
24
25 64. LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected
26 veterans receiving atazanavir. *AIDS* 2017;31(15):2095-106. doi:
27 10.1097/QAD.0000000000001594
28
29
30
31
32 65. Rosenblatt L, Farr AM, Johnston SS, et al. Risk of Cardiovascular Events Among Patients
33 Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens. *Open*
34 *Forum Infect Dis* 2016a;3(2):ofw061. doi: 10.1093/ofid/ofw061
35
36
37
38
39 66. Rosenblatt L, Farr AM, Nkhoma ET, et al. Risk of cardiovascular events among patients with
40 HIV treated with atazanavir-containing regimens: a retrospective cohort study. *BMC*
41 *Infect Dis* 2016b;16:492. doi: 10.1186/s12879-016-1827-1
42
43
44
45
46 67. Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events associated with current
47 exposure to HIV antiretroviral therapies in a US veteran population. *Clin Infect Dis*
48 2015;61(3):445-52. doi: 10.1093/cid/civ316
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 68. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with
4 myocardial infarction rates in a US healthcare system. *J Acquir Immune Defic Syndr*
5 2010;55(5):615-9. doi: 10.1097/QAI.0b013e3181f4b752
6
7
8
9
10 69. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection
11 with acute myocardial infarction. *J Acquir Immune Defic Syndr* 2009;51(3):268-73. doi:
12 10.1097/QAI.0b013e3181a9992c [published Online First: 2009/04/24]
13
14
15
16
17 70. Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events
18 versus death from other causes associated with antiretroviral use. *AIDS*
19 2006;20(15):1941-50. doi: 10.1097/01.aids.0000247115.81832.a1
20
21
22
23
24 71. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among
25 HIV-positive compared with HIV-negative individuals with access to care. *Clin Infect*
26 *Dis* 2015;60(8):1278-80. doi: 10.1093/cid/civ014
27
28
29
30
31 72. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction
32 among HIV-positive individuals with access to care. *J Acquir Immune Defic Syndr*
33 2014;65(2):160-6. doi: 10.1097/QAI.0000000000000009
34
35
36
37
38 73. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*
39 2005;352(16):1685-95. doi: 10.1056/NEJMra043430
40
41
42
43 74. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic
44 mechanisms among HIV-infected patients. *J Infect Dis* 2012;205 Suppl 3:S368-74. doi:
45 10.1093/infdis/jis201
46
47
48
49 75. Cerrato E, Calcagno A, D'Ascenzo F, et al. Cardiovascular disease in HIV patients: from
50 bench to bedside and backwards. *Open Heart* 2015;2(1):e000174. doi: 10.1136/openhrt-
51 2014-000174
52
53
54
55
56
57
58
59
60

- 1
2
3 76. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and
4
5 cardiovascular risk factors among patients with human immunodeficiency virus disease. *J*
6
7 *Clin Endocrinol Metab* 2007;92(7):2506-12. doi: 10.1210/jc.2006-2190 [published
8
9 Online First: 2007/04/26]
- 10
11
12 77. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients:
13
14 epidemiology, pathogenesis, and clinical management. *AIDS* 2010;24(6):789-802. doi:
15
16 10.1097/QAD.0b013e328337afdf
- 17
18
19 78. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-
20
21 emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. *Clin Infect Dis*
22
23 2009;49(10):1591-601. doi: 10.1086/644769
- 24
25
26 79. Alvarez A, Orden S, Andujar I, et al. Cardiovascular toxicity of abacavir: a clinical
27
28 controversy in need of a pharmacological explanation. *AIDS* 2017;31(13):1781-95. doi:
29
30 10.1097/QAD.0000000000001547
- 31
32
33 80. Llibre JM, Hill A. Abacavir and cardiovascular disease: A critical look at the data. *Antiviral*
34
35 *Res* 2016;132:116-21. doi: 10.1016/j.antiviral.2016.05.015
- 36
37
38 81. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized
39
40 clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four
41
42 different protease inhibitors. *AIDS research and human retroviruses* 2003;19(6):449-55.
43
44 doi: 10.1089/088922203766774487
- 45
46
47 82. Crane HM, Heckbert SR, Drozd DR, et al. Lessons learned from the design and
48
49 implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.
50
51 *Am J Epidemiol* 2014;179(8):996-1005. doi: 10.1093/aje/kwu010 [published Online First:
52
53 2014/03/13]
- 54
55
56
57
58
59
60

- 1
2
3 83. Althoff KN, McGinnis KA, Wyatt CM, et al. Comparison of risk and age at diagnosis of
4
5 myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-
6
7 infected versus uninfected adults. *Clin Infect Dis* 2015;60(4):627-38. doi:
8
9 10.1093/cid/ciu869
10
11
12 84. Althoff KN, Gange SJ. A critical epidemiological review of cardiovascular disease risk in
13
14 HIV-infected adults: the importance of the HIV-uninfected comparison group,
15
16 confounding, and competing risks. *HIV Med* 2013;14(3):191-2. doi: 10.1111/hiv.12007
17
18 [published Online First: 2013/02/02]
19
20
21 85. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis *Psychological*
22
23 *Methods* 1998;3(4):486-504.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Titles and Legends

Figure 1. Flow diagram of study selection

Legend: *, Includes several conference abstract records captured through the database search; **, Includes two studies involving a 'general population' comparison group

ART, Combination antiretroviral therapy; CVD, Cardiovascular disease

Figure 2. Forest plot of the meta-analysis of the risk of MI associated with HIV infection

Legend: ART, Antiretroviral therapy; CI, Confidence interval

Figure 3. Forest plot of the meta-analysis of the risk of MI associated with CD4 cell count and plasma viral load levels

Legend: CI, Confidence interval

Figure 4. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NRTI class


Legend: CI, Confidence interval

Figure 5. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NNRTI class

Legend: CI, Confidence interval

Figure 6. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the protease inhibitor class

Legend: CI, Confidence interval



38 **Figure 1. Flow diagram of study selection**

39 **Legend:** *, Includes several conference abstract records captured through the database search; **, Includes two studies involving a 'general population' comparison group
40 ART, Combination antiretroviral therapy; CVD, Cardiovascular disease

41
42
43
44
45 **Figure 1. Flow diagram of study selection**

46 215x279mm (300 x 300 DPI)





Figure 2. Forest plot of the meta-analysis of the risk of MI associated with HIV infection

662x585mm (72 x 72 DPI)



35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3. Forest plot of the meta-analysis of the risk of MI associated with CD4 cell count and plasma viral load levels

152x135mm (300 x 300 DPI)




Figure 4. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NRTI class

152x140mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NNRTI class

152x128mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6. Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the protease inhibitor class

152x138mm (300 x 300 DPI)

Appendix

Appendix Table 1. Search strategy

1	hiv.af.
2	human immunodeficiency virus.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
3	acquired immunodeficiency syndrome.af.
4	hiv aids.af.
5	1 or 2 or 3 or 4
6	stroke.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
7	(myocardial infarction or heart attack).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
8	cardiac death.af.
9	cerebrovascular disease.mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
10	(ischemic heart disease or Ischaemic heart disease).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
11	(cardiovascular disease or cvd).mp. [mp=ti, ot, ab, sh, hw, kw, tx, ct, tn, dm, mf, dv, nm, kf, px, rx, ui]
12	6 or 7 or 8 or 9 or 10 or 11
13	5 and 12
14	limit 13 to human
15	limit 14 to english language
16	Limit 15 to yr= "2000 – Current"
17	remove duplicates from 16

Note: The searches were executed in the following four databases: (1) EBM Reviews - Cochrane Central Register of Controlled Trials <June 2018>, (2) EBM Reviews - Cochrane Database of Systematic Reviews <2005 to July 11, 2018>, (3) Embase <1974 to 2018 July 17>, (4) Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily <1946 to July 17, 2018>

Study selection

The excluded studies included several key CVD review articles,¹⁻⁸ and aggregate clinical trial studies,⁹⁻¹² whose bibliographies were screened for identification of additional relevant studies. We also excluded a number of potentially eligible records when more comprehensive or updated results for the same participants and risk comparison were published in another report;¹³⁻¹⁶ risk associations were reported in a way that would not allow for pairwise grouping with other studies reporting similar associations to facilitate pooling of results;¹⁷⁻²¹ or results were reported as number of events or unadjusted risk estimates only.²²⁻²⁵

Note: the references cited in the paragraph above are listed at the end of the appendix

Appendix Table 2. Characteristics of included studies

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
LaFleur <i>et al</i> 2017 ⁶⁴	Cohort	USA	ATV-cohort: 12 months Non-ATV: 13 months	HIV+	ATV-cohort: 1,529 (96) Non-ATV: 7,971 (92)	50 years	MI	ATV exposure vs. not exposed	HR ^β
Drozd <i>et al</i> 2017 ⁴²	Cohort	North America	HIV+: 4.5 years HIV-: 19.7 years	HIV+/HIV- (NA-ACCORD / ARIC)	HIV+: 28,912 (81) HIV-: 14,308 (44)	HIV+: 80% were < 50 years HIV-: 27% were < 50 years	Type 1 MI	HIV+ vs. HIV- ^{**}	IRR ^β
Rosenblatt <i>et al</i> 2016a ⁶⁵	Cohort	USA	EFV-cohort: 23.2 months EFV-free: 19.3 months	HIV+	EFV-cohort: 11,978 (86) EFV-free: 10,234 (79)	EFV-cohort: 40.2 years EFV-free: 40.7 years	MI	EFV exposure vs. not exposed	HR ^β
Rosenblatt <i>et al</i> 2016b ⁶⁶	Cohort	USA	ATV-cohort: 24 months ATV-free: 21 months	HIV+	ATV-cohort: 2,437 (76) ATV-free: 19,774 (84)	ATV-cohort: 41.0 years ATV-free: 40.4 years	MI	ATV exposure vs. not exposed	HR ^β
Sabin <i>et al</i> 2016 ⁵³	Cohort	Multi-national	7.0 (4.4-11.1) years ^a	HIV+	49,717 (74)	38 (32-44) years ^a	MI	Current ABC exposure vs. not current (1999-2013)	IRR ^β
Salinas <i>et al</i> 2016 ⁵⁴	Cohort	USA	1996-2012 (follow-up)	HIV+	8,168 (97)	46 (40-53) years ^a	AMI	VL at ART initiation ≥ 100,000 copies/mL vs. < 100,000	HR ^β
Desai <i>et al</i> 2015 ⁶⁷	Cohort	USA	~6.7 years	HIV+	24,510 (98)	46.5	MI	Current exposure to ABC vs. not currently exposed Current exposure to DDI vs. not currently exposed Current exposure to ATV vs. not currently exposed Current exposure to TDF vs. not currently exposed Current exposure to LPV vs. not currently exposed Current exposure to FTC vs. not currently exposed Current exposure to 3TC vs. not currently exposed Current exposure to d4T vs. not currently exposed Current exposure to ZDV vs. not currently exposed Current exposure to IDV vs. not currently exposed	OR ^β /HR ^β

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Current exposure to NFV vs. not currently exposed Current exposure to SQV vs. not currently exposed Current exposure to RTV vs. not currently exposed Current exposure to EFV vs. not currently exposed Current exposure to NVP vs. not currently exposed	
Klein <i>et al</i> 2015 ⁷¹	Cohort	USA	HIV+: 4.8 years HIV-: 5.8 years	HIV+/HIV-	282,368 (91)	HIV+: 41 years HIV-: 40 years	MI	HIV+ vs HIV-	IRR ^β
Palella <i>et al</i> 2015 ⁵⁵	Cohort	USA	~3.9 years	HIV+	16,733 (81)	Reported proportion of individuals by age categories	MI	Recent ABC use vs. non-recent use	HR ^β
Rasmussen <i>et al</i> 2015 ⁵⁶	Cohort	Denmark	HIV+: 55,050–57,631 PYs HIV-: 638,204–659,237 PYss	HIV+/HIV-	HIV+: 5,897 (76) HIV-: 53,073 (76)	HIV+: 36.8 years ^a HIV-: 36.8 years ^a	MI	HIV+ vs. HIV-	IRR ^β
Drozd <i>et al</i> 2014 ⁵⁷	Cohort	USA	1996-2012 (follow-up) NR	HIV+ HIV+	18,155 (NR) 17,626 (79)	NR Reported proportion of individuals by age categories	MI Primary MI	Current HIV RNA (log (copies/mL)+1) CD4 < 200 vs ≥ 200	OR ^β HR ^β
Silverberg <i>et al</i> 2014 ⁷²	Cohort	USA	HIV+: 4.5 years HIV-: 5.4 years	HIV+/HIV-	HIV+: 22,081 (90.6) HIV-: 230,069 (90.5)	Reported proportion of individuals by age categories	MI	ART-treated HIV+ vs. HIV- ART-untreated HIV+ vs. HIV- Recent HIV RNA (per 1 log increase) Prior ART (yes vs no) Duration of PI use per year increase Duration of NNRTI use per year increase	IRR ^β
Freiberg <i>et al</i> 2013 ³	Cohort	USA	5.9 years ^a	HIV+/HIV-	HIV+: 27,350 (97.3) HIV-: 55,109 (97.2)	HIV+: 48.2 years HIV-: 48.8 years	AMI	HIV+ vs. HIV- Recent CD4 < 200 (yes/no) Recent PI use (yes/no)	HR ^β
Lang <i>et al</i> 2012 ⁵¹	Nested case control	France	4.0 years	HIV+	Cases: 289 (88.9) Controls: 884 (89.1)	Cases: 47 (41-54) years ^a	MI	Current ABC vs not current HIV RNA per log10 increase	OR ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
						Controls: 46 (40-54) years ^a			
Bedimo <i>et al</i> 2011 ¹²	Cohort	USA	3.9 years ^a	HIV+	19,424 (98)	46 years ^a	AMI	Cumulative ABC HAART per year of exposure Current ABC HAART vs. neither ABC/TDF Cumulative ARV per year of exposure	HR ^β
Choi <i>et al</i> 2011 ²⁴	Cohort	USA	4.5 years ^a	HIV+	10,931 (98)	46 to 49 years (within subgroups by ART use)	MI	Recent ABC vs. not recent ABC or TDF	HR ^β
Durand <i>et al</i> 2011 ⁵²	Cohort	Canada	4.0 years	HIV+/HIV-	HIV+: 7,053 (78); HIV-: 27,681 (78) Cases: 125 (91.2); Controls: 1,084 (92.2)	HIV+: 39.5 years	AMI	HIV+ vs. HIV-	HR ^β
	Nested case control			HIV+		HIV-: 39.7 years Cases: 49.0 years Controls: 47.5 years	AMI	ABC exposure vs. no exposure Recent ABC vs. not recent DDI exposure vs. no exposure Recent DDI vs. not recent TDF exposure vs. no exposure Recent TDF vs. not recent ATV exposure vs. no exposure Recent ATV vs. not recent Recent LPV vs. not recent Recent RTV vs. not recent Recent EFV vs. not recent NVP exposure vs. no exposure Recent NVP vs. not recent FTC exposure vs. no exposure Recent FTC vs. not recent Recent 3TC vs. not recent d4T exposure vs. no exposure Recent d4T vs. not recent ZDV exposure vs. no exposure Recent ZDV vs. not recent Recent IDV vs. not recent	OR ^β

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								NFV exposure vs. no exposure Recent NFV vs. not recent SQV exposure vs. no exposure Recent SQV vs. not recent	
Carman <i>et al</i> 2011 ⁶³	Cohort	USA	1998-2007 (follow-up)	HIV+	66,286 (NR)	NR	AMI	Recent ABC use vs. no use Recent PI use vs. no use	IRR ^β
Lang <i>et al</i> 2010b ⁴³	Cohort	France	2000-2006 (follow-up)	HIV+/ general population	HIV+: ~ 74,958 General population: unclear	35 to 64 years	MI	HIV+ vs general population	SMR
Lang <i>et al</i> 2010a ¹¹	Nested case control	France	2000-2006 (follow-up)	HIV+	Cases: 289 (89) Controls: 884 (89)	Cases: 47 (41-54) years ^α Controls: 46 (40-54) years ^α	MI	Recent ABC exposure vs. no exposure Cumulative ABC exposure vs. no exposure Cumulative DDI per year of exposure Cumulative TDF per year of exposure Cumulative ZVD per year of exposure Cumulative EFV per year of exposure Cumulative NVP per year of exposure Cumulative LPV + RTV per year of exposure Cumulative NFV per year of exposure Cumulative 3TC exposure per year Cumulative d4T exposure per year	OR ^β
Obel <i>et al</i> 2010 ⁸	Cohort	Denmark	~ 6.5 years	HIV+	2,952 (76.4)	39.1 (33.0-46.6) years ^α	MI	ABC exposure vs. no exposure	IRR ^β
Worm <i>et al</i> 2010 ⁵⁸	Cohort	Multi-national	5.8 (3.9-7.5) years ^α	HIV+	33,308 (74)	With MI: 49 (43-65) years ^α Without MI: 44 (38-50) years ^α	MI	Cumulative ABC exposure per year	Relative rate ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Recent TDF exposure vs. not recent Cumulative TDF exposure per year Recent DDI exposure vs. not recent Cumulative LPV-RTV exposure per year Cumulative NFV exposure per year Cumulative NVP exposure per year Cumulative EFV exposure per year	
Triant <i>et al</i> 2010 ⁶⁸	Cohort	USA	5.1 years ^a	HIV+	6,517 (69)	46 years	AMI	CD4 count < 200/mm ³ vs ≥ 200 Nadir CD4 per 50/mm ³ increase VL > 100,000 copies/mL vs. ≤ 100,000 HIV RNA per log 10 increase ART per year since first ART use TDF use vs. none ABC use vs. none DDI use vs. none FTC use vs. none d4T use vs. none NVP use vs. none ATV use vs. none NFV use vs. none SQV use vs. none	OR ^β
Triant <i>et al</i> 2009 ⁶⁹	Cohort	USA	HIV+: 6.0 years HIV-: 5.8 years	HIV+/HIV-	HIV+: 487 (62.8) HIV-: 69,870 (45.6)	HIV+/HIV-: Reported proportion by age categories	AMI	HIV+ vs. HIV-	OR ^β
D:A:D Study Group <i>et al</i> 2008a ¹⁵	Cohort	Multi-national	5.1 years ^a	HIV+	33,347 (74)	With MI: 49 (range: 24-92) years ^a Without MI: 44 (range: 12-95) years ^a	MI	Recent ABC exposure vs. never exposed to ABC Recent DDI exposure vs. never exposed Cumulative DDI exposure per year	Relative rate ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
								Recent ZDV exposure vs. never exposed Recent ZDV exposure vs. not recent Cumulative ZDV exposure per year Recent 3TC exposure vs. not recent Cumulative 3TC exposure per year Recent d4T exposure vs. not recent Recent d4T exposure vs. never exposed Cumulative d4T exposure per year	
D:A:D Study Group <i>et al</i> 2008b ⁵⁹	Cohort	Multi-national	4.5 years ^a	HIV+	28,985 (NR)	Reported by calendar period	MI	Cumulative exposure to PIs per year Cumulative exposure to NNRTIs per year	Relative rate ^β
D:A:D Study Group <i>et al</i> 2007 ⁷	Cohort	Multi-national	4.5 years ^a	HIV+	23,437 (76)	39 (34-45) years ^a	MI	Nadir CD4 per 50 cells/mm ³ increase	Relative rate ^β
Obel <i>et al</i> 2007 ⁶⁰	Cohort	Denmark	HIV+: 6.9 years ^a HIV-: 8.1 years ^a	HIV+/ HIV-	HIV+: 3,953 (76.8) HIV-: 373,856 (76.3)	HIV+: 36.8 (30.8-44.6) years ^a HIV-: 36.4 (30.6-44.0) years ^a	MI	HIV+, on HAART+ vs. HIV- HIV+ not on HAART- vs. HIV-	IRR ^β
Kwong <i>et al</i> 2006 ⁷⁰	Cohort	USA and Netherlands	3.49 (range: 0.02-18.46) years ^a	HIV+	18,603 (82.63)	36 (range: 18-92) years ^a	MI	PI per year of exposure NNRTI per year of exposure HAART per year of exposure	RR ^β
Mary-Krause <i>et al</i> 2003 ⁶	Cohort	France	With MI: 28 (18-39) months ^a Without MI: 33 (15-48) months ^a	HIV+ men	34,976 (100)	With MI: 41.9 years Without MI: 37.7 years	MI	Exposure to PI	Relative hazard ^β
Holmberg <i>et al</i> 2002 ⁶¹	Cohort	USA	~ 3.1 years	HIV+	5,672 (82)	42.6 years	MI	PI use (yes vs no)	HR ^β

Author, year	Study type	Location	Mean follow-up	Population	Sample size (% male)	Mean age	Outcome	Relevant risk association(s) examined	Effect measure
Rickerts <i>et al</i> 2000* ⁶²	Cohort	Germany	24.6 ± 18.1 months	HIV+	2,861 (78)	36.6 ± 9.5 years	MI	Prior HAART (yes vs. no)	OR ^β

Legend: ^α, median (including lower and upper quartiles, where reported); ^β, adjusted estimate; *, extracted data from the ART era only; **, this was a general population comparison group and may not have consisted of HIV- individuals only; Note: a superscript alongside the author name/year is used to denote the reference number of the study; **ABC**, abacavir; **AMI**, acute myocardial infarction; **ARIC**, Atherosclerosis Risk in Communities; **ART**, antiretroviral therapy; **ATV**, atazanavir; **DDI**, didanosine; **d4T**, stavudine; **EFV**, efavirenz; **FTC**, emtricitabine; **HAART**, highly active antiretroviral therapy; **HR**, Hazard ratio; **IDV**, indinavir; **IRR**, incidence rate ratio; **LPV**, lopinavir; **LPV-RTV**, lopinavir-ritonavir; **MI**, myocardial infarction; **NA-ACCORD/ARIC**, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)/Atherosclerosis Risk in Communities (ARIC) cohorts; **NFV**, nelfinavir; **NNRTI**, non-nucleoside reverse transcriptase inhibitor; **NR**, not reported; **NRTI**, nucleoside reverse transcriptase inhibitor; **NVP**, nevirapine; **OR**, Odds ratio; **PI**, protease inhibitor; **RR**, relative risk; **RTV**, ritonavir; **SMR**, standardized morbidity ratio; **SQV**, saquinavir; **TDF**, tenofovir; **VL**, viral load; **ZDV**, zidovudine; **3TC**, lamivudine


Appendix Table 3. Risk of bias in the included studies

Author, year	Publication type	Study design	Clearly defined eligibility criteria	Description of participants/group(s) selection	Potential for bias in case/group representation	Comparability among group(s) based on design or analysis	Adequate exposure/outcome ascertainment	Sufficient follow-up for outcome occurrence?	Funding source
LaFleur <i>et al</i> 2017 ⁶⁴	Journal	Cohort (R)	+	+	No	+	-	-	Public, industry
Drozd <i>et al</i> 2017 ⁴²	Journal	Cohort (P & R)	+	+	Yes*	-	+	+	Public
Rosenblatt <i>et al</i> 2016a ⁶⁵	Journal	Cohort (R)	+	+	No	+	-	+	Industry
Rosenblatt <i>et al</i> 2016b ⁶⁶	Journal	Cohort (R)	+	+	No	+	-	+	Industry
Sabin <i>et al</i> 2016 ⁵³	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Salinas <i>et al</i> 2016 ⁵⁴	Journal	Cohort (P)	+	+	No	+	-	+	Public
Desai <i>et al</i> 2015 ⁶⁷	Journal	Cohort (R)	+	+	No	+	-	+	Public
Klein <i>et al</i> 2015 ⁷¹	Journal	Cohort (R)	+	+	No	+	+	+	Private, industry
Palella <i>et al</i> 2015 ⁵⁵	Abstract	Cohort (P & R)	+	+	No	-	+	+	-
Rasmussen <i>et al</i> 2015 ⁵⁶	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Drozd <i>et al</i> 2014 ⁵⁷	Abstract	Cohort (P)	-	+	No	-	+	-	Public
Silverberg <i>et al</i> 2014 ⁷²	Journal	Cohort (R)	+	+	No	+	+	+	Private, industry
Freiberg <i>et al</i> 2013 ³	Journal	Cohort (P)	+	+	No	+	+	+	Public
Lang <i>et al</i> 2012 ⁵¹	Journal	Nested case-control	+	+	No	+	+	+	Public
Bedimo <i>et al</i> 2011 ¹²	Journal	Cohort (R)	+	+	No	+	-	+	-
Choi <i>et al</i> 2011 ²⁴	Journal	Cohort (R)	+	+	No	+	-	+	Public
Durand <i>et al</i> 2011 ⁵²	Journal	Cohort (R), & nested case-control	+	+	No	+	-	+	Industry
Carman <i>et al</i> 2011 ⁶³	Abstract	Cohort (R)	-	+	-	-	-	+	-


Author, year	Publication type	Study design	Clearly defined eligibility criteria	Description of participants/group(s) selection	Potential for bias in case/group representation	Comparability among group(s) based on design or analysis	Adequate exposure/outcome ascertainment	Sufficient follow-up for outcome occurrence?	Funding source
Lang <i>et al</i> 2010a ¹¹	Journal	Nested case-control	+	+	No	+	+	+	Public
Lang <i>et al</i> 2010b ⁴³	Journal	Cohort (R)	+	+	No	-	+	+	Public
Obel <i>et al</i> 2010 ⁸	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Worm <i>et al</i> 2010 ⁵⁸	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Triant <i>et al</i> 2010 ⁶⁸	Journal	Cohort (R)	+	+	No	+	-	+	Public
Triant <i>et al</i> 2009 ⁶⁹	Journal	Cohort (R)	+	+	No	+	-	+	Public
D:A:D Study Group <i>et al</i> 2008a ¹³	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
D:A:D Study Group <i>et al</i> 2008b ⁵⁹	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
D:A:D Study Group <i>et al</i> 2007 ⁷	Journal	Cohort (P)	+	+	No	+	+	+	Public, industry
Obel <i>et al</i> 2007 ⁶⁰	Journal	Cohort (P)	+	+	No	+	-	+	Public, private
Kwong <i>et al</i> 2006 ⁷⁰	Journal	Cohort (R)	+	+	No	+	-	+	Public, industry
Mary-Krause <i>et al</i> 2003 ⁶	Journal	Cohort (R)	+	+	No	+	+	+	Public
Holmberg <i>et al</i> 2002 ⁶¹	Journal	Cohort (P)	+	+	No	-	+	+	Public
Rickerts <i>et al</i> 2000 ⁶²	Journal	Cohort (P)	+	+	No	+	+	+	-

Legend: + means this is clearly described and adequate; - means this is unclear, inadequate or not reported; *, The HIV+ cohort (NA-ACCORD study) was compared to a general population cohort from a different study (Atherosclerosis Risk in Communities [ARIC] study); Note: a superscript alongside the author name/year is used to denote the reference number of the study; NA, Not applicable; P, Prospective; R, Retrospective


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Appendix Figure A1. Forest plot of the meta-analysis of the risk of MI associated with any exposure to antiretroviral therapy
 Legend: CI, Confidence interval




Appendix Figure A2. Forest plot of the meta-analysis of the risk of MI associated with any exposure to drugs of the NRTI class
 Legend: CI, Confidence interval




34 **Appendix Figure A3. Forest plot of the meta-analysis of the risk of MI associated with any exposure**
 35 **to drugs of the NNRTI class**

36 Legend: CI, Confidence interval




Appendix Figure A4. Forest plot of the meta-analysis of the risk of MI associated with any exposure to protease inhibitors (both as a class and individually)
 Legend: CI, Confidence interval




36 **Appendix Figure A5. Forest plot of the meta-analysis of the risk of MI associated with cumulative**
 37 **exposure to antiretroviral therapy (ART) including class of ART**

38 Legend: ART, Antiretroviral therapy; CI, Confidence interval; NNRTI, Non-nucleoside reverse
 39 transcriptase inhibitors; PI, Protease inhibitors




Appendix Figure A6. Forest plot of the meta-analysis of the risk of MI associated with cumulative exposure to drugs of the NRTI class
 Legend: CI, Confidence interval




36 **Appendix Figure A7. Forest plot of the meta-analysis of the risk of MI associated with cumulative**
 37 **exposure to NNRTI (both as a class and individually)**

38 Legend: CI, Confidence interval; NNRTI, Non-nucleoside reverse transcriptase inhibitors




Appendix Figure A8. Forest plot of the meta-analysis of the risk of MI associated with cumulative exposure to protease inhibitors (both as a class and individually)

Legend: CI, Confidence interval; PI, Protease inhibitors



Appendix Figure S1. Forest plot of the sensitivity analysis for the meta-analysis of the risk of MI associated with HIV infection, where two additional studies involving a general population comparison group were included

Legend: *, This study had a 'general population' comparison group and may not have consisted of HIV-negative individuals only; CI, Confidence interval



Appendix Figure S2. Forest plot of the sensitivity analyses for the meta-analysis of the risk of MI associated with HIV infection, where estimates reported using similar relative effect measures were pooled

Legend: CI, Confidence interval; HR, Hazard ratio; IRR, Incidence rate ratio

Appendix References (for study selection section only)

1. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. *PLoS One*. 2013;8(3):e59551.
2. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*. 2012;61(4):441-7.
3. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. *AIDS*. 2011;25(16):1993-2004.
4. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *HIV Med*. 2012;13(8):453-68.
5. Friis-Moller N, Smieja M, Klein D. Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. *Curr Opin HIV AIDS*. 2008;3(3):220-5.
6. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. *AIDS*. 2010;24(6):789-802.
7. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. *Eur Heart J*. 2014;35(21):1373-81.
8. Escarcega RO, Franco JJ, Mani BC, Vyas A, Tedaldi EM, Bove AA. Cardiovascular disease in patients with chronic human immunodeficiency virus infection. *Int J Cardiol*. 2014;175(1):1-7.
9. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. *J Acquir Immune Defic Syndr*. 2009;51(1):20-8.
10. Ribaud HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. *Clin Infect Dis*. 2011;52(7):929-40.
11. Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. *AIDS research and human retroviruses*. 2003;19(6):449-55.
12. Da Silva B, Tschampa J, Beron J, Fredrick L, Patwardhan M, Zachry W, et al. Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases. *Int J Clin Pharmacol Ther*. 2012;50(6):391-402.
13. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med*. 2003;349(21):1993-2003.
14. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? *J Acquir Immune Defic Syndr*. 2002;30(5):471-7.
15. Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. *Clin Infect Dis*. 2015;60(4):627-38.
16. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med*. 2010;11(7):462-8.
17. Strategies for Management of Anti-Retroviral Therapy/Insight, D:A:D. Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *AIDS*. 2008;22(14):F17-24.
18. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, et al. Associations between immune depression and cardiovascular events in HIV infection. *AIDS*. 2013;27(17):2735-48.
19. Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. *AIDS*. 2013;27(3):407-15.
20. Brouwer ES, Napravnik S, Eron JJ, Jr., Stalzer B, Floris-Moore M, Simpson RJ, Jr., et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. *Epidemiology*. 2014a;25(3):406-17.
21. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Heckbert SR, Budoff MJ, et al. Incidence and risk of myocardial infarction (MI) by Type in the NA-ACCORD [CROI Abstract 748]. In Special Issue:

1
2
3 Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. *Top Antivir Med.*
4 2015;23(e-1):335.

5 22. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label,
6 prospective, observational study of the incidence of coronary artery disease in patients with HIV infection
7 receiving highly active antiretroviral therapy. *Clin Ther.* 2003;25(9):2405-18.

8 23. Engstrom K, Garcia M. Initial antiretroviral therapy with protease inhibitors is associated with
9 increased risk of heart failure in HIV-infected patients [ACC.14 Abstract 1261-192]. In: Abstracts from the
10 American College of Cardiology 63rd Annual Scientific Session & Expo. *JACC.* 2014;63(12):A955.

11 24. Triant VA, Regan S, Grinspoon SK. MACE incidence among HIV and non-HIV-infected patients
12 in a clinical care cohort [CROI abstract 738]. In Special Issue: Abstracts from the 2014 Conference on
13 Retroviruses and Opportunistic Infections. *Top Antivir Med.* 2014;22(e-1):376-77.

14 25. Brouwer E, Moga D: Differences in myocardial infarction risk among persons living and those not
15 living with HIV: an evaluation of a commercially insured population seeking care in the United States
16 [AIDS Abstract THPE038]. In:20th International AIDS Conference. Melbourne, Australia 2014b.

Reporting checklist for meta-analysis of observational studies.

Based on the MOOSE guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the MOOSE reporting guidelines, and cite them as:

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-2012.

	Reporting Item	Page Number
#1	Identify the study as a meta-analysis of observational research	1
#2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number (From PRISMA checklist)	2
#3a	Problem definition	5
#3b	Hypothesis statement	6
#3c	Description of study outcomes	5
#3d	Type of exposure or intervention used	5, 6

1	#3e	Type of study designs used	6	
2				
3	#3f	Study population	7	
4				
5				
6	Search	#4a	Qualifications of searchers (eg, librarians and investigators)	6
7	strategy			
8				
9				
10		#4b	Search strategy, including time period included in the synthesis and	6
11			keywords	
12				
13		#4c	Effort to include all available studies, including contact with authors	7
14				
15				
16		#4d	Databases and registries searched	7
17				
18		#4e	Search software used, name and version, including special features	7
19			used (eg, explosion)	
20				
21				
22		#4f	Use of hand searching (eg, reference lists of obtained articles)	7
23				
24				
25		#4g	List of citations located and those excluded, including justification	See note
26				1
27				
28				
29		#4h	Method of addressing articles published in languages other than English	6
30				
31		#4i	Method of handling abstracts and unpublished studies	7
32				
33		#4j	Description of any contact with authors	8
34				
35				
36		#5a	Description of relevance or appropriateness of studies gathered for	6-8
37			assessing the hypothesis to be tested	
38				
39				
40		#5b	Rationale for the selection and coding of data (eg, sound clinical	5-8
41			principles or convenience)	
42				
43				
44		#5c	Documentation of how data were classified and coded (eg, multiple	7,8
45			raters, blinding, and interrater reliability)	
46				
47				
48		#5d	Assessment of confounding (eg, comparability of cases and controls in	n/a
49			studies where appropriate)	
50				
51				
52		#5e	Assessment of study quality, including blinding of quality assessors;	8,9
53			stratification or regression on possible predictors of study results	
54				
55				
56		#5f	Assessment of heterogeneity	9
57				
58		#5g	Description of statistical methods (eg, complete description of fixed or	8, 9
59				
60				

random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated

#5h	Provision of appropriate tables and graphics	9, 10
#6a	Graphic summarizing individual study estimates and overall estimate	10-14
#6b	Table giving descriptive information for each study included	36
#6c	Results of sensitivity testing (eg, subgroup analysis)	32
#6d	Indication of statistical uncertainty of findings	32
#7a	Quantitative assessment of bias (eg. publication bias)	9
#7b	Justification for exclusion (eg, exclusion of non-English-language citations)	10
#7c	Assessment of quality of included studies	8, 10
#8a	Consideration of alternative explanations for observed results	18
#8b	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	18
#8c	Guidelines for future research	18
#8d	Disclosure of funding source	19

Author notes

1. 10, Appendix

Reproduced with permission from JAMA. 2000. 283(15):2008-2012. Copyright © 2000 American Medical Association. All rights reserved. This checklist was completed on 06. August 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)